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Homocysteine (Hcy) has been identified as a primary risk factor for atherosclerosis 
as it induces endothelial cell (EC) activation/dysfunction and thus potentially initiating 
atherosclerotic plaque formation. There is accumulating evidence indicating a key role for 
oxidative stress in mediating Hcy atherogenic effects. The aim of this study was to evaluate 
the effects of chronic treatment with Hcy on EC activation and to explore the role of 
oxidative stress in these effects.  
Human umbilical vein endothelial cells (HUVEC) were cultured and treated 
chronically with DL-Hcy for 5-9 days. An in vitro flow system was also used to 
characterize the different types of interactions between DL-Hcy-treated HUVEC and 
neutrophils under physiological flow conditions. EC activation was studied by 
characterizing the activation of the JNK pathway and the up-regulation of different cell 
adhesion molecules (CAM) and cytokines, using different techniques including western 
blot, immunohistochemical staining, enzyme-linked immunosorbent assay and polymerase 
chain reaction. The role of oxidative stress was investigated by measuring the production of 
ROS and evaluating the efficiency of antioxidants. Furthermore, the role of nitric oxide and 
nitric oxide synthase in modulating Hcy effects was investigated. 
Chronic treatment with DL-Hcy did not kill the EC however, it inhibited cell 
proliferation. Furthermore, this treatment induced EC activation/dysfunction which was 
characterized by sustained activation of the JNK pathway, which in turn mediated up-
regulation of E-selectin, ICAM-1 and to lesser extent P-selectin. Furthermore, DL-Hcy 
induced production of IL-8 protein. These CAM and chemokines collectively mediated 
different interactions between DL-Hcy-treated HUVEC and neutrophils under flow 
conditions including tethering, rolling, adherence and transmigration. DL-Hcy was also 
shown to induce significant ROS generation which mediated activation of the JNK 
pathway. Antioxidants restored DL-Hcy-induced interactions under flow to the basal level. 
DL-Hcy was shown to induce eNOS uncoupling which mediated, at least in part, the DL-
Hcy-induced ROS production. Furthermore, short term treatment with NO inhibited DL-
Hcy-induced HUVEC:neutrophil interactions in a cGMP-independent manner.  
In summary, this research showed that DL-Hcy has several proatherogenic effects, 
mediated at least in part by the JNK pathway, and induces EC activation/dysfunction 
priming for atherosclerosis initiation. The data supports that oxidative stress mediates the 
majority of Hcy atherosclerotic effects. Antioxidants tested, JNK inhibitors and NO showed 
promising results in reversing all DL-Hcy effects and restoring EC normal status. 
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CHAPTER 1 
INTRODUCTION 
1.1. THE ENDOTHELIUM AND HOMOCYSTEINE 
1.1.1. Endothelial cells (EC) 
Until the late1980’s, the endothelium was thought to be simply a “non stick” lining 
of blood vessels, its only functions being to prevent blood coagulation and working as a 
passive barrier to diffusion of solutes and nutrients. However, it is now known that the 
endothelium plays more complicated roles particularly in cardiovascular physiology and 
pathology (reviewed by Cines et al (1998)) and that there are roughly 10
14
 endothelial cells 
in our vasculature protecting us against atherosclerosis and thrombosis (Forstermann and 
Munzel, 2006). In an average person, weighing 70kg, the total surface area of endothelial 
cells is equivalent to six tennis courts and has a total weight of about 1800g, which is a bit 
heavier than the liver (Born et al., 1998).  
Endothelial cells (EC) exist as a monolayer of specialized epithelium lining the 
inner surface of blood vessels, separating the vascular wall from the circulating blood and 
its components (Bonetti et al., 2003; Lerman and Burnett, 1992). They are connected to 
each other by specific junctional structures at their border (Dejana et al., 1995). The 
endothelium responds to physical and chemical stimuli, releasing substances like nitric 
oxide (NO), angiotensin II and reactive oxygen species (ROS) and expressing adhesion 
molecules like intercellular adhesion molecule-1 (ICAM-1), vascular adhesion molecule-1 
(VCAM- 1) and E-selectin (reviewed by Esper et al (2006)). Some of these substances 
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maintain vasomotor balance and vascular-tissue homeostasis. The importance of the 
endothelium in the vascular system was confirmed following the discovery that EC produce 
molecules that influence contractility of vascular muscle cells whose vasoactive tone 
determines blood flow to any organ (Highsmith, 1998). Substances produced by EC also 
play an important role in regulating vascular permeability, leukocyte adhesion, platelet-
vessel wall interaction and vascular remodelling (Born et al., 1998). EC dysfunction leads 
to abnormal vasodilatory responses, increased production of vasoconstrictors, impaired 
endothelial control of fibrinolysis and inflammation, besides altered expression of adhesion 
molecules (Brevetti et al., 2008; Cai and Harrison, 2000). Thereafter, EC dysfunction leads 
to the development of atherosclerosis. At the site of injury, remnant cells can replicate 
rapidly and replace the lost ECs. Furthermore, circulating endothelial progenitor cells 
provide an additional repair mechanism for the endothelium (Asahara et al., 1997).  
Nitric oxide (NO) is one of the main factors required for efficient EC function, as 
well as vasodilatation. It is a gaseous lipophilic free radical cellular messenger whose half-
life is only 10 to 20s in physiological media (Lefer, 1997). Several studies demonstrated 
that NO is synthesized from L-arginine and that this production is catalyzed by an enzyme 
called nitric oxide synthase (NOS) (Amezcua et al., 1989; Furchgott, 1998; Ignarro et al., 
1990; Palmer and Moncada, 1989). Three different isoforms, neuronal (nNOS), inducible 
(iNOS) and endothelial NOS (eNOS) (reviewed by Naseem (2005)). Both eNOS and nNOS 
produce constitutively low levels of NO in response to stimulus. While, iNOS produces 
large amount of NO after induction by external stimuli and can work at low levels of Ca
2+ 
(Bruckdorfer, 2005). Activation of eNOS and therefore production of NO could happen 
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through Ca
2+
-sensitive pathway by mediators like histamine and ATP or through Ca
2+
-
insensitive pathway by mediators like shear stress or adenosine (Fleming et al., 1997).  
NO activates soluble guanylyl cyclase in vascular smooth muscle, leading to 
accumulation of cyclic guanosine monophosphate (cGMP) and vessel relaxation (Amezcua 
et al., 1989; Lentz, 2005; Palacios et al., 1989). NO is also involved in recruiting 
endothelial progenitor cells which can differentiate to EC (Lowenstein, 2007). NO prevents 
leukocyte adhesion and subsequent migration into the subendothelial space. It can down-
regulate the expression of cell surface adhesion molecules (CAM) on EC (Kosonen et al., 
2000; Zampolli et al., 2000) and leukocytes (Kosonen et al., 1999; Kubes et al., 1991) 
resulting in anti-inflammatory effects (nitric oxide will be discussed in more details in 
Chapter 5).  
EC responses to exogenous agents result in surface expression of several adhesion 
molecules, important in acute inflammation but also in disease. Therefore, their expression 
and regulation will be considered in more detail below. 
1.1.1.1. Cellular adhesion molecules (CAMs) 
CAMs are glycoproteins located on the cell surface and play an important role not 
only in appropriate acute inflammation but also in inflammatory as well as neoplastic 
diseases  (Haier and Nicolson, 2000; Yamada and Geiger, 1997). They are transmembrane 
receptors composed of three domains: an intracellular domain which interacts with the 
cytoskeleton, a transmembrane domain and an extracellular domain that interacts either 
with other CAMs of the same kind (homophilic binding) or with different CAMs or the 
extracellular matrix (heterophilic binding) (Elangbam et al., 1997). Interactions between 
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CAMs result in binding with other cells or with the extracellular matrix (ECM) resulting in 
cell adhesion. Four main groups of human CAMs have been recognized so far: integrins 
(Stewart et al., 1995), cadherins (Elangbam et al., 1997), the immunoglobulin superfamily 
(IgSF CAMs) (Penberthy et al., 1997) and selectins (Bevilacqua, 1993). 
1.1.1.1.1. Integrins 
The integrins are a family of heterophilic CAMs and that are expressed by almost 
every cell type and they consist of two non-covalently linked molecules, alpha and beta 
subunits (Penberthy et al., 1997). The combination of alpha and beta subunits determines 
ligand specificity. Integrins are also dependent on the divalent cations, Ca
2+
, Mg
2+
 or Mn
2+
 
for both structural and functional integrity (Bevilacqua and Nelson, 1993; Luscinskas and 
Lawler, 1994). They bind to components of the ECM extracellularly and to the 
cytoskeleton intracellularly, functionally connecting the cell interior to its exterior; in blood 
cells, integrins are also involved in cell-cell adhesion (Ruoslahti, 1991). It has been 
suggested that different integrins may recognize different specific domains on the same 
ligand  and might function differently in the same cell type (Juliano and Haskill, 1993). 
1.1.1.1.2. Immunoglobulin superfamily  
The immunoglobulin superfamily (IgSF CAMs) consists of adhesion receptors, 
which share the immunoglobulin domain and include antigenic specific receptors of either 
T- or B-lymphocyte or both (Springer, 1994). Intercellular CAMs (ICAMs) are either 
homophilic or heterophilic and bind integrins or different IgSF CAMs. Human ECs express 
intercellular adhesion molecules ICAM-1, ICAM-2 and ICAM-3, vascular cell adhesion 
molecule-1 (VCAM-1) and mucosal addressing cell adhesion molecule-1 (MadCAM-1) 
(Penberthy et al., 1997). ICAMs help localize leukocytes to areas of tissue injury 
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(Elangbam et al., 1997) and are constitutively expressed. However, many cytokines, such 
as interferon-γ (IFN-γ), interleukin-1 (IL-l), and tumour necrosis factor α (TNF-α), induce 
expression of ICAM on the surface of EC (Dustin et al., 1986). ICAM-1 expression is 
believed to occur through two co-operating pathways, NF-κB-dependent and JNK-
dependent pathways (Miho et al., 2005). Human VCAM-1 is a cell surface protein 
expressed by activated EC and certain leukocytes (such as macrophages). VCAM-1 has 
many isoforms that differ in the number of integrin binding sites (Springer, 1994). VCAM-
1 expression is induced by IL-1 beta, IL-4, TNF-α and IFN-γ with maximal activity reached 
by 6-12h (Bevilacqua, 1993). It regulates the adhesion of monocytes, lymphocytes, 
basophils, and eosinophils to EC (Elangbam et al., 1997), leading to leukocyte diapedesis at 
the site of inflammation (Heidemann et al., 2006).  
1.1.1.1.3. Selectins  
Selectins are a family of calcium-dependent and heterophilic cell-surface adhesion 
molecules. They were called selectin to highlight the presence of an amino terminal lectin 
domain, which is primarily responsible for their adhesive activity (Muller, 2002), as well as 
to emphasize the selective nature of the expression and function of these molecules 
(Bevilacqua et al., 1989). They are expressed by leukocytes and EC and bind fucosylated 
carbohydrates, e.g. mucins (Bevilacqua and Nelson, 1993). Lectin domains on selectins will 
interact, selectively, but with low affinity, with their glycoconjugate ligands during cell-cell 
adhesion (McEver and Cummings, 1997). A functional synergism has been suggested 
between ICAMs and selectins (Steeber et al., 1998). Steeber’s group demonstrated in an in 
vivo study using mice that ICAM-1 expression is required to optimize selectin-mediated 
rolling.  
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Structurally, selectins are glycoprotein with an NH2-terminal C-type lectin domain, 
followed by an epidermal growth factor-like domain (EGF), a series of short consensus 
repeats, a transmembrane domain, and a short cytoplasmic tail (Figure 1) (McEver and 
Cummings, 1997). Selectins are identical in their N-terminal and the lectin domain. EGF 
has sequence similarity while each complement regulatory-like module is about 60 amino 
acid length with six cysteinyl residues capable of disulfide bond formation (Bevilacqua and 
Nelson, 1993). The structural differences between selectins are mainly due to the number of 
repeated complement regulatory domains (Muller, 2002). L-selectin has two, E-selectin has 
six while P-selectin has nine complement protein-related domains. 
The human selectin domains 
 
Figure 1: Human selectin domains. From left to right: amino terminal domain 
homologous to lectins, epidermal growth factor-like domain (EGF), complement 
regulatory-like modules (CR), transmembrane sequence, short cytoplasmic sequence 
at carboxyl terminus. Adapted from Gahmberg et al (1999). 
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A standard nomenclature has been agreed upon which designates each family 
member according to the cell type on which it was originally identified (Penberthy et al., 
1997).  
1.1.1.1.3.1. E-selectin 
E-selectin (CD62E), also called ELAM-1, is expressed mainly on activated EC and 
binds to its ligands on leukocytes (McEver and Cummings, 1997). E-selectin’s expression 
is induced by pro-inflammatory agents including TNF-α and IL-1. It is synthesized de novo 
and expressed optimally on the EC surface 4-8h after cytokine stimulation (Bevilacqua and 
Nelson, 1993). The E-selectin gene is transcriptionally silent in non activated ECs. 
However, when these cells are stimulated, E-selectin is expressed rapidly resulting in 
leukocyte rolling on ECs (Whelan et al., 1991). Surface expressed E-selectin will be 
internalized in EC but was not detected in the Golgi apparatus so it is short-lived and is 
degraded in lysosomes (Subramaniam et al., 1993). TNF-α-induced E-selectin expression 
has been shown to happen through two signalling pathways. The first one involves NF-κB 
activation (Kaur et al., 2003), while the other pathway involves JNK of the MAP kinase 
family which in turn leads to activation of the transcription factor ATF-2/c-Jun (Min and 
Pober, 1997). The E-selectin promoter contains a binding site for both ATF-2/c-Jun 
heterodimer and NF-κB  and studies showed that both pathways are required for full 
activation of E-selectin gene transcription (Read et al., 1997).  
1.1.1.1.3.2. L-selectin 
L-selectin (CD62L) is constitutively expressed on all circulating leukocytes except  
memory T cells (Konstantopoulos and McIntire, 1996; Tedder et al., 1989) and when 
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expressed binds to its ligand, PSGL-1 which is expressed on EC (McEver and Cummings, 
1997).  
1.1.1.1.3.3. P-selectin 
P-selectin has a mass of 140kDa and is considered the largest among the selectin 
family. It extends about 40nm from the endothelial surface. Megakaryocytes and EC 
constitutively synthesize P-selectin (McEver et al., 1989) and store it in the alpha granules 
of platelets (Bevilacqua and Nelson, 1993) and in irregular cigar-shaped structures called 
Weibel-Palade bodies (WPB)  in EC  (Weibel and Palade, 1964). De novo synthesis of P-
selectin was proven to be induced by TNF-α in mice and to peak in 3h (Weller et al., 1992). 
Two possible pathways for P-selectin expression have been described, immediate 
transient expression and late prolonged expression. The immediate one is induced by 
activators like thrombin and histamine and the stored P-selectin in WPB is quickly 
mobilized to the cell surface as rapidly as 2min (Hattori et al., 1989). P-selectin expression 
peaks in 10min and returns back to its basal levels within a few hours even in the 
continuous presence of the stimulators (Blann et al., 2003). Therefore, these stimulators 
seem to mediate acute inflammation (Khew-Goodall et al., 1999). On the other hand, the 
expressed P-selectin in late prolonged expression is synthesized de novo. When P-selectin 
synthesis increases in response to chronic inflammation or appropriate stimulators in mice, 
the sorting pathways into WPB may become saturated and the extra synthesized P-selectin 
can be delivered directly to the cell surface (Hahne et al., 1993). Once expressed on the cell 
surface, P-selectin binds to its ligand PSGL-1 on leukocytes (McEver and Cummings, 
1997) leading to leukocyte recruitment.  
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1.1.1.1.3.4. P-selectin life cycle 
In vivo, exocytosed P-selectin remains in the membrane for a short period (Hattori 
et al., 1989) and is then internalised and recycled to WPB through the trans-Golgi network 
(Arribas and Cutler, 2000). The remnant P-selectin which fails to be internalised is shed by 
proteolysis (Hartwell et al., 1998). It has been shown that  50% of internalised P-selectin is 
targeted to the lysosomes and degraded within 90min (Arribas and Cutler, 2000), while the 
other 50% appears in Golgi apparatus within 60-90min after P-selectin’s surface expression 
(Subramaniam et al., 1993) and is recycled to WPB. Subsequently, WPB containing 
recycled P-selectin start budding from Golgi apparatus and spread throughout cytoplasm 
within few hours (Subramaniam et al., 1993). It has been shown that expression levels of P-
selectin varies between different types of human EC (McEver et al., 1989). HUVEC, small 
vessels within gastric mucosa and high EC in lymph node showed high expression of P-
selectin. However, venules showed variable expression and endothelium in thyroid gland 
showed no expression of P-selectin (McEver et al., 1989).  
1.1.1.1.3.5. Selectin ligands 
The main ligand for all selectins is termed PSGL-1 which stands for P-selectin 
glycoprotein ligand-1 (Muller, 2002) as it was initially thought to be specific for P-selectin 
only. However, PSGL-1 has also been shown to bind to both L-selectin (Sperandio et al., 
2003) and E-selectin (reviewed by Ley (2003)). Thus, the term PSGL-1 is misleading 
because the mucin is not a glycoprotein ligand for only P-selectin. Instead, it could be said 
that PSGL-1 has multifunctional properties. PSGL-1 is a 240 kDa homodimer consisting of 
two 120kDa polypeptide chains. It is constitutively expressed on all leukocytes and 
primarily found on the tips of the microvilli. It has a glycosylation pattern allowing it to 
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bind to endothelial selectins (McEver and Cummings, 1997). PSGL-1 structure includes the 
sialyl-Lewis
x
 component, which is expressed on neutrophils, monocytes and certain T 
lymphocytes (Ohyama et al., 1999) and plays a key role in the recruitment of leukocytes. 
For optimal P-selectin and L-selectin binding, tyrosine residues on the amino terminus of 
the protein bearing sialyl-Lewis
x
 must be sulfated (Sako et al., 1995; Vestweber and 
Blanks, 1999). A recent study in mice showed that in addition to PSGL-1, EC express 
another L-selectin ligand distinct from PSGL-1 that plays important role in neutrophil 
homeostasis and trafficking (Shigeta et al., 2008). 
1.1.1.1.4. Cadherins  
The cadherins are a family of homophilic calcium dependent CAMs that are 
involved in establishing and maintaining intercellular connections (cell-cell association). 
Three subclasses are recognized of this family and these are E-cadherins (epithelial), P-
cadherins (placental) and N-cadherins (neural) (Elangbam et al., 1997). Cadherins play an 
important role in controlling the tight junctions between EC in the monolayer and therefore 
controlling the permeability (Taddei et al., 2008). 
1.1.1.2. Mitogen-activated protein kinase (MAP kinase) 
The mitogen-activated protein kinases, MAPK, are a group of intracellular signal 
transduction enzymes that mediate cellular responses to external stimuli including soluble 
factors like growth factors, hormones and cytokines (Barr and Bogoyevitch, 2001) as well 
as physical factors like UV light or osmotic stress (Chang and Karin, 2001). MAP kinases, 
with other messenger systems work together to achieve integrated function of cells in an 
organism. They were identified early in evolution and are expressed in all cell types. They 
are involved in development processes like cell differentiation, cell proliferation, cellular 
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survival and death and also in controlling embryogenesis and metabolic responses in 
vertebrates (Barr and Bogoyevitch, 2001; Marshall, 1994; Pearson et al., 2001). Many 
functional responses controlled by MAP kinases require information to be sent to the 
nucleus (Huang and Ferrell, 1996) resulting in specific phosphorylation and activation of 
many transcription factors, thereby modulating gene expression. The MAP kinase pathway 
is composed of three consecutive kinase families (termed MAPKKK, MAPKK, and 
MAPK). MAPKKK phosphorylates and activates MAPKK, which in turn phosphorylates 
and activates MAPK (Figure 2), which phosphorylate and activate their specific target 
proteins such as transcription factors (Barr and Bogoyevitch, 2001; Huang and Ferrell, 
1996). There are several MAPKKKs, MAPKKs and MAPKs which can be activated by 
diverse stimuli and significant cross talk between pathways exists. All MAP kinases have 
two activating phosphorylation sites in the kinase activating loop, a tyrosine and a threonine 
(Ferrell, 1996) so MAPK activation occurs through dual phosphorylation on Thr-X-Tyr 
motif (Hoefen and Berk, 2002). The activation cascade is initiated by one of a wide range 
of extracellular signals and each MAPK pathway has highly-specific signalling 
intermediates that maintain accurate signalling (Barr and Bogoyevitch, 2001). In addition, 
recent work has shown the importance of scaffolds in producing the appropriate response 
(Seeliger and Kuriyan, 2009).  
Three different parallel pathways (Figure 2) have been identified with discrete 
functions but there is overlap in activation by certain stimuli. Extracellular signal-regulated 
kinase (ERK) consists of two proteins, ERK1 and ERK2 (Boulton et al., 1991). They are 
expressed ubiquitously at different levels in different tissues (Pearson et al., 2001). ERK1 
and ERK2 can be activated by growth factors, cytokines, certain stresses, ligands for G 
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protein-coupled receptors (GPCRs), and transforming agents (Pearson et al., 2001). The 
second MAP kinase cascade is p38, initially identified as a reactivating kinase for MAP 
kinase activated protein (MAPKAP) kinase-2 (Rouse et al., 1994) but now known to 
activate a number of transcription factors (Chang and Karin, 2001). The p38 subfamily 
contains p38α, p38β, p38γ and p38δ (Stein et al., 1997). p38 proteins are activated by 
cytokines, hormones, GPCRs, osmotic and heat shock, as well as other stresses (Pearson et 
al., 2001). p38 plays an important role in the expression of some CAMs. It was shown to 
regulate cytokine-induced VCAM-1 expression at the postranscriptional level (Pietersma et 
al., 1997) and also to regulate TNF-α-induced expression of MCP-1 (Goebeler et al., 1999). 
Furthermore, activation of MAPK-activated kinase-2 (MAPKAP-2) by p38 activates heat 
shock protein 27, which regulates cellular morphology by uncapping actin filaments 
(Hoefen and Berk, 2002). Therefore, activated p38 plays a role in cytoskeleton remodeling 
and subsequent neutrophil transmigration following adherence to the endothelium (Wang 
and Doerschuk, 2001). On the other hand, p38-mediated cytoskeletal regulation is known to 
play an important role in response to inflammatory stimuli. Collectively, p38-mediated 
regulation of cytoskeletal remodeling seems to play a role in the inflammatory events. 
The last MAP kinase family is termed JNK which is also known as stress-activated 
protein kinase (SAPK). JNK/SAPKs of 46 and 54 kDa were purified by affinity adsorption 
to a c-Jun fusion protein (Hibi et al., 1993). Structurally, at least 10 different JNK isoforms 
have been identified and all of these are splice variants of JNK1, 2 and 3, known also as 
SAPK-γ, SAPK-α and SAPK-β, respectively (Kyriakis et al., 1994). JNK1 (46 kDa) and 
JNK2 (54 kDa) are ubiquitously expressed, while JNK3 (54 kDa) is expressed only in the 
brain and testes (Barr and Bogoyevitch, 2001). Despite homology between the active sites 
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of JNK1, 2 and 3,  each protein is the product of a different gene (Szczepankiewicz et al., 
2006). Like other MAP kinases, JNK/SAPKs are activated upon phosphorylation of 
tyrosine and threonine (Tyr
185 
Thr
183
 in JNK1), which are separated by a proline residue 
(Pro
184
) (Derijard et al., 1994). JNK is activated by a variety of exogenous stimuli like 
growth factor deprivation, pro-inflammatory cytokines such as TNF-α, UV irradiation 
(Zhang et al., 2001a) and by all stimulants causing ER stress (Dimmeler et al., 1997), for 
example agents that interfere with DNA and protein synthesis. 
Schematic view of MAPK cascade 
 
 
Figure 2: Schematic view of MAPK cascade. Three different parallel pathways have 
been identified, ERK, p38 and JNK pathway. Activation pathway of all MAPK is 
composed of three consecutive kinases (MAPKKK, MAPKK, and MAPK). 
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ASK1 is a ubiquitously expressed MAPKKK which has been shown to be a specific 
target for reactive oxygen species (ROS) (Shen and Liu, 2006). ASK1 activates the MAPK 
kinases, MKK4 and MKK7 which have been implicated in JNK/SAPK activation (Pearson 
et al., 2001; Tournier et al., 2001). In vitro, MKK4 preferentially phosphorylates the 
tyrosine residue in the activation loop motif of JNK/SAPKs, while MKK7 preferentially 
phosphorylates the threonine residue. Therefore, it has been suggested that these kinases 
cooperate to activate JNK/SAPKs (Lawler et al., 1998). Different molecular targets for 
JNK have been identified including transcription factor AP-1 a dimer of proteins belonging 
to the c-Jun family: ATF-2, JunB and the insulin receptor substrate (IRS-1 and 2) (reviewed 
by Shen and Liu (2006)). c-Jun is specifically phosphorylated by JNK on Ser 63 and Ser 73 
(Pulverer et al., 1991) and this specificity was explained by specific docking requirements 
explaining why other mammalian MAPK members don’t phosphorylate c-Jun (Barr and 
Bogoyevitch, 2001). c-Jun and ATF-2 are found to be constitutively bound as a 
heterodimer to the E-selectin promotor and their phosphorylation increases E-selectin gene 
transcription (Read et al., 1997). 
Crosstalk between different MAPK family members is a key mechanism of 
regulating MAPK-mediated signaling pathways. There are different pathways by which a 
MAPK family member can inhibit the activity of another member of MAPK family by 
inhibiting an upstream kinase or deactivating phosphorylation. Different studies found that 
some MAPK traditionally associated with stress mediated responses (JNK or p38) may 
inhibit the activation of another MAPK more associated with proliferation and 
differentiation (ERK1/2). Many studies, reviewed by Berk (2008), suggested a dynamic 
balance between growth factor-activated ERK1/2 and stress-activated p38/JNK pathways 
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may be important in determining whether a cell survives or undergoes apoptosis.  
Furthermore, it has been reviewed that ERK1/2 regulates the expression of MAPK 
phosphatase 2 (MKP2) which deactivates JNK (Hoefen and Berk, 2002). Phosphorylated 
p38 can also directly interact with ERK1/2 and prevent its phosphorylation by MEK1/2. 
Collectively, it seems that the crosstalk among JNK/p38 and ERK1/2/BMK1 may play a 
critical role in determining the inflammatory status of EC.  
1.1.2. The role of EC in inflammation  
The inflammatory process is a vital response. However, wrong timing and location 
might lead to potentially fatal diseases, e.g. atherosclerosis and autoimmune disease. 
Regulation of cell adhesion molecule expression is one mechanism to prevent an unwanted 
inflammatory response.  
Two main forces prevent flowing blood cells from binding to the vessel, 
hemodynamic forces due to blood flow and adhesive forces mediated by CAMs and their 
ligands. Under normal conditions, neutrophils will circulate for few hours and then will be 
depleted by removal in the spleen (Coxon et al., 1999). In addition to adhesion molecules, 
several soluble factors, reviewed by Konstantopoulos and McIntire (1996), have been 
found to be involved in leukocyte interactions with endothelium during their circulation in 
the blood stream; e.g. chemokines produced by endothelium like interleukin-8 (IL-8) and 
platelet-activating factor (PAF). Lawrence’s group was the first to refer to the receptor-
dependent adhesive events and defined the different stages like rolling and firm adhesion 
(Lawrence et al., 1987). During the inflammatory response (Figure 3), adhesion molecules 
from circulating leukocytes interact with their ligands on the ECs lining the vessel wall, 
tethering them for a microsecond causing activation and then these activated leukocytes roll 
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on EC, adhere and finally transmigrate through the endothelial monolayer to the inflamed 
area. 
1.1.2.1. Capture or tethering 
The first contact between leukocytes and EC is termed capture or tethering. 
However, prior to that, margination starts when leukocytes leave the blood stream initiating 
leukocyte-EC interactions by close mechanical contacts. L-selectin and P-selectin 
expressed on activated leukocytes and EC respectively mediate tethering through binding to 
their counter receptor on the opposing cell (Carlos and Harlan, 1994; Muller, 2002). One 
report (Henderson et al., 2001) suggested that leukocyte VLA-4 interaction with VCAM-1 
on inflamed endothelium may have a role in tethering. Furthermore, one early study 
suggested that E-selectin might contribute to neutrophil tethering (Lawrence et al., 1994). 
Selectin-ligand interaction happens quickly and detachment must also occur quickly. These 
interactions must be strong enough to overcome the shear forces-dissociation effects 
(Konstantopoulos and McIntire, 1996). Furthermore, leukocytes can attach to adherent 
leukocytes, and this is called secondary tethering, mainly mediated by L-selectin-PSGL-1 
binding (Bargatze et al., 1994) amplifying recruitment of leukocytes to the vascular wall. 
Furthermore, activated platelets express P-selectin which will bind to PSGL-1 and leading 
to more recruitment of leukocytes to the site of inflammation  (McEver and Cummings, 
1997). 
1.1.2.2. Rolling 
Leukocyte tethering leads to transient adherence to endothelium; then the next 
stage, rolling, occurs. Once again, the selectins mediate this stage, with the family member 
responsible depending on the time subsequent to inflammatory stimulus. Following the 
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appropriate stimulation, e.g. trauma or by histamine, P-selectin is rapidly surface-expressed 
on the endothelium and makes it “sticky” to leukocytes. P-selectin on the EC and L-selectin 
on the leukocytes, and their ligands on the opposing cells like PSGL-1, (Carlos and Harlan, 
1994; McEver and Cummings, 1997) have been shown to be responsible for  early stage of 
leukocyte rolling. Studies showed that histamine release from mast cells was indeed 
responsible for the “baseline rolling” seen in intravital microscopy experiments and 
induced by P-selectin expression (Kubes and Kanwar, 1994).  
Collectively, leukocytes roll along the endothelium and during the process bonds 
form at the leading edge of rolling cells and are broken at the trailing edge. When P-selectin 
is absent, L-selectin will mediate the whole process. However, rolling velocity is 3-5 times 
faster in this case. Therefore, it could be said that L-selectin is much less effective then P-
selectin in mediating rolling. The role of E-selectin in this process appears later in vivo, 
because it requires de novo synthesis and therefore is only expressed after several hours; E-
selectin mediates slow rolling and initiates the next step, firm adhesion (Carlos and Harlan, 
1994). 
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The different stages in inflammatory response 
 
 
Figure 3: Sequential steps in leukocytes emigration through ECs in inflammatory 
response. The ligand in (A) are from leukocytes and those in (B) are from EC. Adapted 
from Muller (2002). 
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1.1.2.3. Slow rolling 
This stage has been termed slow rolling to distinguish it from the much faster 
rolling that P-selectin is responsible for and requires E-selectin expression on EC 
interacting with CD18 integrins on the rolling leukocytes as studies on mice showed that 
exposure to TNF-α resulted in decreasing leukocyte rolling velocity to an average between 
5-10µm/s (Jung and Ley, 1999; Kunkel et al., 2000). Slow rolling has been shown to 
happen in vitro on E-selectin substrate and P-selectin substrate using artificial lipid bilayers 
containing the same amounts of the two selectins (Lawrence and Springer, 1991) meaning 
the slow rolling is not based on the unique property of E-selectin. However, in vivo P-
selectin is expressed at a much lower level compared to E-selectin (Blann et al., 2003) 
which is not enough to mediate rolling in vivo. Furthermore, rolling has been shown in in 
vivo studies in genetically modified mice to require the expression of E-selectin on EC 
(Jung and Ley, 1999). Collectively, E-selectin plays the key role in mediating slow rolling. 
Leukocytes need to spend a certain amount of time in a position favourable for bond 
formation. However, Jung et al have found that slow rolling is not strictly required because 
high concentrations of chemoattractants can arrest fast-rolling leukocytes (Jung et al., 
1998). Furthermore, it has been shown (Kubes et al., 1995) that rolling velocity must be 
decreased by more than 90% to significantly reduce firm adhesion. It appears that E-
selectin and CD18 integrin work synergistically to control the time a leukocyte needs to roll 
through an inflamed area and to convert rolling to firm adhesion (Jung et al., 1998) and a 
correlation has been established between rolling transit time, which defines to the duration 
when leukocytes are rolling closely to ECs, and the amount of firm adhesion (Jung et al., 
1998; Kunkel et al., 2000). 
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1.1.2.4. Firm adhesion 
Rolling leukocytes do not stop abruptly, but they show a decrease in their rolling 
velocity allowing bonds (Blann et al., 2003) to be formed between them and EC, initiating 
the next step, firm adhesion. The leukocytes, while they are rolling along the vessel, 
integrate chemoattractant signals until they reach a critical level of activation and become 
firmly adherent (Jung et al., 1998). This step is mainly controlled by the leukocyte’s 
integrins which bind to counter receptors which are members of the immunoglobulin 
superfamily on the EC (Muller, 2002; Sligh et al., 1993). CD18 integrin participates in the 
leukocyte arrest. Neutrophils also express small amount of VLA-4 [α4β1 integrin] which 
can bind endothelial VCAM-1 and mediates firm adhesion (Luscinskas et al., 1995). 
Furthermore, lymphocyte function-associated antigen 1 integrin (LFA-1) plays a key role in 
mediating leukocyte adherence through binding to ICAM-1 on EC. Other integrins like 
macrophage differentiation antigen-1 (MAC-1) are expressed on neutrophils and can bind 
ICAM-1 and ICAM-2 on the endothelium, however MAC-1 has been suggested to play a 
role in activating neutrophils and phagocytosis rather than in their adherence and LFA-1 
was suggested to play more important role in leukocyte arrest (Dunne et al., 2002). Despite 
this, the same study suggested that both LFA-1 and MAC-1 are required for leukocyte 
rolling on inflamed venules. 
1.1.2.5. Transmigration 
All of the preceding steps in leukocyte recruitment are reversible. However, 
diapedesis is the “point of no return”.  In vitro experiments showed that chemokines like 
IL-8 induced dose-dependent increases in neutrophil transmigration (Furie et al., 1991). 
Therefore, when appropriate exogenous chemoattractant is present, like IL-8, leukocytes 
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squeeze between the opposing activated ECs and migrate across endothelium and undergo a 
change in their cytoskeleton and extend themselves across endothelial border (Muller, 
2002).  It is believed that this step is stimulated by chemoattractants from the inflammatory 
environment including factors released from necrotic host cells and chemokines made by 
host cells, including EC, in response to inflammatory stimuli (Muller, 2002).  
While these steps have been represented in the previous paragraphs as sequential, it 
would be true to say that there is significant overlap at each stage and knock out studies 
have shown that some of the adhesion molecules can substitute for each other under certain 
conditions. 
1.1.3. Signal transduction in endothelial cell activation 
The MAPK family plays an important role in mediating the signal transduction 
from the cell surface to transcription factors in nucleus, resulting in alterations in gene 
expression (Chang and Karin, 2001). For example, cellular exposure to cytokines or 
environmental stress causes JNK activation and that presents a possible role of JNK in 
mediating the inflammatory response. Experiments showed that cytokine-stimulated 
cultured ECs express E-selectin. TNF-α-mediated transcription of E-selectin peaks in 2h 
and returns into base-line after 12h of induction with the expression of the protein peaking 
after 4-6h (Read et al., 1997; Wadgaonkar et al., 2004). Different studies in co-cultured 
EC/SMC (Chiu et al., 2007) or in animal models (reviewed by Ip and Davis (1998)), 
showed that cytokine-induced E-selectin expression, is mediated by a variety of 
intracellular signaling intermediates including JNK, p38, and NF-κB. The role of JNK in E-
selectin expression was confirmed by the reduction in its expression in the presence of the 
selective JNK inhibitor SP600125 in co-cultures of EC/VSMC treated with the cytokine IL-
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1. TNF-α interacts with its receptor TNFR1 and results in different TNF-α-induced signals. 
Consequently there will be activation of JNK/p38 and NF-κB leading to activation of ATF-
2 and AP-1 (Gupta et al., 1996; Sluss et al., 1994). In turn, this leads to activation of the E-
selectin promoter and thus full gene transcription. Therefore, induction of endothelial E-
selectin gene expression by inflammatory mediators is mediated by signalling pathways 
involving MAP kinase family members and NF-κB and this E-selectin expression confirms 
the role of the MAPK family in mediating inflammatory response. The roles of JNK in 
mediating expression of adhesion molecules in response to diverse stimuli are still unclear 
and different studies are underway to clarify such functions of MAP kinases.  
1.1.4. EC and the development of atherosclerosis 
Endothelial dysfunction involves different abnormalities in the homeostatic level of 
vascular endothelium including disturbed vascular tone, haemostasis, and inappropriate 
inflammation (Cai and Harrison, 2000). These abnormalities lead to impairment of 
endothelium-dependent relaxation of blood vessels, ultimately resulting in cardiovascular 
disorders (Schachinger et al., 2000). Deanfield et al (2007) proposed that under certain 
circumstances, eNOS can induce the production of ROS in a process known as eNOS 
uncoupling. The low levels of either the cofactor BH4 or the substrate L-arginine induces 
eNOS uncoupling and the formation of superoxide or hydrogen peroxide respectively 
(Forstermann and Munzel, 2006). Furthermore, under inflammatory conditions, as in 
atherosclerosis, activated leukocytes are attracted to the endothelial site of injury and 
generate significant amounts of ROS which worsen the injury. Under normal conditions, 
ROS play a role in diverse signalling pathways and they are involved in regulating vascular 
tone, cell growth and apoptosis (Papatheodorou and Weiss, 2007). In addition to generating 
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ROS, EC have scavenging mechanisms like antioxidant enzymes that prevent build-up of 
ROS and damage. However, in different cardiovascular diseases, ROS overcome 
antioxidant defences resulting in what is known as oxidative stress (Davidson and Duchen, 
2007). The early events of atherosclerosis include sublethal changes in EC where the 
endothelium shows increased permeability to plasma proteins and lipoproteins, like LDL, 
albumin and fibrinogen. LDL binds to extracellular matrix proteins of the subendothelial 
space and accumulates in the artery wall, where it can be oxidised. Subsequently, 
leukocytes are recruited to the lesion area and interact with EC, tether, roll, adhere and 
migrate to the subendothelial space. Activated EC produce growth factors like macrophage 
colony-stimulating factor which induces activation and differentiation of transmigrated 
monocytes to resident macrophages (Lusis, 2000). These macrophages in turn internalize 
oxidized LDL (Lusis, 2000) forming lipid-laden foam cells, the hallmark of the fatty streak 
(Frei, 1999). EC and leukocytes release different chemokines that cause proliferation and 
migration of smooth muscle cells (SMC) from the media to the intima. SMC help in 
accumulation of collagen and proteoglycan which are essential factors for the plaque 
stability (Braunersreuther et al., 2007). Two phenotypes of plaque have been identified, 
those with thick fibrous cap and small lipid core and termed stable plaques and they do not 
pose much danger of inducing atherosclerosis complications. Unstable plaques are 
characterized by large lipid core and thin fibrous cap and are prone to rupture inducing 
thrombosis leading to acute vascular events (Fuster et al., 1999; Tedgui and Mallat, 2006).  
Collectively, chronic exposure to cardiovascular risk factors activates different 
molecular pathways in EC leading to the expression of different cytokines, chemokines and 
CAM (Deanfield et al., 2007). Consequently, these ECs will become dysfunctional and lose 
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their vasoprotective functions. Furthermore, a number of risk factors like TNF-α can induce 
EC apoptosis which leads to loss of the protective function of EC. Severely damaged ECs 
play a primary role in the initiation of atherosclerosis by a variety of mechanisms that are 
still under investigation.  
1.1.5. Homocysteine 
1.1.5.1. Homocysteine chemistry 
Homocysteine (Hcy) is a sulphur-containing amino acid (Ling and Hajjar, 2000); it 
is not present in naturally occurring proteins and is not a dietary constituent (Bolander-
Gouaille, 2002). Therefore, all Hcy found in organisms is primarily derived from 
demethylation of dietary methionine (D'Angelo and Selhub, 1997; Scalera et al., 2006). 
Hcy can form a disulphide bond, through its thiol group, with another homocysteine 
molecule forming homocystine, with free cysteine (Cys), or with the thiol group of plasma 
proteins like albumin (Medina et al., 2001). Normally, 1% of Hcy exists in the plasma in 
the free reduced form and the rest in oxidized form. About 70 % of Hcy is bound to 
albumin and the remainder forms disulphides (Bolander-Gouaille, 2002). Hcy and Cys have 
the same chemical structure as methionine with one and two methyl groups less 
respectively (Figure 4). 
 
 
Figure 4: The chemical structure of methionine, homocysteine and cysteine. 
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1.1.5.2. Hcy transportation to the cell and its metabolism 
Amino acids use different systems for transport into the cell which can be divided 
into two major groups, Na
+
-dependent and Na
+
-independent amino acid transporters. In 
addition to sodium ions, other different factors may regulate the transporter systems like 
pH, size of the amino acid and the ionic charge of the amino acid side chain (reviewed by 
Mann et al (2003)). Hcy is a neutral amino acid and its transport is pH insensitive (Ewadh 
et al., 1990). Its transport into the cells is essential for Hcy signalling and to induce its 
cellular effects. Ewadh et al showed, using [
35
S] Hcy, that Hcy cellular uptake in HUVEC 
happens through at least two different systems, the alanine-serine-cysteine (ASC) (Na
+
-
dependent) system and the large branched-chain neutral amino acid system (system L) 
(Na
+
-independent) both of which are also responsible for transporting Cys (Ewadh et al., 
1990). Furthermore, a recent study found that two additional sodium-dependent transporter 
systems XAG and A are involved in Hcy binding and uptake by HAEC (Budy et al., 2006). 
However, transport system ASC has been suggested to dominate Hcy transport in EC 
(Budy et al., 2006; Ewadh et al., 1990). Ewadh et al (1990) found that including Cys in the 
media inhibited Hcy uptake and suggested that Hcy transport happens through one of the 
systems used to transport Cys. They suggested that the inhibitory effects of cystine and 
homocystine on the uptake of the reduced form Hcy could be due to the formation of mixed 
disulphides.  
Methionine is converted to Hcy through two mediator compounds (Figure 5), S-
adenosylmethionine (SAM) which is the methyl donor for most cellular methyltransferase 
reactions. SAM in turn is demethylated to S-adenosylhomocysteine (SAH). Resulting Hcy 
is remethylated through the methionine cycle which is mediated by methionine synthase, 
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vitamin B12, methyltetrahydrofolate reductase (MTHFR) and folate (Lawrence de Koning 
et al., 2003). Hcy might also be metabolized through an irreversible reaction to cysteine 
through the transsulphuration pathway as animal cells cannot synthesize Hcy from Cys 
(Finkelstein, 1998). The transsulphuration pathway is mainly mediated by cystathionine-β-
synthase (CBS) with its cofactor vitamin B6 and it is the only reaction that removes Hcy 
from the methionine cycle (Finkelstein, 1998). These two overlapping pathways (Figure 5), 
transsulphuration and remethylation, are responsible for elimination of Hcy (D'Angelo and 
Selhub, 1997; Ling and Hajjar, 2000). Specific cellular Hcy export mechanisms are 
responsible for depositing excess Hcy into the blood and maintaining the intracellular level 
of Hcy at a low intracellular concentrations limiting intracellular toxicity (D'Angelo and 
Selhub, 1997). The kidney plays an important role in Hcy clearance mainly through the 
transsulphuration pathway (Bostom and Lathrop, 1997) and that explains why people with 
renal failure have a high incidence of vascular complications as they will have elevated Hcy 
levels (Ji and Kaplowitz, 2004). Hcy can also be deaminated  in the liver where the amino 
group is removed and converted to ammonia which in turn will be converted to urine or 
uric acid (Medina et al., 2001). Furthermore, in the liver and the kidney, some Hcy is 
methylated to methionine by the enzyme betaine:homocysteine methyltransferase (Selhub, 
1999). SAM was suggested to have a regulatory role in Hcy metabolism as Mato et al 
(2002) illustrated that SAM inhibits MTHFR and betaine:homocysteine methylatransferase 
(BHMT) and activates CBS. Low SAM favours remethylation and directs Hcy for 
methionine synthesis, while high SAM favours transsulphuration. 
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Homocysteine metabolism 
 
 
 
Figure 5: Homocysteine metabolism: DHF: dihydrofolate, THF: tetrahydrofolate, 
CH2THF: methylene tetrahydrofolate, CH3THF: methyl tetrahydrofolate, MTHFR: 
methyltetrahydrofolate reductase, MS: Methionine synthase, CBS: cystathionine β 
synthase, SAM: S-adenosylemethionine, SAH: S-adenosylehomocysteine. 
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1.1.5.3. Hyperhomocysteinemia  
Abnormal metabolism of Hcy could be due to defects in either demethylation or 
transsulphuration pathways and results in a disease called hyperhomocysteinemia (hHcy) 
(den Heijer et al., 1996). hHcy could also be caused by nutritional defects, renal 
dysfunction, alcoholism, hyperthyroidism, or certain medications (reviewed by Lentz and 
Haynes (2004)). Three ranges of hHcy have been defined: moderate (16-30 μM) which 
occurs in 5-7% of the population (Lawrence de Koning et al., 2003), intermediate (31-100 
μM) and severe (> 100μM) (Ji and Kaplowitz, 2004; Lentz and Haynes, 2004). hHcy has 
been reported to be accompanied by other abnormalities like cardiovascular diseases 
(Lawrence de Koning et al., 2003), osteoporosis (van Meurs et al., 2004), dislocation of 
ocular lens, neural tube defects and mental retardation (D'Angelo and Selhub, 1997; 
Selhub, 1999).  
The remethylation pathway required for Hcy metabolism could be impaired due to 
inadequate status of either folate or vitamin B12 or due to a defect in the gene encoding for 
N-5-methyltetrahydrofolate (MTHF) (Kang et al., 1988; Zhang et al., 2001a). Such genetic 
defect leads to a significant increase of Hcy in plasma. MTHFR deficiency might result 
from a point mutation, C to T substitution at nucleotide 677 (C677→T), in the open reading 
frame of MTHFR gene. This mutation causes substitution of valine for alanine in the 
functional enzyme, resulting in a thermolabile variant of the enzyme with decreased total 
activity (reviewed by Ji and Kaplowitz (2004)). The frequency of this mutation varies 
among ethnic groups with 13% of homozygous and 50% of heterozygous among Caucasian 
and Asian populations. On the other hand, impairment in the transsulphuration pathway 
could result from hetereozygous defects in CBS gene or insufficient levels of vitamin B6 
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(Kokame et al., 1996; Selhub and Miller, 1992). Several mutations in human CBS have 
been defined (D'Angelo and Selhub, 1997), the most frequent are T833→C and G919→A, 
located in the exon 8 and inherited as an autosomal recessive disorder, and 1224-2AC, 
which cause exon 12 to be deleted. Homozygous CBS deficiency is a rare syndrome which 
results in plasma Hcy concentration of up to 400µM and pleiotropic clinical manifestations, 
including mental retardation, ectopia lentis, osteoporosis, skeletal abnormalities and hepatic 
steatosis (reviewed by Ji and Kaplowitz (2004)). However, heterozygous CBS deficiency is 
relatively common with a prevalence of 1% of the population (Boers et al., 1985; Lawrence 
de Koning et al., 2003).  
Hcy concentration in the plasma may differ depending on which of these two 
pathways is defective. Several studies  reported that the worst complications were observed 
in patients with defective MTHFR (reviewed by D’Angelo and Selhub (1997)). 
Furthermore, although other studies reported that MTHFR-deficient mice have a similar 
basic phenotype to those with CBS-deficiency, they showed higher susceptibility to the 
development of  atherosclerosis (Chen et al., 2001b; Lawrence de Koning et al., 2003). 
Methylation is the main pathway for elimination of Hcy in human vascular tissues while 
transsulphuration pathway enzymes were shown not to be expressed in these tissues (Chen 
et al., 1999). That might explain the above described results by Chen et al (2001b) and 
Lawrence de Koning et al (2003). Toxicity of hHcy is a result of different Hcy metabolites 
like Hcy thiolactone (HcyT), S-nitroso-Hcy (Jakubowski, 2004) in addition to protein 
homocysteinylation which all may lead to protein damage either directly or indirectly 
(Jakubowski et al., 2000).  
30 
 
In addition to methylation and transsulphuration metabolic pathways of Hcy, 
intracellular Hcy could be converted by methionyl tRNA synthase to Hcy-AMP complex 
which is in turn catabolised to Hcy thiolactone, which could be considered as an alternative 
pathway for the conversion of Hcy into methionine (Medina et al., 2001) and indicates a 
sign of poor methylation of Hcy-tRNA to methionine-tRNA. Hcy thiolactone, due to its 
reactive properties, can lead to homocysteinylation of lysine residues and free amino 
groups of cellular protein decreasing their biological activity and causing them to degrade. 
Hcy thiolactone is also secreted into the circulation and causes modification of some 
plasma proteins which might contribute to liver and cardiovascular disorders (reviewed by 
Ji and Kaplowitz (2004)).  
1.1.5.4. Pathogenesis of Hcy effects 
1.1.5.4.1. Cardiovascular diseases and Hcy involvement 
Cardiovascular disease (CVD) refers to any disorder which affects the 
cardiovascular system and mainly to the atherosclerosis-related diseases such as myocardial 
infarction and stroke. Atherosclerosis is initiated at  the site of vascular injury on the level 
of EC (as explained in section 1.1.4), and progresses in a silent manner until the formation 
of stratified lesions in the arterial walls, which contain cholesterol, immune infiltrate and 
connective tissue elements (Braunersreuther et al., 2007), leading to acute events like heart 
attack (Lawrence de Koning et al., 2003). Different risk factors are involved in the progress 
of atherosclerosis such as gender (Jousilahti et al., 1999), lipid levels, diabetes, blood 
pressure, diet, smoking, alcohol (reviewed by Vinereanu (2006)). Some biomarkers also 
have been considered as risk factors including fibrinogen, homocysteine, asymmetric 
dimethylarginine (ADMA). All of these factors are known to cause EC damage and 
31 
 
dysfunction (Celermajer, 1997) and different pharmacologic approaches and diet changes 
have been suggested in order to reverse the damage of ECs (Mensah et al., 2007).  
hHcy was reported few decades ago to be involved in the development of CVD. In 
1964, Gerritsen and Waisman first reported a fatal pulmonary thromboembolism in a one 
year old child with hHcy (Gerritsen and Waisman, 1964). The second observation was 
made by McCully in 1969 when he reported the death of an infant with homocystinuria 
who had widespread severe arteriosclerosis (McCully, 1969). From these data, the Hcy 
theory of arteriosclerosis was formulated (McCully and Wilson, 1975). In 1976, Wilcken 
and Wilcken showed that, compared with normal subjects, those with coronary artery 
disease exhibited higher plasma Hcy levels following a challenge with oral methionine (up 
to 30µM of Hcy-Cys mixed disulfide) (Wilcken and Wilcken, 1976). Since that, a number 
of groups have shown that up to 40% of patients diagnosed with coronary, cardiovascular, 
or peripheral atherosclerosis have hHcy (D'Angelo and Selhub, 1997; Lawrence de Koning 
et al., 2003; Selhub et al., 1995) and it has been shown that mild increase in Hcy (3µM 
above normal range) may be associated with higher risk of atherosclerosis (Nygard et al., 
1998; Tsai et al., 1994), stroke (Lentz, 2005) and deep-vein thrombosis (den Heijer et al., 
1996). In addition, a decrease of 25% in Hcy has been associated with an estimated 10% 
lower risk for CVD or 20% less for stroke (Herrmann et al., 2003).  
Different circulating concentrations have been used to define hHcy, 15.8µM 
(Stampfer et al., 1992), 13.9µM (Joosten et al., 1993), 11.4µM for male and 10.4 µM for 
female (Selhub et al., 1995). Currently, the American Heart Association science advisory 
statement suggested that 10μM or less is a reasonable target for patients at high 
cardiovascular risk. However, a European expert panel has proposed a slightly higher target 
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level (13–15 μM) (reviewed by (Lentz and Haynes, 2004)). Different factors have been 
found to affect these suggested reference ranges for example, increasing age (Bates et al., 
1997; Selhub et al., 1999), low folate intake (Nygard et al., 1998), smoking and caffeine 
consumption.  
The contribution of Hcy to the onset of cardiovascular diseases has been explained 
by several pathogenesis mechanisms. The most widely accepted is the oxidative stress 
theory which will be discussed in detail in Chapter 4. hHcy has been found to induce 
several genetic alterations as Ling and Hajjar (2000) showed that when EC were treated 6 – 
42h with Hcy, these cells exhibited significantly increased steady state mRNA levels for the 
elongation factors (EF) EF-1α, β and δ, and a reduction in protein levels. EF1 is a 
transcription factor that appears to play a general role in cell growth, proliferation and 
differentiation (Proud, 1994). Outinen (1999) found that Hcy also alters the expression of 
number of genes, which are known to mediate cell growth and differentiation, for example 
GADD45, GAD153, ATF4, and YY1, suggesting that Hcy causes a dose-dependent 
decrease in DNA synthesis in HUVEC and so causes a dose-dependent decrease in EC 
growth. Furthermore, Dardik et al (2002) found that under physiologic flow conditions, 
Hcy influences gene/proteins mediating cytoskeleton organization, for example it up-
regulates profilin-I and down-regulates endothelial cell-cell adhesion molecule alpha-
catenin. 
Hcy was also suggested to interfere with the fibrin elimination process by impairing 
EC ability to generate plasmin in vitro (Chacko et al., 1998; Hajjar et al., 1998). 
Furthermore, different studies reported increased affinity of Lp(a) for fibrin and 
strengthened Lp(a) effect in the presence of homocysteine (Harpel et al., 1992; Sotiriou et 
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al., 2006). Collectively, Lp(a) induces recruitment of inflammatory cells to activated EC in 
addition to accumulation of fibrin and both effects help in the build up of the 
atherosclerotic plaque.  
Hcy has been implicated in ER stress through increasing the expression of several 
endoplasmic reticulum (ER) stress response genes like GRP78, GRP94, Herp and RTP (Ji 
and Kaplowitz, 2004; Kokame et al., 1996). Excess Hcy might disturb disulphide bond 
formation and protein folding leading to ER stress (Kokame et al., 1996; Outinen et al., 
1998; Outinen et al., 1999) and thus inducing the unfolded protein response (UPR) to 
enhance cell survival (reviewed by  Lawrence de Koning et al (2003)). However, failed 
UPR induction and prolonged ER stress can induce alteration in several cellular functions 
like dysregulation of lipid metabolism, apoptotic cell death, and inflammation which in turn 
might lead to vascular injury (reviewed by Austin et al (2004)). Furthermore, it has been 
suggested that Hcy-induced UPR leads to overproduction of ER lipid components and the 
accumulation of these products in affected cells (Lawrence de Koning et al., 2003). This 
suggestion was linked to the fact that lipid rich atherosclerotic lesions are developed in 
patients with hHcy despite their normal serum lipid levels. 
All of these possible mechanisms in addition to other contributing mechanisms like 
smooth muscle cell proliferation, increased collagen production and platelet aggregation 
might account for Hcy effects on increasing susceptibility to CVD. It could be said that one 
mechanism cannot account for the whole effects of Hcy and these mechanisms are working 
in parallel to induce the EC damage and the initiation of atherosclerosis. 
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1.1.5.4.2. Hcy lowering therapy in clinical trials 
Several clinical trials reviewed by Loscalzo (2006), such as vitamin intervention for 
stroke prevention (VISP) (Toole et al., 2004), the Norwegian vitamin trial (NORVIT) 
(Bonaa et al., 2006) and Heart outcomes prevention evaluation (HOPE) (Lonn et al., 2006) 
investigated the use of vitamin supplements, such as B6, B12 and folate, to enhance Hcy 
metabolism and therefore, to reduce its level to the normal range. However, these trials 
found that vitamin based lowering of plasma homocysteine was of no benefit in reducing 
cardiovascular risk. These findings contradict the findings of most published in vitro and in 
vivo studies about the positive correlation between Hcy and CVD.  
Different possible explanations could account for this controversy. Firstly, folic 
acid, which was used in these trials, can induce cell proliferation by inducing thymidine 
synthesis (Loscalzo, 2006). Therefore, folate might have the same effects in the 
atherosclerotic plaque, thus worsening the injury. In addition, the use of folate and vitamin 
B12 will enhance the remethylation of Hcy to methionine and thereafter, this methionine 
will be converted into SAM (Figure 5). SAM is an essential methyl donor for all 
methylation reactions in the cell (Lu, 2000). The increase in SAM level leads to increase in 
the methylation potential, which in turn increases cell proliferation, modifies gene 
expression and therefore, affects endothelial function. Collectively, all of these effects 
might contribute to the atherosclerotic plaque formation. Furthermore, methylation of l-
arginine will generate asymmetric
 
dimethylarginine ADMA which in turn, inhibits NOS 
and therefore decreases the bioavailable NO, which is associated with an increased risk of 
vascular disease (Boger, 2003; Boger et al., 2001). Another possible explanation for the 
low efficiency of vitamin lowering therapy in reversing Hcy effects could be due to EC, 
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after being chronically exposed to high level of Hcy in hyperhomocysteinemic patients, 
having developed some kind of sensitivity toward Hcy. Therefore, Hcy, even at low levels, 
due to vitamin treatment, may be still effective in keeping the EC activated. Alternatively, 
it could be suggested that chronic exposure to Hcy for many years might have induced 
irreversible damage to the EC, and therefore removing Hcy would not be able to restore EC 
functions. The outcomes of these clinical trials might highlight a fact that there is a need to 
develop other therapeutic approaches to treat the consequences of high Hcy levels, such as 
inhibition of the pathways involved in mediating Hcy effects or restoring normal function 
and/or structure of enzymes which have been altered by Hcy.  
1.1.5.4.3. Homocysteine and endothelial cell dysfunction 
The first in vivo evidence that Hcy can alter EC function and predispose to 
complications of vascular diseases was published in the JCI in 1996 (Lentz et al., 1996). 
They reported in monkeys with diet-induced hHcy that a two-fold increase in Hcy altered 
vasomotor regulatory function, EC anticoagulant function in addition to impairing 
endothelium-dependent vasodilation. A positive correlation between plasma homocysteine 
levels and age has since been demonstrated (Nygard et al., 1998). Subsequently, Xu et al 
showed that Hcy can accelerate aging, which is often defined as replicative senescence, in 
cultured human HUVEC through a redox-dependent pathway (Xu et al 2000) and it has 
also been shown to induce necrosis in HUVEC (Dong et al., 2005). Further studies using 
different models like genetic- or diet-induced hHcy in animal models and Hcy-treated EC 
in culture strongly support a relationship between hHcy and EC dysfunction (reviewed by 
Austin et al (2004)).  
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Because it has been proven that in the human cardiovascular system Hcy 
metabolism is limited to the remethylation pathway catalyzed by MS (Chen et al., 1999), 
atherosclerotic initiation could be due to either failure of these patients’ EC to detoxify 
endogenous Hcy due to lack of MS efficiency or from the direct toxicity of high 
concentrations of extracellular Hcy (Finkelstein, 1998). 
Several studies, reviewed by Jakubowski (2004), showed that Hcy has inhibitory 
effects on the growth rate of yeast and E. coli cells. Furthermore, Zhang et al found that 
Hcy does not support growth and induces apoptotic death in human EC (Zhang et al., 
2001a). Therefore, Jakubowski suggested that Hcy interferes with biological processes in 
different types of live cells with a common consequence of inhibiting their proliferation 
(Jakubowski, 2004). Even though some studies reported circulating ECs in the serum of 
patients with severe hHcy or after an oral dose of methionine (100mg/kg), suggesting EC 
death in response to Hcy (Hladovec et al., 1997), Outinen et al (1999) used relatively high 
concentrations of Hcy (≥ 10mM) in their study and that did not affect cell viability. They 
concluded that cultured EC from normal individuals are relatively resistant to high doses of 
Hcy. Although less than 1% of exogenous Hcy which was added to the media, was taken up 
intracellularly (Outinen et al., 1999; Stamler et al., 1993), even this has been shown to be 
enough to damage the cells (Cai et al., 2000; Ji and Kaplowitz, 2004; Kokame et al., 1996) 
and those studies suggested that intracellular Hcy is the main agent responsible for Hcy 
effects.  
It was believed previously that most Hcy biological effects could be mimicked by 
cysteine which has a higher susceptibility to thiol auto-oxidation (D'Angelo and Selhub, 
1997), and its normal concentration in plasma 20-25 fold higher than that of Hcy. However, 
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Wang et al (1997) was the first study to demonstrate that detrimental biological effects are 
specific to Hcy and that Cys does not have similar effects and that has been confirmed by 
later studies (Carmel and Jacobsen, 2001; Jacobsen, 2000; Sengupta et al., 2001) who 
found that EC incubation with cysteine has no detrimental effects on EC and cysteine 
should not be considered as a risk factor in atherosclerosis development. However, Hcy-
thiol group can perform disulfide exchange with cysteine residues in proteins. This S-
thiolation by Hcy will alter the function of different proteins which are critical for 
maintaining vascular function like albumin, fibronectin, transthyretin, factor V, and 
Annexin II (reviewed by Lentz (2005)). 
To summarize, Hcy appears to work through a variety of different mechanisms 
leading to EC dysfunction and thus initiating atherosclerosis plaque formation. However, 
the signalling pathway involved in mediating Hcy-induced effects in EC is still unclear. 
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1.2. JNK ROLE IN HCY-MEDIATED EC ACTIVATION 
1.2.1. Functional effects of cellular JNK activation  
JNK is a member of the MAP kinase family as already described in section 1.1.1.2 
and is involved in pivotal cellular functions like apoptosis (Tournier et al., 2000; Xia et al., 
1995), oncogenic transformation (Raitano et al., 1995), cell proliferation (Xu et al., 1996), 
EC activation and the development of atherosclerosis (Sumara et al., 2005). Several studies 
have been reviewed by Barr and Bogoyevitch (2001) and suggested that JNK might play a 
role in both cell death and in cell survival. It has been shown in PC12 neuronal-like cell line 
to be critical for the initiation of cell death following cellular insult (Xia et al., 1995). 
Conversely, it has been proposed that JNK might act to enhance cell survival following 
exposure to cell stress like in TNF-α-induced apoptosis (Roulston et al., 1998). Therefore, 
it could be concluded that the JNK pathway might mediate different consequences 
depending on cell type, stimuli and environmental circumstances (Hoshino et al., 2005). 
TNF-α is the best characterised JNK activator requiring TRAFs and IRE1s (Urano et al., 
2000). TRAFs are TNF receptor-activated factors and their effector function depends on the 
integrity of their NH2-terminal domain. IRE1s are ER-resident transmembrane kinases that 
function as ER stress sensor proteins and they sense stress through their conserved luminal 
domain and both of TRAFs and IREs are required for stress-induced JNK activation such as 
in the case of Hcy-induced JNK activation (Zhang et al., 2001b). 
Stress, like malfolded proteins or exposure to TNF-α, induces oligomerization and 
activation of inositol auxotrophy (IRE1) (Shamu and Walter, 1996; Urano et al., 2000) and 
that could lead to clustering of TRAF2 which is bound to the COOH-terminal cytoplasmic 
portion of  IRE1. Clustering of TRAF2 to the cytosolic side of the TNF receptor (Reinhard 
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et al., 1997) then activates proximal components of the JNK kinase
 
cascade which in turn 
leads to JNK activation (Figure 6). Therefore, it could be said that JNK activation in 
response to ER stress might occur through a similar pathway to that activated by TNF-α 
(Urano et al., 2000). Zhang et al (2001b) demonstrated that Hcy induces JNK activation 
downstream of IRE-1 and TRAF2 since inhibition of IRE-1 or TRAF-2 reversed Hcy 
effects on JNK activation. Activation of MAPK family members, including JNK, leads to 
activation of transcription factors which can result in immediate gene transcription of 
important cellular proteins and cytokines as well as MAP kinase phosphatase (MKPs) 
(Farooq and Zhou, 2004). MKP are a family of protein phosphatases that inactivate 
MAPKs through dephosphorylation of threonine and tyrosine residues within the active 
loop and thus work as a negative feedback mechanism for MAPK activity (Ralph and 
Morand, 2008). Those proteins have two distinct phospho-binding sites for the binding of 
p-tyrosine and p-threonine within the MAPK motif.  
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The effects of Hcy-induced ER stress and the subsequent activation of the JNK 
pathway 
 
 
 
Figure 6: Hcy induces ER stress which will be sensed by IRE-1, an ER stress 
sensor, and initiates a cascade of events including kinase cascade activation. That 
leads to activation of JNK and its downstream substrate c-Jun. Activated c-Jun has 
binding sites on the promoter of several genes and thus induces their expression. 
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1.2.2. JNK in atherosclerosis 
Different studies have shown JNK to be highly activated in atherosclerotic lesions 
in human (Nishio et al., 2001) and rabbits (Metzler et al., 2000). Furthermore, JNK2
-/-
 mice 
were shown to have reduced atherosclerosis (Ricci et al., 2004). JNK was also shown to 
mediate the up-regulation of different CAM in response to diverse stimuli (as explained in 
Chapter 2) and therefore mediating inflammatory responses. Collectively, that implicates 
JNK involvement in the atherosclerotic process. Atherosclerotic plaques can rupture and 
lead to further complications like coagulation and thrombosis (Lusis, 2000). Various 
proteases are involved in the degradation of the plaque including collagenases and matrix 
metalloproteins (MMPs). MMP9 is highly expressed in atherosclerotic plaques and JNK 
has been shown to be involved in the expression of MMP9 (Crowe et al., 2001). Therefore, 
in addition to being involved in the early stages of the formation of the plaque through 
mediating CAM expression, JNK is also involved in the late stages of atherosclerotic 
plaque rupture (reviewed by Sumara et al (2005)). 
1.2.3. JNK and Hcy-induced endothelial cell dysfunction  
Hcy has been shown to induce JNK activation in different cell types and that led to 
different consequences such as cardiomyocyte (Levrand et al., 2007) or VSMC apoptosis 
(Yuan et al., 2007), up-regulation of different proinflammatory mediators like IL-8 and 
MCP-1 in cultured human whole blood (Zeng et al., 2005) and cell adhesion molecules 
(Koga et al., 2002; Postea et al., 2006; Pruefer et al., 1999).  
The involvement of the JNK signalling pathway in Hcy-mediated activation of EC 
has been investigated in several studies. Acute exposure to Hcy was suggested to exert a 
cell type-specific inhibition of AP-1, downstream of JNK signalling pathway (Suzuki et al., 
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2000). Other studies showed that Hcy caused activation of JNK and induced apoptosis in 
HUVEC (Dong et al., 2005; Zhang et al., 2001b). Cai’s group also found that acute 
treatment for 8h with 3mM Hcy induced JNK phosphorylation in HUVEC (Cai et al., 
2000). Although it has been demonstrated that Hcy induces JNK activation, different 
mechanisms have been suggested and are still under investigation. Some investigators 
believe that ROS mediate the Hcy-induced activation of JNK in VSMC (Yuan et al., 2007). 
However, several studies reviewed by Lawrence de Koning et al (2003) suggested that Hcy 
interferes with disulphide bond formation in ER and thus induces ER stress which will 
trigger the kinase cascade leading to JNK actication (as previously shown in Figure 6). 
1.2.4. JNK as a target for therapeutic approaches  
A recent study gave evidence that knocking out JNK from animals provides some 
therapeutic advantages (Bogoyevitch, 2005). Furthermore, JNK2
-/-
 mice were shown to 
have reduced atherosclerosis (Ricci et al., 2004). SP600125, (anthra[1,9-cd] pyrazol-6 
(2H)-one), is a reversible, ATP-competitive inhibitor of JNK and has been shown to exhibit 
selectivity of > 20-fold relative to other tested kinases and an IC50 value of 40, 40, 90 nM 
for JNK1, JNK2 and JNK3 respectively (Bennett et al., 2001). SP600125 was found to 
inhibit JNK activity in mice for a short period (4 weeks) and to efficiently inhibit 
atherosclerosis (Ricci et al., 2004). The ATP-binding pockets of the JNK molecule provide 
an optimal binding environment for SP600125. However, in p38, which is not inhibited by 
SP600125, ATP-binding pockets appear larger and unable to provide suitable conditions 
for hydrophobic binding of SP600125 (all reviewed by Bogoyevitch (2005)). 
On the other hand, some other papers provided evidence that the specificity of 
SP600125 inhibitory effects towards JNK is still under debate (Bain et al., 2003). They 
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provided evidence that 13 more protein kinases are inhibited to the same or greater extent 
by SP600125. However, none of these kinases is thought to be involved in mediating the 
effects of proinflammatory cytokines or other stresses that lead to expression of different 
CAMs. 
To summarise, the JNK signalling pathway is highly suspected to mediate Hcy-
induced EC damage and targeting this pathway might provide a potential therapeutic 
approach to protect from atherosclerosis. However, the mechanism through which Hcy 
induces activation of JNK pathway and the subsequent effects under flow is still in debate. 
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1.3. THE ROLE OF OXIDATIVE STRESS IN HCY-MEDIATED EC 
ACTIVATION 
1.3.1. Reactive oxygen species in cell function and dysfunction 
Oxygen is an essential molecule for aerobic metabolism and one electron reduction 
of oxygen produces the highly reactive free radical superoxide anion (O2
•−
) (Sies, 1997). 
Superoxide production is spontaneous in the electron-rich aerobic environment in the 
vicinity of the inner mitochondrial membrane with the respiratory chain, however, it cannot 
penetrate lipid membranes and therefore is trapped where it was generated (Nordberg and 
Arner, 2001). The reduction of molecular oxygen via 1-electron transfer, produces 
superoxide anion and other radicals including OH-radicals and hydrogen peroxide which all 
belong to a family called the reactive oxygen species (ROS) (Nordberg and Arner, 2001):  
 
All of these molecules are known to be highly reactive due to the presence of 
unpaired valence shell electrons. ROS level is maintained by the balance between ROS-
generating mechanisms and the efficiency of antioxidant enzymes (explained in Figure 7). 
However, generation of high levels of ROS and/or impaired defective function of 
antioxidant defence system results in a cellular condition called oxidative stress (Sies, 
1997). 
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The enzyme systems involved in the production and elimination of  
reactive oxygen species 
 
Figure 7: (A) Overproduction of reactive oxygen species results in oxidative stress and 
superoxide dismutase catalyzes dismutation of superoxide into oxygen and hydrogen 
peroxide. (B) Enzymes which might be responsible for producing ROS. (C) Hydrogen 
peroxide can be detoxified via different enzymes: GSH: monomeric glutathione; GSSG: 
reduced glutathione; Trx: thioredoxin. Adapted from Forstermann (2008). 
 
ROS have been shown to exist in biological cells and tissues at low but measurable
 
concentrations (Droge, 2002) and different cell types like SMC, fibroblasts and EC have 
been shown to produce ROS at relatively low levels in response to extracellular signals or 
stimuli (reviewed by Kunsch and Medford (1999)). Different redox-sensitive transcriptional 
pathways have been described and ROS were suggested to play a role as second 
messengers to mediate signal transduction pathways which lead to gene expression and 
posttranslational modification of proteins (Kunsch and Medford, 1999; Zhang and 
Gutterman, 2007). They are also involved in regulating oxygen sensing, vascular tone, cell 
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growth and apoptosis (Droge, 2002). Furthermore, ROS play a vital role in killing invading 
bacteria, thus are a defence mechanism against infection (Nordberg and Arner, 2001). 
On the other hand, once ROS are produced in excess leading to oxidative stress 
conditions, they can readily react with most biomolecules, starting a chain of free radical 
formation. They also have detrimental effects that trigger alternative pathways and the 
transcription of several genes which leads to an altered expression of cytokines, 
chemokines and adhesion molecules (Papatheodorou and Weiss, 2007) and causes cell 
damage and toxicity (Kyaw et al., 2004). ROS can also induce DNA damage and chemical 
modification of DNA (Nordberg and Arner, 2001). They induce oxidation of low-density 
lipoproteins (LDL) which are then taken up by phagocytes forming foam cells in the 
earliest stage of atherosclerotic plaque formation (Lusis, 2000). 
The major sources of ROS are NADPH oxidase, xanthine oxidase, the enzymes of 
mitochondrial respiratory chain and uncoupled eNOS (Forstermann, 2008). NADPH 
oxidases are multicomponent enzymes that work in the membrane of vascular EC, SMC 
and fibroblasts and several studies have provided evidence of increased activity of the 
NADPH oxidase in atherosclerotic arteries (Sorescu et al., 2002). Furthermore, several 
studies reviewed by Forstermann (2008) have used genetic disruption of NADPH oxidase 
subunits and confirmed the role of NADPH oxidase-derived ROS in hypertension and 
atherosclerosis. Xanthine oxidase donates electrons to molecular oxygen and thus produces 
superoxide and hydrogen peroxide (Figure 7) (Forstermann, 2008). It is found membrane-
associated on EC and also found to be responsible for vascular oxidative reactions leading 
to endothelial dysfunction (Ullrich and Bachschmid, 2000). Two more sources of ROS 
have been also defined, eNOS uncoupling (to be discussed in detail in Chapter 5) and the 
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mitochondrial enzymes which are believed to reduce 1% of the oxygen that is consumed by 
mitochondria, forming superoxide (Forstermann, 2008). 
Several enzymes have been identified which protect from oxidative stress (reviewed 
by Forstermann (2008) and Nordberg and Arner (2001)) and illustrated in Figure 7 
including: superoxide dismutase (SOD) which catalyzes the dismutation of superoxide into 
oxygen and hydrogen peroxide. Catalases which catalyze the dismutation of hydrogen 
peroxide to water and molecular oxygen and also bind NADPH, which protects the enzyme 
from inactivation and increases its efficiency. Glutathione peroxidase (GPx) which reduces 
lipid hydroperoxides to their alcohol and reduces free hydrogen peroxide into water. Some 
studies indicate that GPx works as antioxidant under physiological conditions (Jones et al., 
1981), while others believe that the enzyme is important only in events of oxidative stress 
(Kelner and Bagnell, 1990). 
1.3.2. Oxidative stress and vascular endothelium 
Oxidative stress has been suggested to induce EC activation and dysfunction by 
altering different pathways (Cai and Harrison, 2000). The transcription factors NF-κB and 
AP-1 have been shown to be redox sensitive and to be regulated by intracellular redox state 
(Meyer et al., 1994) and these transcription factors are involved in the regulation of many 
genes such as ICAM-1, VCAM-1, E-selectin and MCP-1. All of the previous genes encode 
for different receptors and chemokines which play important roles in the initiation of 
healthy acute inflammation, but also atherosclerosis (Forstermann, 2008; Kunsch and 
Medford, 1999). Oxidative stress also has a very well established relationship with 
hypertension as angiotensin II signalling leads to NADPH oxidase up-regulation and 
activation resulting in oxidative stress (Zalba et al., 2001). Furthermore, ROS have been 
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shown to mediate activation of MAPK family members like p38 in cultured vascular SMC 
(Ushio-Fukai et al., 1998) and JNK in fibroblasts (Kamata et al., 2005) and both pathways 
are involved in the activation of several genes encoding proinflammatory cytokines and 
CAM (Chang and Karin, 2001). The relaxing factor NO also presents another target for 
ROS as under oxidative stress conditions, O2
•−
 might interact with NO decreasing its 
bioavailability and forming the very potent oxidant peroxynitrite which leads to impairment 
of endothelium-dependent vasorelaxation and activation of EC (Cai and Harrison, 2000). 
Lipid peroxidation is another target for ROS and, for example, oxidized LDL is very 
cytotoxic for EC and induces inflammatory cell recruitment to the endothelium; it also 
interacts with NO and decreases its bioavailability (Chin et al., 1992). All of the previously 
described ROS-altered pathways and genes work together to activate EC and promote the 
initiation of atherosclerosis.  
1.3.3. Homocysteine and oxidative stress-mediated vascular dysfunction 
Hcy interferes with redox signalling in EC and that contributes, at least in part, to 
Hcy-induced impairment of normal EC functions which leads to development of 
atherosclerosis (Papatheodorou and Weiss, 2007). Methionine loading induced 
homocysteinemia in healthy donors leading to EC damage (Bellamy et al., 1998; Chambers 
et al., 1998; Kanani et al., 1999). The previous groups characterized EC damage by 
reporting impaired brachial artery flow-mediated dilatation which is known to be mediated 
by endothelial NO and that suggested impaired endothelial NO activity in healthy 
individuals during acute hHcy. These effects were reversed by administering vitamin C, a 
ROS scavenger (Kanani et al., 1999), suggesting that Hcy effects were mediated by ROS. 
Different mechanisms have been suggested to explain how Hcy may increase ROS in 
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vascular cells and tissues (Figure 8). Auto-oxidation of the thiol group in Hcy will generate 
superoxide anions (O2
•−
) (Misra, 1974).  
2RSH + O2 → RSSR + [O2
•−] → H2O2 
RSH: Hcy and RSSR: homocystine 
Hcy was suggested also to disturb eNOS efficiency by reduction of its cofactor 
tetrahydrobiopterin (BH4) leading to eNOS uncoupling which will start generating 
superoxide anions instead of NO (Heydrick et al., 2004) (this theory will be discussed in 
more detail in Chapter 5). Hcy has been suggested also to inhibit or alter the efficiency of 
antioxidant enzymes in BAEC like cellular haem oxygenase 1 (Sawle et al., 2001) or 
cellular glutathione peroxidase (Handy et al., 2005). Hcy also has been shown to decrease 
the activity and steady-state mRNA levels of glutathione peroxidase in BAEC (Loscalzo, 
1996; Upchurch et al., 1997) and to suppress the expression of glutathione peroxidase in 
HUVEC (Outinen et al., 1999). Furthermore,  the presence of copper ions was suggested to 
be essential for Hcy to cause oxidative cell injury and suppress glutathione peroxidase and 
superoxide dismutase in HUVEC (Zhang et al., 2001a). Collectively, Hcy promotes 
endothelial dysfunction by indirectly impairing the endothelial antioxidant defence 
mechanism and inducing oxidative stress.  
Dong et al found that acute treatment with Hcy induced ROS generation in HUVEC 
which they suggested to be mediated by NADPH oxidase and/or JNK (Dong et al., 2005). 
Several other studies also reported that Hcy induces NADPH oxidase activity. It was 
suggested this was by activating de novo synthesis of ceramide which stimulates Rac 
GTPase activity in rat mesangial cells (Yi et al., 2007; Yi et al., 2004). Another group 
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(Edirimanne et al., 2007) showed in rats that overloading with methionine markedly 
induced NADPH oxidase activity, particularly p22
phox
 which was responsible for increased 
production of superoxide anion, as apocynin (NADPH oxidase inhibitor) managed to 
reverse these effects. Furthermore, administration of apocynine restored endothelium-
dependent relaxation in the aortas of hHcy rats (Edirimanne et al., 2007). Hcy was also 
shown to induce stimulation of NADPH oxidase p47
phox
 and p67
phox
 subunits in monocytes 
(Siow et al., 2006) and neutrophils (Alvarez-Maqueda et al., 2004). Data from these studies 
indicate the importance of NADPH oxidase in mediating Hcy-induced oxidative stress in 
different vascular cells. 
Extracellular superoxide dismutase (SOD) from the endothelial surface was 
suggested to be a target for Hcy interference (Wilcken et al., 2000). SOD has a Cys residue 
at the active site which might form disulfide bonds with the free thiol group of Hcy and 
thus inhibit the enzyme activity (Atmaca, 2004). Interestingly enough, one study found that 
hHcy was associated with elevated levels of extracellular SOD suggesting a protective role 
of extracellular SOD against the oxidant effects associated with hHcy (Wilcken et al., 
2000). Furthermore, Hcy was shown to activate NADPH oxidase which is the main source 
of O2
•−
 in vascular cells (Alvarez-Maqueda et al., 2004; Dong et al., 2005; Ungvari et al., 
2003).  
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Figure 8: Pathways through which Hcy induces generation of ROS and the 
consequences of these ROS. Expanded from Papatheodorou and Weiss (2007). 
 
Some studies (Ballinger et al., 2002; Ide et al., 2001) have demonstrated that 
increased generation of ROS is associated with mitochondrial damage on different levels: 
increased lipid peroxidation in mitochondria, decreased mitochondrial DNA copy number, 
decreased mitochondrial RNA transcripts and reduced oxidative capacity due to low 
enzyme activity. Mitochondrial DNA can easily be damaged by ROS and the mutated 
mitochondrial DNA accelerates ageing and the development of CVD (Ballinger et al., 
2002; Lim et al., 2001). Furthermore, Hcy-induced ROS act as upstream factors for 
mitochondrial membrane depolarization (Tyagi et al., 2006). This group found, in rat heart 
microvascular EC, that Hcy-induced ROS generation causes mitochondrial membrane 
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depolarization, cytochrome-c release and activation of caspase-9 therefore leading to EC 
apoptosis (Tyagi et al., 2006). It is highly likely that all of these mechanisms, or at least 
some of them, work synergistically to mediate Hcy-induced oxidative stress in EC. 
However, the effects of chronic Hcy-induced oxidative stress have not yet been illustrated 
and also the mechanism by which ROS mediate Hcy atherogenic effects is not fully 
addressed. 
1.3.4. The efficiency of antioxidant treatment 
Antioxidants could be divided into two major groups, enzymatic (explained earlier 
in section 1.3.1) and non enzymatic antioxidants. Non-enzymatic antioxidants have been 
widely used in different in vivo and in vitro studies like vitamin C (Yamashita et al., 2005), 
vitamin E (Kerkeni et al., 2006), glutathione and NAC (Takacs et al., 2001) to overcome 
oxidative stress and retrieve normal cell conditions. Two different non-enzymatic 
antioxidants, vitamin C and NAC, were used in this thesis to confirm that any effects are 
due to ROS scavenging and not to any interactions with Hcy. 
1.3.4.1. N-acetyl Cysteine  
N-acetyl Cysteine (NAC) could be derived from food or produced within the human 
body from Cys and is rapidly metabolized to intracellular glutathione which acts as a 
powerful antioxidant in the body (Atmaca, 2004). Synthesis of the antioxidant glutathione 
requires three amino acids, glutamic acid, glycine and Cys. Both glutamic acid and glycine 
are plentiful in cells and therefore the availability of Cys controls glutathione production 
(Atmaca, 2004). NAC enters the cell and is readily hydrolyzed to Cys thus inducing the 
production of glutathione (Sochman, 2002). NAC was shown to inhibit NF-κB activation in 
HUVEC cultured with plasma from women with severe preeclampsia (Takacs et al., 2001). 
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The effect was shown to be through scavenging ROS which are known to activate NF-κB 
and also block the expression of ICAM-1 mediated by NF-κB. NAC was also shown to 
inhibit TNF-α-induced cytokine expression like IL-8 and MCP-1 in human synovial cells 
(Sato et al., 1996). Furthermore, NAC was shown to block TNF-α-induced JNK activation 
in a transformed EC cell line (ECV-304) (Gu et al., 2002) and also could reduce 
peroxynitrite formation by direct reaction of thiol group in NAC and NO to produce 
nitrothiol compounds (Atmaca, 2004). NAC was also suggested to form disulphide bonds 
with thiol-containing molecules like Hcy, increasing their renal clearance efficiency 
(Ventura et al., 1999). Ventura’s study showed that single intravenous administration of 
NAC to healthy subjects induces an efficient and rapid clearance of plasma thiols like Hcy 
and therefore, decreases plasma levels of the reduced form of Hcy which has the 
deleterious consequences. 
1.3.4.2. Vitamin C  
Vitamin C primarily exists as ascorbic acid (a reduced form) in human plasma and 
is the most effective water soluble antioxidant in human plasma (Forstermann, 2008; 
Yamashita et al., 2005). In HUVEC, Hcy was shown to be involved in the reduction of 
dehydroascorbic acid, the oxidized form of ascorbic acid, to ascorbic acid and in the 
meantime homocysteine is oxidized to homocystine (Park, 2001): 
 
The authors mixed the two compounds in HEPES/phosphate buffer and the 
interaction happened very quickly within 3min. They believe that this interaction reduces 
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the deleterious effects of homocysteine (Park, 2001). Park believes that homocysteine and 
homocystine are in a steady state equilibrium and the reduction of dehydroascorbic acid to 
ascorbic acid can shift this equilibrium toward producing homocystine which was thought 
to be not as harmful as Hcy (Cai et al., 2000). However, another study found that 
homocystine has the same deleterious effects as Hcy (Heydrick et al., 2004) which 
contradicts Park’s findings and indicates that vitamin C effects are due to scavenging ROS 
and not due to any effects on a Hcy/homocystine equilibrium. Several reports illustrated 
that acute administration of vitamin C reduced oxidative stress and reversed Hcy coronary 
effects in patients with experimentally induced hHcy (Yamashita et al., 2005) and other 
groups found that vitamin C administration (1g per day) blocked the EC dysfunction which 
was induced by oral methionine load (100mg/kg) in human subjects (Chambers et al., 
1999; Nappo et al., 1999). Furthermore, vitamin C and vitamin E reduced Hcy-induced 
apoptosis in HUVEC by 45% (Kerkeni et al., 2006). 
Vitamin C protects NO levels by scavenging ROS or preventing oxidized LDL 
formation and thus preserving NO bioavailability. Some other studies suggest that vitamin 
C enhances the availability and stability of BH4 or increases its affinity to eNOS and 
therefore vitamin C restores EC function by restoring BH4 and thus restoring eNOS activity 
rather than just scavenging ROS (Heller et al., 2001). However, other antioxidants like 
vitamin E can become a radical itself and that could limit its efficiency as an antioxidant in 
vivo (Forstermann, 2008).  
1.3.4.3. Antioxidants in clinical trials 
All the in vivo and in vitro studies described above demonstrated the efficiency of 
antioxidants in reversing endothelial damage and preventing development of 
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atherosclerosis. Furthermore, some studies found inverse relationship between CVD and 
plasma levels of vitamins E and C (Gey et al., 1991; Su et al., 1998). These encouraging 
findings lead to different randomised clinical trials that have been conducted using 
antioxidants to study whether scavenging ROS might have any therapeutic benefits in 
patients with high risk of CVD. However, no beneficial effect was noticed from vitamin C 
supplementation in terms of reducing the risk of coronary diseases or cardiovascular 
morbidity or mortality (Paolini et al., 2003). Furthermore, randomized trials reviewed by 
Stanner et al (2004) have failed to show any consistent benefit from the use of antioxidant 
supplements on CVD where they used single antioxidant nutrients given at relatively high 
doses. Forstermann in his review (Forstermann, 2008) summarizes some potential reasons 
for the lack of effects of antioxidants in clinical trials. Inappropriate dosing might lead to 
insufficient supplement of the antioxidant and therefore they won’t be able to overcome the 
oxidative stress situation. Furthermore, Forstermann explains that vitamin C and vitamin E 
interaction with superoxide happens at a rate constant of 4-5 times of magnitude lower than 
the rate constant of the reaction between NO and superoxide. Furthermore, those 
antioxidants have no effects on hydrogen peroxide or hypochlorous acid which both might 
be involved in vascular damage (Forstermann, 2008). More studies are needed to explain 
the lack of efficiency of antioxidants in clinical trials and to identify possible combinations 
of these antioxidants which might help to improve the efficiency of the treatment.  
To summarize, it is clear that chronic Hcy induces oxidative stress in EC which was 
responsible for activating JNK pathway and all the subsequent effects under static and flow 
conditions. However, the source of Hcy-induced ROS production is still unclear. 
 
56 
 
1.4. THE ROLE OF NITRIC OXIDE AND NITRIC OXIDE SYNTHASE 
IN HCY-MEDIATED ATHEROGENIC EFFECTS 
1.4.1. Nitric oxide biology 
Nitric oxide is one of the smallest molecules found in nature consisting of one atom 
of nitrogen and one atom of oxygen which results in unpaired electron making NO a radical 
(Lincoln et al., 1997). NO has been studied intensively as a key factor in the functions of 
EC and also has antiatherosclerotic properties including SMC relaxation reducing vascular 
tone, inhibition of platelet aggregation and inhibition of leukocyte adhesion (reviewed by 
Naseem (2005)). It has been also reported that NO can inhibit LDL oxidation by reacting 
with lipid peroxyl radicals (Rubbo et al., 1994). Furthermore, NO has been studied as a 
potential therapeutic agent and NO donors like nitroglycerine are being used in protection 
from myocardial infarction and other CVD complications (Gryglewski and Minuz, 2001). 
In biological systems, NO has a very short half-life of about 30s and, as it is 
uncharged, it diffuses within cells and across membranes. NO is synthesized from the 
amino acid L-arginine in a reaction which is mediated by the enzyme nitric oxide synthase 
(NOS). In addition to L-arginine and NOS, cofactors required for NO synthesis are: 
calcium/calmodulin, BH4, haem, flavin adenine dinucleotide (FAD) and flavin 
mononucleotide (FMN) (Butler and Nicholson, 2003) (Figure 9). A lack of any of these 
factors will negatively affect the efficiency of NO production. NOS is synthesized as a 
monomer and includes a reductase domain and oxygenase domain that carries a haem 
group. Monomers can bind neither the substrate L-arginine nor the cofactor BH4 and 
therefore cannot catalyze NO production. The haem allows the active NOS dimer to be 
formed and plays a major role in the interaction between the reductase and oxygenase 
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domains and the electron flow from the flavin to the haem of the opposite monomer. In the 
presence of sufficient L-arginine and BH4, NOS dimers couple their haem and start 
synthesizing NO and the byproduct L- citrulline (Forstermann and Munzel, 2006) (Figure 
9). Three different isoforms of NOS have been identified and are named in accordance to 
the location where they were first found, endothelial NOS (eNOS) in endothelial cells, 
neuronal NOS (nNOS) in the brain and the inducible form (iNOS) in macrophages. These 
isoforms are also known as NOS-3, NOS-1 and NOS-2 respectively (Alderton et al., 2001). 
Reactive nitrogen species (RNS) are nitrogenous products includes in addition to 
NO, compounds like nitrogen dioxide (NO2) which are produced by NOS. These products 
have chemical and biological properties and can cause nitrosation and nitration of different 
molecules leading to nitrosative stress. Furthermore, ROS and RNS can work 
synergistically and produce compounds which exert both oxidant and nitrosative activities 
like ONOO
- 
(reviewed by Shen and Liu (2006)).  
 
  
58 
 
The structure of eNOS and the production of NO 
 
 
Figure 9: eNOS structure and the catalysis of NO production. (A): monomeric structure. 
(B): dimeric structure, the haem allows the active NOS dimer to be formed. Haem plays a 
major role in the interaction between reductase and oxygenase domains and the electron 
flow from the flavin to the haem of the opposite monomer. Once sufficient L-arginine 
and BH4 are present, NOS dimers couple their haem and start synthesizing NO and the 
byproduct L-citrulline (C). Adapted from Forstermann and Munzel (2006). 
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1.4.2. Nitric oxide and endothelial cells 
NO can be synthesized by different cell types where it can control different 
physiological processes and this thesis will focus on the NO produced by EC. eNOS is the 
main enzyme in EC responsible for NO production. However, there is some evidence that 
iNOS can be expressed in EC and induces NO generation in response to some stimuli 
(Kroll and Waltenberger, 1998). NO action is via two different mechanisms, the first one 
happens via activating soluble guanylyl cyclase (sGC) and the production of cGMP 
(Schlossmann et al., 2003), while the second mechanism depends on NO ability to cause 
nitrosylation of some target proteins altering their efficiency (Lowenstein, 2007). 
1.4.2.1. cGMP-dependent effects 
NO binds to the iron of the haem at the active site of sGC inducing its activation to 
generate the cGMP. cGMP activates different proteins like cGMP-dependent protein 
kinases which regulates vascular tone and platelet aggregation. These kinases are thought to 
reduce intracellular calcium release and lower the calcium sensitivity of the contractile 
apparatus leading to vasorelaxation in SMC (reviewed by Schlossmann et al (2003)). 
1.4.2.2. Nitrosylation 
Nitrosylation has emerged as a posttranslational modification of signalling proteins 
(Derakhshan et al., 2007). It happens when the free sulfur atom from Cys or Hcy residues 
reacts with NO resulting in S-nitrosothiol moieties (Gaston et al., 2003). In proteins which 
are known to undergo significant nitrosylation, it is noted that only one out of many Cys 
residues undergoes a detectable level of NO addition (Derakhshan et al., 2007). Several 
studies reviewed by Lowenstein (2007) showed that NO interferes with protein trafficking 
from the Golgi apparatus to the plasma membrane and from the plasma membrane to the 
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endosome. Some proteins show higher susceptibility for nitrosylation than others and 
Jaffrey’s group suggested a possible explanation could be because they contain a higher 
number of cysteine residues (Jaffrey et al., 2001). However, this group were unable to 
detect nitrosylation by endogenously produced NO which might be due to the fact 
nitrosylated proteins present at low levels compared to nitrosothiols which are formed after 
treatment with exogenous NO donors. The effects of nitrosylation vary between different 
proteins. It up-regulates Ras and the ryanodine receptor (Derakhshan et al., 2007; Sun et 
al., 2001) as well as down-regulating the activity of caspase-3 in EC (Hoffmann et al., 
2003), JNK in murine macrophages and microglial cells (Park et al., 2000a) and NF-κB in 
human respiratory cells and murine macrophages (Marshall and Stamler, 2001). Some of 
these effects, such as down-regulating JNK and NF-κB, suggest atheroprotective effects of 
NO via nitrosylation and hence these effects of NO may present another way to control 
inflammation and thrombosis. Therefore, endothelial cellular ability to synthesize NO is 
key for maintaining healthy vessel tone, haemostasis and reducing leukocyte adhesion and 
blood pressure (Naseem, 2005). 
1.4.3. Anti-inflammatory effects of NO in EC 
Exposure of HUVEC to shear stress (15 dynes/cm
2
, 24h) increased the overall 
content of S-nitrosylated proteins in a time dependent manner, reaching a maximum after 
24h (Hoffmann et al., 2003). Therefore, Hoffmann’s group concluded that shear-stress 
induced production of NO which in turn induces nitrosylation of specific signaling proteins 
might represent an atheroprotective mechanism of shear stress. Nitrosylation effects vary 
between different targets and the consequences have attracted lots of attention in the past 
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few years as a mechanism by which NO regulates the pathways that control different 
cellular functions.  
1.4.3.1. NO regulates CAM expression 
NO has been suggested to be involved in regulating CAM expression as a way to 
control inflammatory responses and limit EC activation (Takahashi et al., 1996). However, 
effects of NO on CAMs vary between different molecules and different cells. NO was 
shown to suppress VCAM-1 expression (Khan et al., 1996; Takahashi et al., 1996; 
Zampolli et al., 2000) in cytokine-stimulated EC. Information about NO effects on ICAM-1 
expression is still contradictory as NO donors were reported to inhibit ICAM-1 expression 
in cytokine-stimulated human EC (Spiecker et al., 1998; Takahashi et al., 1996), while 
another study found that NO donors didn’t have any effects on lipopolysaccharide-induced 
ICAM-1 expression in HUVEC (Kosonen et al., 2000). Furthermore, other studies have 
demonstrated that NO suppresses P-selectin expression at the transcriptional level in 
cultured human iliac endothelial cells (Armstead et al., 1997) and in vivo in mice (Gauthier 
et al., 1994). Some of these studies demonstrated that, unlike other NO cardiovascular 
effects discussed earlier, NO-mediated CAM down-regulation was cGMP-independent 
(Spiecker et al., 1998; Takahashi et al., 1996). Furthermore, Conran et al postulated that 
endogenously produced NO inhibits the expression of VLA-4-integrin on the neutrophil 
surface in a cGMP-independent manner and thus inhibits the adhesion of neutrophils to 
extracellular matrix components (Conran et al., 2003). Furthermore, Adams et al showed in 
cultured HUVEC that L-arginine reduces monocyte adhesion to EC. This effect was 
associated with decreased endothelial expression of ICAM-1 and VCAM-1 (Adams et al., 
1997).  
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NF-κB is a transcription factor required for some CAM expression and its activation 
by cytokines such as TNF-α is thought to occur, in part, via ROS. It is believed that NO 
inhibits NF-κB, at least in part through scavenging and inactivating the superoxide anion, 
and that accounts for NO inhibitory effects on these CAMs in cytokine-stimulated EC 
(Conran et al., 2003; Khan et al., 1996). NO was also suggested to S-nitrosylate NF-κB and 
thus inhibit its activity which in turn leads to down-regulation of CAM expression 
(Marshall and Stamler, 2001). Collectively, it could be said that suppressing the expression 
of such CAM leads to inhibition of adhesion of neutrophils to EC and thus contributes to 
the prevention of the development of atherosclerotic lesions in vivo.  
Nitrosylation of some key signalling proteins like JNK (Park et al., 2000a) or 
transcription factors like NF-κB (Marshall and Stamler, 2001) might be responsible for the 
NO-mediated down-regulation of some CAM. Furthermore, certain thiol groups on EC 
surface are thought to contribute to normal EC:leukocyte adhesion. Those thiol groups were 
suggested to be nitrosylated by RNS which will inhibit their contribution to EC:leukocyte 
interactions and thus disturb the inflammatory response (reviewed by Hall et al (2000)). 
These effects of NO are thought to be related to its actual interaction with Cys residues in a 
range of proteins to form s-nitrosothiols and that the common NO downstream cGMP is not 
involved in this mechanism (Gaston et al., 2003). 
On the other hand, a study showed that both IL-1β and histamine-induced P-selectin 
expression in HUVEC were down-regulated by activation of sGC and therefore the 
production of cGMP (using BAY 41-2272) while activating sGC had no effects on IL-1β-
induced E-selectin or ICAM-1 expression (Ahluwalia et al., 2004). Furthermore, they 
reported that eNOS knockout mice showed increased leukocyte rolling and adhesion. 
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However, activating sGC and the subsequent production of cGMP inhibited leukocyte 
adhesion in the eNOS knockout mice. The anti-leukocyte effect was noticed immediately 
after treatment, meaning it cannot be a result of decreased selectin mRNA production and 
Ahluwalia’s group suggested this effect was a rapid reversal of the proadhesive activity of 
the relevant adhesion molecule by an as yet unknown mechanism.  
1.4.3.2. Weibel -Palade body (WPB) exocytosis and nitrosylation  
WPB exocytosis allows delivery of their contents of P-selectin and vWF to the cell 
surface and this process involves a series of discrete stages (Lowenstein et al., 2005). In the 
Golgi apparatus, the WPB granule is loaded with vWF and P-selectin before leaving the 
Golgi. The granule is directed by kinesin along a network of microtubules to the plasma 
membrane where one molecule of vesicle SNARE (v-SNARE) protein on the granule 
membrane interacts with two target-SNARE (t-SNARE) proteins on the plasma membrane 
leading to granule docking with the plasma membrane and it becoming primed for fusion. 
The complex of three SNARE molecules specifies which vesicle will fuse with a particular 
membrane (Figure 10). An influx of calcium then triggers fusion of the granule and 
cytoplasmic membranes, causing exocytosis. N-ethylmaleimide sensitive factor (NSF) is a 
protein superfamily that is involved in regulating exocytosis. NSF primes the granule for 
fusion, facilitates empty granule recycling, or may mediate both processes (reviewed by 
Lowenstein (2007) and Lowenstein et al (2005)). The formation of the ternary SNARE 
complex is a key step in vesicle trafficking, and different proteins accelerate the formation 
of this complex like Sec/Munc proteins, whereas NSF converts the chemical energy of ATP 
hydrolysis into mechanical energy to disassemble the SNARE complex (reviewed by 
Lowenstein (2007)). Several factors which trigger EC exocytosis were reviewed by 
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Lowenstein et al 2005 and they suggested that EC exocytosis is a final common pathway 
by which EC responds to injury. Interfering with WPB exocytosis has important 
consequences concerning P-selectin expression and thus the interactions between 
leukocytes and EC. Different compounds can inhibit WPB exocytosis, like H2O2 and NO 
(Lowenstein et al., 2005), thus limiting, at least in part, the vascular inflammation. 
Lowenstein’s group suggested that H2O2 inhibits WPB exocytosis in cultured EC by 
inhibiting the ATPase activity of NSF. It has been suggested by the same group and others, 
that NO nitrosylates NSF protein in HAEC (Matsushita et al., 2003) and in platelets 
(Morrell et al., 2005)  thus inhibiting its activity and therefore preventing WPB exocytosis. 
Therefore, it could be concluded that NSF activity is redox sensitive and in the presence of 
physiological levels of oxidants, NSF controls exocytosis, therefore limiting leukocyte 
trafficking and the inflammatory response. 
WPB exocytosis and the role of NO in regulating this process 
 
 
Figure 10: WPB exocytosis. Several protein superfamilies are involved in the exocytosis. 
NSF can be nitrosylated by NO which will inhibit their activity and therefore inhibit 
WPB exocytosis. Adapted from Lowenstein (2007). 
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1.4.3.3. JNK nitrosylation 
JNK has a cysteine residue (Cys
116
 in JNK1) which is sensitive to thiol-modifying 
agents, like nitrosylating agents (Park et al., 2000b). This cys
116
 is conserved only among 
the JNK subgroup of MAP kinases which might mean that NO may specifically repress 
JNK activity by nitrosylation  (Hall et al., 2000). 
Some researchers believe that RNS might inhibit the activity of JNK by S-
nitrosylating the thiol group of JNK as endogenously produced NO has been shown to 
inhibit JNK activation in macrophages (Park et al., 2000a). Another study showed that c-
Jun, which is the main substrate of JNK and an important component of the AP-1 
transcription factor, could be also nitrosylated which will inhibit its DNA binding activity 
(Klatt et al., 1999). Furthermore, in HEK293 cells, NO was shown to directly interact with 
JNK1 causing suppression of this kinase (Park et al., 2006). The authors illustrated that the 
mechanism of this suppression is cGMP-independent but that it is thiol-redox-sensitive, 
involving nitrosylation of Cys
116
 on JNK1. This contrasts with a study in mice which found 
that cGMP accounts for the anti-adhesive effects of NO (Ahluwalia et al., 2004). 
Nitrosylation was also proposed to cause either steric constraint or unfavourable packing 
within the active site of JNK which ultimately disrupts the network of hydrogen bonds 
between JNK1 and the ATP molecule, preventing JNK using ATP for the phosphotransfer 
reaction (Hall et al., 2000). 
Others studies reviewed by Shen and Liu (2006) provided evidence that different 
RNS such as NO or ONOO
−
 can induce the activity of JNK. It could be said that the actual 
effects of RNS on JNK depend on different factors like the actual RNS species, their 
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concentration, cell types and the presence of other stressing factors like ROS (Shen and 
Liu, 2006). 
The effects of NO in modulating CAM expression are well established but the 
mechanism is still under debate. However, nitrosylation of some key proteins might play an 
important role in inhibiting CAM synthesis through JNK or NF-κB nitrosylation and/or 
modulation of CAM expression through inhibition of WPB exocytosis. 
1.4.4. The relation between Hcy and NO 
The bioavailability of NO is highly affected by Hcy levels (Stuhlinger et al., 2001; 
Upchurch et al., 1997) and Hcy-induced ROS consume NO and form the damaging 
peroxynitrite  (Dayal et al., 2002; Jacobsen, 2000; Lawrence de Koning et al., 2003; Lim et 
al., 2001; Loscalzo, 1996). However, the effects are on bioavailability as studies show that 
expression of eNOS is not suppressed by Hcy (Upchurch et al., 1997; Zhang et al., 2000). 
ADMA is an L-arginine analogue that acts as a competitive inhibitor of eNOS and therefore 
inhibits NO production (Boger, 2003). ADMA is metabolized to citrulline in an interaction 
which is catalyzed by an enzyme called dimethylarginine dimethylaminohydrolase 
(DDAH) (Boger, 2003). DDAH contains sulfhydryl groups in the Cys residues of its amino 
acid sequence which are critical for the enzyme’s functionality and are thought to be a 
potential target for Hcy interference through forming disulfide bonds, inactivating DDAH 
(Stuhlinger et al., 2001). Hcy was reported to inhibit DDAH in BAEC (Stuhlinger et al., 
2001). Furthermore, other studies in humans and animals reviewed by Dayal and Lentz 
(2005) reported that Hcy inhibits DDAH expression and activity leading to accumulation of 
ADMA and therefore inhibition of NO production (Boger, 2003; Boger et al., 2001; Dayal 
and Lentz, 2005). 
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The relationship between NO and Hcy is complex however, as nitrosylation of Hcy 
by NO prevents it from generating ROS and from cyclizing to form thiolactone (Carmel 
and Jacobsen, 2001) a molecule which has deleterious effect 2-4 times greater than Hcy 
(Kerkeni et al., 2006). Therefore, NO reduces the atherogenecity of Hcy. 
 
S-nitrosothiols (SNO) have a broad spectrum of antiatherogenic properties (Stamler 
et al., 1993). This group hypothesized that Hcy and NO exist in a balance within a healthy 
vascular system and the effects of Hcy may be tightly regulated by production of NO from 
endothelium, which converts it to S-nitrosohomocysteine. However, high levels of Hcy will 
result in theolactone formation leading to oxidative stress and ROS scavenging NO and 
leading to an imbalance between Hcy and NO levels. The end result could be uncontrolled 
Hcy production and decreased S-nitrosohomocysteine. Finally, Carmel and Jacobsen 
(2001) suggested that NO converts Hcy from “pathological mediator into physiological 
weapon” against atherosclerosis and they postulated that the ratio of NO to Hcy provides a 
better marker for atherogenic plasma than total Hcy in plasma (Carmel and Jacobsen, 
2001). On the other hand, different studies reported that NO down-regulates MS in rat liver 
(Nicolaou et al., 1997), platelets (Nicolaou et al., 1994a) and rat brain synaptosomes 
(Nicolaou et al., 1994b). MS was reported as a key enzyme in Hcy remethylation pathway 
(Lawrence de Koning et al., 2003). Therefore, it has been suggested that this inhibition 
breaks the Hcy remethylation pathway thus leading to Hcy accumulation. Furthermore, this 
inhibition leads to a decrease in the SAM level and therefore affects metabolic pathways 
and metabolite levels that mediate signal transduction. Nicolaou’s group demonstrated that 
these results might explain the cytotoxic effects of NO in CVD once present in excess and 
R-SH NO R-SNO H+ e-+ + + 
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also suggested a different kind of relationship between NO and Hcy where NO works as 
promoter for Hcy accumulation. However, none of these studies investigated the effects of 
accumulating Hcy on the studied cells.  
These data could be merged together in a possible theory, under healthy conditions 
(Figure 11), NO which is produced moderately in EC regulates the MS activity thus 
maintaining balanced remethylation of Hcy. On the other hand Hcy might play a role as a 
negative regulator of NO production by controlling eNOS activity (via direct disulphide 
bond formation or interference with ADMA) in order to avoid NO overproduction thus 
avoiding MS inhibition and Hcy accumulation. Once NO is produced in excess (Figure 11), 
it will inhibit MS leading to accumulation of Hcy. Two possibilities arise here, NO might 
interact with the excess Hcy forming S-nitrosothiols and therefore overcoming the 
atherogenic effects of excess Hcy. If NO was not able to overcome overproduced Hcy, then 
this Hcy might induce ROS production which will interact with NO forming peroxynitrite 
which will be responsible for different atherogenic effects. The relationship between Hcy 
and NO is very complicated and still needs further investigation.  
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Figure 11: The relation between Hcy and NO under healthy and unhealthy conditions. 
 
 
  
70 
 
1.4.5. eNOS uncoupling 
Under a number of pathological conditions, NOS enzymatic activity is disturbed 
and NOS starts producing O2
•−
 at the expense of NO. This phenomenon is termed NOS 
uncoupling (Xia et al., 1998). Xia’s group showed that O2
•−
 generation by eNOS is still a 
calcium/calmodulin-dependent process suggesting that O2
•−
 synthesis requires electron 
transfer from the reductase domain to the oxygenase domain. This O2
•−
 interacts with NO to 
form peroxynitrite decreasing vascular protection and eventually eNOS becomes an 
enzyme that generates only O2
•−
. Both nNOS and iNOS were shown to produce O2
•−
 in L-
arginine depleted cells (Pou et al., 1992; Xia and Zweier, 1997).  
O2
•− 
will interact with NO producing ONOO
−
 which is a destructive molecule 
causing oxidation of nearly all organic molecules. Peroxynitrite (
−O−O−N=O) chemical 
reactivity is due to its easy protonation and the easy O−O bond cleavage in the 
transconfiguration of its acid form (Ullrich and Bachschmid, 2000). 
 
It was reviewed that O2
•− 
 generation by NOS can be due to the failure of the 
enzyme to form dimers and that the NOS monomers were able to generate O2
•−
 although 
the enzyme has less enzymatic efficiency than the dimeric form (Forstermann and Munzel, 
2006). NOS catalyse flavin-mediated electron transfer from
 
the C-terminally bound 
NADPH to the haem on the N terminus. However, eNOS uncoupling happens when the 
electron flow within NOS is disturbed, then the ferrous-dioxygen complex dissociates and 
electrons flowing from reductase domain to oxygenase domain are diverted to molecular 
oxygen rather than to L-arginine (Forstermann and Munzel, 2006). Therefore, O2
•−
 is 
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generated from the oxygenase domain instead of NO and thus dysfunctional eNOS 
produces ROS at the expense of NO (Xia et al., 1998).  
Maintenance and stabilization of NOS dimers are dependent on BH4 (Channon, 
2004) which is a critical cofactor for the efficient function of NOS. If BH4 level is 
decreased for any reason like excess amount of ROS, eNOS starts producing O2
•−
 instead of 
NO (Forstermann and Munzel, 2006; Landmesser et al., 2003; Topal et al., 2004; Zhang et 
al., 2000). Generated oxidative stress will oxidize BH4 to BH3
•
 radicals within seconds and 
accelerates BH4 degradation (Topal et al., 2004) which enhances eNOS uncoupling. Folate 
stimulates the regeneration of endogenous BH4 from dihydrobiopterin (BH2) (Cines et al., 
1998) and that could explain the ability of folate to restore the lost NO-generating activity 
of the enzyme. Furthermore, BH3
• 
can be reduced back to BH4 by appropriate reducing 
agents like vitamin C which will lead to eNOS recoupling (Kuzkaya et al., 2003). Hcy 
might decrease the NO release through oxidative stress in EC, which could lead to 
conversion of BH4 to BH2 and inhibition of NO-generating activity of eNOS (Zhang et al., 
2000). Furthermore, Topal et al (2004) found that Hcy (100µM/24h) decreased by 80% the 
intracellular amount of BH4 in HUVEC leading to eNOS uncoupling. Furthermore, this 
group and others (Xia et al., 1998) also found that Hcy-induced ROS generation was 
markedly blocked by NOS inhibitor L-NAME. Collectively, the previous data suggest 
eNOS uncoupling as a possible mechanism for Hcy-induced oxidative stress. 
L-arginine depletion has also been shown to cause NOS uncoupling in vitro. 
However, the KM of eNOS for L-arginine is 3µM in vivo and L-arginine plasma 
concentration is about 100µM with nearly 10-fold accumulation within cells so it has been 
argued that it hardly falls below 60µM. Furthermore, human EC can effectively recycle L-
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citrulline to L-arginine and can obtain L-arginine directly from protein breakdown. On the 
other hand, EC expresses arginase that competes with eNOS for substrate, and if highly 
expressed “starves” eNOS (reviewed by Förstermann and Münzel (2006)). The same group 
reported enhanced arginase activity in HUVEC 24h after stimulation with inflammatory 
cytokines. Hcy was reported to decrease L-arginine intracellular uptake which was 
suggested also to induce eNOS uncoupling (Jin et al., 2007). 
In summary, under conditions of depleted L-arginine or BH4, electrons derived from 
NADPH oxidation are transferred to oxygen molecules leading to O2
•−
 formation (Xia et 
al., 1998). This study showed that O2
•−
 generation is a common feature of all NOS 
isoforms. nNOS and iNOS ability to generate O2
•− 
is triggered by low levels of L-arginine 
or BH4. However, Xia’s group study found that eNOS ability to generate O2
•−
 is not 
affected by the presence of L-arginine while BH4 blocks O2
•−
 formation in a dose dependent 
manner. Therefore, they concluded that “insufficient BH4 availability will switch eNOS 
from NO to O2
•− generation leading to NO decrease and ROS accumulation” (Xia et al., 
1998). As BH4 plays a key role in maintaining eNOS dimerization, the conversion of eNOS 
dimer to monomer affects the interchange of NO/O2
•−
 generation from this enzyme. 
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1.5. THE EFFECTS OF CHRONIC EXPOSURE TO DL-HCY ON 
ENDOTHELIAL CELL CYTOKINE PRODUCTION 
1.5.1. Cytokines and their role in the inflammatory response 
Cytokines are a category of signalling molecules that could be proteins, peptides or 
glycoproteins and includes more than 50 secreted factors involved in regulating different 
cellular functions in addition to intercellular communications and regulation of fundamental 
biological processes including body growth, lactation, adiposity, and hematopoiesis 
(Tedgui and Mallat, 2006). Inflammation is the tissue response to damage in an attempt to 
restore homeostasis and is highly controlled by different factors including cytokines. 
Cytokines play key roles in mediating inflammation and they participate in both acute and 
chronic inflammation. Cytokines like IL-1, IL-8 and TNF-α are involved in acute 
inflammation and are responsible for the primary response (Feghali and Wright, 1997). 
However, prolonged up-regulation of such cytokines will lead to the chronic inflammatory 
response (Muller, 2002). Cytokines are classified depending on their involvement in 
inflammatory response into two major groups, pro-inflammatory like TNF-α, INF-γ and IL-
1 and anti-inflammatory like IL-4, IL-10 and IL-13 and there is a balance between pro- and 
anti-inflammatory cytokines which is crucial for lesion development (Kleemann et al., 
2008). Therefore, any factor that induces and maintains pro-inflammatory cytokines and 
thus induces imbalance toward the pro-inflammatory cytokines level will favour the 
development of atherosclerosis. 
Chemokines are a subfamily of cytokines characterized by well conserved Cys 
residues (Harada et al., 1996). They are small chemotactic cytokines such as IL-8 and 
monocyte chemoattractant protein-1 (MCP-1) which both play a key role in recruiting the 
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inflammatory cells in the intima during acute inflammation, but also during the 
development of chronic inflammation such as atherosclerosis (Reape and Groot, 1999). 
Chemokines need to bind to their coupled receptors on the target cells to induce cellular 
changes and several studies in animal models, which are reviewed by Braunersreuther et al 
(2007) suggest that blocking chemokines:chemokine receptor interactions may serve as a 
suitable approach to treat atherosclerosis. 
Different signalling pathways can be triggered in response to pro-inflammatory 
cytokines like JNK/AP-1, which has already been discussed in detail in this thesis (Chapter 
3), and NF-κB. Both JNK and NF-κB signalling pathways have common downstream 
effects in regulating the expression of several genes encoding for other pro-inflammatory 
cytokines, chemokines and adhesion molecules (Bevilacqua, 1993; Read et al., 1997; Zhou 
et al., 2007) all of which play key roles in the inflammatory response and the initiation of 
atherosclerosis. Dysregulation of cytokine expression in vascular cells may contribute to 
the atherosclerotic process and some studies reviewed by Kleemann et al (2008) and 
Tedgui and Mallat (2006) have demonstrated that TNF-α, IL-8 (Rus et al., 1996), IL-1, IL-
2, IL-6 and INF-γ are present in atherosclerotic lesions.  
1.5.2. IL-8 and its role in DL-Hcy induced EC activation  
IL-8 is a member of C-X-C class of chemokines. It is produced by macrophages and 
other cell types such as EC which store IL-8 in WPB (Wolff et al., 1998). IL-8 was found 
to be highly expressed in atherosclerotic lesions (Apostolopoulos et al., 1996). It has been 
suggested to play a key role in recruiting leukocytes to vessel walls through mediating the 
firm adhesion of rolling neutrophils on EC (Gerszten et al., 1999; Rot, 1992). This 
chemokine not only works as a chemoattractant, but also is essential for the conformational 
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changes of leukocyte integrins into the adhesive form and thus triggering firm adhesion 
(Gerszten et al., 1999). Therefore, dysregulation of expression of this chemokine in 
vascular cells may contribute to the atherosclerotic process (Apostolopoulos et al., 1996; 
Poddar et al., 2001). IL-8 mechanism of action has been suggested to depend on its binding 
to heparin and heparan sulphate present on EC or in the basement membrane and which 
will enhance neutrophil chemotactic activity (Harada et al., 1996). 
TNF-α-mediated IL-8 gene transcription in EC has been shown to require 
cooperation between transcription factors like AP-1 and NF-κB (Natarajan et al., 2001). 
The same group has showed that NO represses JNK-induced phosphorylation of c-jun and 
that leads to deactivation of the downstream transcription factor AP-1. Disruption of the 
JNK pathway leads to repression of the expression of IL-8. Furthermore, NO inhibits 
cytokine-induced IL-8 expression in EC through its effects on NF-κB activity (De Caterina 
et al., 1995). Therefore, in addition to the other mechanisms (described in Chapter 5), NO 
can additionally reduce endothelial injury by modulating IL-8 expression.  
Acute treatment with Hcy induced the production of IL-8 protein and mRNA in 
cultured EC (Poddar et al., 2001). However, the effects of long treatment with Hcy on 
cultured EC have not been addressed. Hcy was also suggested to augment cytokine-
mediated IL-8 expression in VSMC at both protein and mRNA levels (Desai et al., 2001). 
Collectively, all of this data suggests a key role for IL-8 in mediating Hcy 
proatherosclerotic effects. 
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1.5.3. TNF-α and its role in DL-Hcy atherogenic effects  
TNF-α is a pleiotropic cytokine with a potent effector pro-inflammatory function 
that is involved in systemic inflammation (Kleemann et al., 2008). It functions through two 
distinct receptors, TNFR-1 and TNFR-2 causing activation of two major transcription 
factors, AP-1 and NF-κB which in turn activate transcription of several genes involved in 
chronic and acute inflammatory responses (Wajant et al., 2003). TNF-α is an acute phase 
protein which initiates a cascade of cytokines and increases vascular permeability, thereby 
recruiting macrophages and neutrophils to a site of infection. It can regulate the selection 
between pro-apoptotic and anti-apoptotic signalling pathways, and the control of cell 
proliferation and inflammation (Baud and Karin, 2001).  
TNF-α expression and/or signalling are implicated in a number of inflammatory 
diseases reviewed by Baud and Karin (2001) including Crohn's disease, rheumatoid 
arthritis and neuropathologies such as stroke. Furthermore, TNF-α has been associated with 
an elevated risk of recurrent myocardial infarction and cardiovascular death after a first 
myocardial infarction (Bennet et al., 2006; Tedgui and Mallat, 2006). TNF-α is also higher 
in diabetics who have elevated CVD risk (Abdel Aziz et al., 2001). Data about TNF-α 
involvement in the initiation and/or progress of atherosclerosis is still contradictory. In vivo 
studies reviewed by Galkina and Ley (2009) showed that  knocking out TNF-α in Apoe-/- 
mice resulted in reductions in lesion formation (Ohta et al., 2005). However, knocking out 
TNFR caused development of larger lesions compared to the control group (Schreyer et al., 
1996). Furthermore, Blocking TNF-α suppresses inflammation in ~70% of patients with 
rheumatoid arthritis (Sattar et al., 2007) and is used widely in the treatment of chronic 
inflammatory and autoimmune disorders (Hurlimann et al., 2002; Ohta et al., 2005). 
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Despite these encouraging results for TNF-α blockers, one clinical study of only one case 
suggested that TNF-α blockers can induce plaque rupture (Settergren and Tornvall, 2004). 
It could be said that the role of TNF-α in inducing EC dysfunction leading to 
atherosclerosis initiation was studied intensively (Zhang et al., 2009). A very few studies 
have reported positive correlation between TNF-α and Hcy levels in patient with high risk 
of CVD (Abdel Aziz et al., 2001; Akalin et al., 2008). However, the actual role of TNF-α 
in initiating and mediating Hcy-mediated inflammatory responses is still unclear. 
Macrophages and monocytes represent the primary source for TNF-α in the site of 
injury (Kleemann et al., 2008) and TNF-α effects on the EC have been studied intensively 
and shown to induce EC activation/dysfunction (Eccles et al., 2008; Xia et al., 2006; Zhou 
et al., 2007). However, most studies used exogenous TNF-α to induce EC 
activation/dysfunction. Therefore, it is still unclear whether leukocytes are the main source 
of TNF-α in atherosclerotic lesion in vivo and whether EC can produce TNF-α and 
contribute to its total production in atherosclerotic lesion. Therefore, we will investigate 
whether EC express any basal production of TNF-α and whether Hcy can induce such 
production. 
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1.6. AIMS 
HUVEC were used to study the functional chronic effects of Hcy as a model for 
atherosclerotic plaque formation and the mechanisms resulting in these effects. Therefore 
the aims were as follows: 
 Investigation the effects of chronic treatment with Hcy on HUVEC viability and 
proliferation rate. 
 Assess the expression of ICAM-1, E-selectin and P-selectin on EC surface in 
response to Hcy chronic treatment under static conditions.  
 Use an in vitro flow model to study the functional effects of Hcy chronic treatment 
on EC:neutrophil interactions under flow conditions.  
 Study the effects of chronic Hcy exposure on the activation of JNK and its 
downstream substrate c-Jun and the role of activated JNK in mediating P-selectin, 
E-selectin and ICAM-1 expression in response to chronic Hcy exposure under static 
and flow conditions by using a specific JNK inhibitor.  
 Assessment of whether Hcy induces ROS generation in HUVEC and therefore 
induces oxidative stress and the involvement of Hcy-induced oxidative stress in 
JNK pathway activation. 
 Study of the involvement of Hcy-induced oxidative stress in HUVEC:neutrophil 
interactions. 
 Investigation of the benefit of antioxidants in preventing all of the previous effects.  
 Investigation of the effects of NO donors on DL-Hcy-induced HUVEC:neutrophil 
interactions and also investigate the mechanism of action of these donors. 
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 Study the effects of inhibiting eNOS by L-NAME on DL-Hcy-induced superoxide 
anion generation in HUVEC and on HUVEC:neutrophil interactions. 
 To quantify the effects of chronic treatment with Hcy on IL-8 and TNF-α protein 
production and on IL-8 and TNF-α mRNA expression in HUVEC. 
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CHAPTER 2 
2. THE ENDOTHELIUM AND HOMOCYSTEINE 
Atherosclerosis is currently well defined as a chronic inflammatory disease of the 
wall of large arteries (Galkina and Ley, 2009). Due to its role in maintaining vascular 
homeostasis, anything that causes dysfunction of EC could be considered among the 
primary causes of atherosclerosis (Davignon and Ganz, 2004). Some researchers (Deanfield 
et al., 2007) tend to refer to endothelial dysfunction as endothelial activation where 
quiescence (a feature mainly mediated by NO) is lost and cells play a role in disease 
development due to alteration in redox signaling. Endothelial dysfunction or activation in 
vivo can be assessed by different markers such as increased plasma levels of EC-generated 
molecules like von Willebrand factor (vWF), numbers of circulating EC and endothelial 
progenitor cells as well as vascular activity to an appropriate stimulus (Brevetti et al., 
2008). EC activation in vitro can be assessed by up-regulation of several cell adhesion 
molecules as well as increases in the different types of interactions between leukocytes and 
EC.  
One independent risk factor for atherosclerosis present in up to 7% of the 
population is hyperhomocysteinemia. Since its identification as a risk factor over 30 years 
ago (McCully, 1969), many studies have identified the involvement of homocysteine (Hcy) 
in atherosclerotic plaque formation (Nygard et al., 1998; Selhub et al., 1995; Tsai et al., 
1994). There is abundant evidence for homocysteine mediated damage of endothelial cells 
in vitro (Chang et al., 2008; Dalal et al., 2003; Koga et al., 2002; Outinen et al., 1999) and 
in vivo (Hofmann et al., 2001) which is likely to be a key step in accelerated atherogenesis 
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since EC represent the primary site for the initiation of atherosclerosis. Therefore, in this 
chapter, Hcy-induced activation of EC in culture was investigated by characterizing EC 
which were chronically treated with Hcy. That involved assessment of Hcy effects on EC 
morphology, proliferation, expression of CAM and their interactions with neutrophils under 
flow conditions. 
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2.1. MATERIALS AND METHODS 
2.1.1. MATERIALS  
2.1.1.1. Cell culture 
All tissue culture reagents used were of tissue culture grade. Endothelial cell growth 
medium (C-22020) was purchased from Promocell (Sickingenstrasse, Germany). Human 
serum was obtained from Lonza (14-402F, Biowhittaker Lonza, Walkersville, MD, USA) 
or from the Blood Transfusion Services, Sheffield. Commercial serum was used directly 
while serum from the Blood Transfusion Services was centrifuged after collection at 3000g 
for 15min at 4°C and sterile filtered using 0.22μM bottletop filters from Corning Costar 
(High Wycombe, Bucks, UK). The serum was stored in 50ml aliquots at -20°C. Dulbecco's 
Phosphate Buffered Saline (DPBS, BE17-513F and BE17-512F) was obtained from Lonza, 
(Verviers, Belgium). Penicillin/streptomycin (15140-114), L-glutamine (25030-024), 
Amphotericin B (fungizone, 15290-026), trypsin/ethylenediaminetetraacetic acid (EDTA) 
(45300-019), Hanks Balanced Salt Solution (14025-050) and RPMI-1640 (52400) were 
obtained from Gibco (Paisley, Scotland, UK). Lymphoprep (NYC-1114545) was purchased 
from Axis Shield. Heparin sodium (PL 0043/0038R, PA 46/3612) was supplied by Leo 
Laboratories limited, Bucks, UK.  All tissue culture plastics used: 25cm
2
 and 75cm
2
 flasks, 
35mm dishes, 96-well plates and 6-well plates were either from Corning Incorporation 
(Corning, NY 14831, USA) or Becton-Dickinson (Falcon), (Leeds, England UK). 
Disposable sterile pipettes of volume 5, 10 and 25ml were from Costar Corporation, 
Cambridge or from LIP (Equipment & Services) Ltd, Shipley, England. Disposable 
syringes were purchased from National Health Supplies (Leeds, UK).  
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Medium 199 (M-2154), collagenase type IA (C/N C-2674), dextran (M.W. 513,000, 
D-5251), dextrose (G-7021), histamine dihydrochloride (H-7250), N-2-
hydroxyethylpiperazine-N’-2-ethanesulphonic acid (HEPES, H-0891), tris base (T-6066), 
bovine serum albumin (BSA, A-4503), gelatine (G1393), trypan blue (T6146), 
dimethylsulphoxide (DMSO, D-8779), DL-homocysteine (H-4628), L-cysteine (C-7352), 
SP600125 (S-5567), recombinant human tumour necrosis factor-alpha (TNF-α, T-0157), 
normal donkey serum (D9663),  paraformaldehyde (P6148) and MTT (M2003) were all 
purchased from Sigma-Aldrich Chemical Company (Poole Dorset, UK).  
2.1.1.2. Antibodies  
ELISA 
Mouse monoclonal antibodies against human intercellular cell adhesion molecule 1 
(ICAM-1) (CD54, C/N BBA3, clone #BBIG-I1 (11C81)), E-selectin (CD62E, C/N BBA16, 
clone #BBIG-E4 (5DII)) and P-selectin (CD62P, C/N BBA30, clone #9E1) and negative 
control antibody mouse IgG1 (C/N MAB002) were obtained from R&D Systems, Oxon, 
UK. Polyclonal rabbit anti mouse immunoglobulins-HRP (P.0260) was obtained from 
Dakocytomation Glostrup, Denmark.  
Immunofluorescence 
Fluorescein-conjugated mouse monoclonal antibodies against human intercellular 
cell adhesion molecule 1 (ICAM-1) (CD54, C/N BBA20, clone #BBIG-I1), E-selectin 
(CD62E, C/N BBA21, clone #BBIG-E5 (10C10)) and P-selectin (CD62P, C/N BBA34, 
clone #9E1) were obtained from R&D Systems, Minneapolis, MN, USA. Fluorescein-
conjugated sheep polyclonal antibodies against human Von Willebrand Factor (ab8822) 
were obtained from abCAM, Cambridge, UK. Fluorescein-conjugated mouse monoclonal 
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antibodies against human CD31 (PECAM-1) (F8402) were obtained from Sigma-Aldrich 
Chemical Company (Poole Dorset, UK).  
2.1.2. METHODS 
2.1.2.1. Cell culture 
2.1.2.1.1 Collection of umbilical cords 
Umbilical cords were collected in the Maternity unit in the Bradford Royal 
Infirmary by nurses and midwifery staff from healthy donors with consent of the local 
ethical board (LERC NO: 03/12/433) (ethical approval letter is attached: Appendix 4) in 
RPMI 199 medium containing penicillin/streptomycin (100U/100mg/ml), fungizone 
(2.5µg/ml) and heparin (10U/ml) and stored at 4°C until isolation of EC. Samples from 
donors with inflammatory diseases, diabetes, smokers or those using anti-inflammatory 
medications were excluded from the experiments (data sheet for each donor is displayed in 
Appendix 5).  
2.1.2.1.2. Isolation of human umbilical vein endothelial cells (HUVEC) 
EC were isolated using an enzymatic technique, based on a procedure developed in 
the University of Bradford (Lim, 1995). The veins were first washed to remove any blood 
clots and cell debris by flushing through phosphate buffered saline (PBS) containing 
penicillin/streptomycin (100U/100mg/ml) and fungizone (2.5µg/ml) using a disposable 
syringe. Following flushing, the vein was clamped at one end and filled with 0.1% v/v 
collagenase in serum free medium 199. The vein was then clamped at the top and incubated 
for 15min in an atmosphere of 95% air/CO2 at 37°C. Collagenase solution was collected 
after incubation and the vein flushed through twice with PBS containing antibiotics and 
once with air to remove any residual EC detached by the collagenase. The resulting 
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suspension was centrifuged at 560g for 5min at 20°C. The supernatant was discarded and 
the pellet resuspended in 5ml of complete medium (M199-M2154 containing 20% v/v 
human serum, penicillin/streptomycin (100U/100mg/ml), fungizone (2.5µg/ml) and L-
glutamine (2mM)). The cell suspension was plated into a T25 culture flask and into a T75 
culture flask if the cord was very long. All cell culture plastics used for the culture of 
HUVEC were coated in 10% v/v bovine gelatin in PBS prior to use for at least 30min and 
rinsed with PBS prior to addition of cells.  
2.1.2.1.3. Culture of HUVEC 
After isolation, cells were incubated in an atmosphere of 95% air and 5% CO2 at 
37°C. Medium was changed 24h later to remove any dead cells, cell debris and collagenase 
traces and cells were washed twice with warm PBS. Subsequently, medium was changed 
every 48h. HUVEC were used up to passage 4 as they have been characterized within the 
lab (Cooper, 2000) to respond to stimuli in a manner consistent with newly isolated 
endothelium until passage 4. In addition, the endothelial phenotype was confirmed using 
phase-contrast microscopy and immunostaining for vWF and CD 31 (PECAM-1: platelet 
endothelial cell adhesion molecule-1) in addition to the distinct cobblestone like 
arrangement at confluence. 
2.1.2.1.4. Immunocharacterisation of EC 
Chamber slides (Nunc, Roskilde Denmark) were seeded with a concentration of 2 x 
10
5
 cells per ml (500µl/chamber). Confluent monolayers of HUVEC were fixed using 2% 
w/v paraformaldehyde (in PBS) for 10min at 4°C and then washed thoroughly with PBS. 
The cells were blocked with blocking buffer (5% v/v donkey serum and 1% w/v BSA in 
PBS, 90min) and then they were incubated with 200µl sheep polyclonal anti human vWF 
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antibodies (1:20) or mouse monoclonal anti human CD31 antibodies (1:20) for 2h at 4°C. 
Cells from same donors were incubated with FITC-tagged rabbit anti-mouse 
immunoglobulin antibody and considered as negative control. Vectashield with 4’,5-
Diamidino-2-phenylindole (DAPI) (Vector laboratories, Burlingame, CA, USA) was used 
to counter stain nuclei. Cells were viewed on an Eclipse TE2000 inverted research 
microscope (Nikon, Tokyo, Japan) and photographed with a cooled Hamamatsu digital 
camera (Hamamatsu, Japan) using 20x objective. Photos of randomly chosen fields were 
taken in each experiment using the FITC- filter and DAPI- filter for antibodies-treated and 
non-treated cells and compared to check the basal.  
2.1.2.1.5. Expansion of cultures 
When cells were confluent, cells were passaged at a ratio of 1:3. Culture media was 
discarded and cells were rinsed twice with PBS and then treated with Trypsin/EDTA 
(0.05%/0.02%) to detach the cells from the base of the flask. Cells were observed under the 
microscope and the trypsin was removed as the cells started rounding up i.e. losing cell-cell 
contacts. The flask was then incubated at 37°C for approximately 1min, and then the flask 
was tapped against the palm to detach the cells. Detached cells were resuspended in an 
appropriate volume of complete medium M199, seeded into the appropriate container and 
returned to the incubator. 24h later, cells were washed with warm PBS and the medium was 
changed. Consequently, medium was changed every 48h until confluence was reached.  
2.1.2.1.6. Cryopreservation of cell stocks 
Cells were cryopreservred between passage 2 and 4. After trypsinizing the cells as 
described above in section 2.1.2.1.5, cells were resuspended in complete M199 media and 
centrifuged at 560g for 5min at room temperature to repack the cells. The cell pellet was 
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resuspended in 4°C foetal calf serum containing 10% v/v DMSO. Cells were frozen at a 
density of 1x10
6 
cells/ml. cells were placed in cryovial and placed immediately on ice. The 
cryovials were wrapped in layers of tissue paper and placed in -80°C for 24h before they 
were transferred to liquid nitrogen Dewar flasks and stored until required. 
2.1.2.1.7. Resuscitation of cells   
In order to maintain cell viability, resuscitation of frozen cells was carried out as 
quickly as possible. The cryovial of frozen cells was removed from liquid nitrogen and 
placed in a water bath at 37°C. Once thawed, the cells were transferred to a T75 cell culture 
flask and resuspended in appropriate volume of complete M199 media. 24h later, cells were 
washed with warm PBS and the medium was changed to remove any traces of DMSO and 
any dead cells. Consequently, medium was changed every 48h. 
2.1.2.1.8. Determination of cell concentration and cell viability 
When required, the concentration of the cells was determined by counting in a 
haemocytometer under light microscopy. Cells were trypsinized off the flask, as described 
in section 2.1.2.1.3 and resuspended in 10ml complete M199 medium. 10μl cell suspension 
was loaded onto each chamber of a standard haemocytometer and cells were allowed to 
settle randomly over the grid. The total amount of the cells in an area of 0.4 mm
2
 (within 
four corners from the grid) was counted under the light microscope. The cell concentration 
was calculated according to the formula: 
 
Cell concentration (cells/ml)
TC
=
4
X Dilution factor  X  104
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Trypan blue, a vital dye, was used to detect cell viability. Viable cells exclude the 
trypan blue whilst this dye enters to the non-viable cells and which are easily identified 
during counting in the haemocytometer. Dyed cells and non-dyed cells were counted and 
the percentage viability was calculated as follows: 
Unstained cells (viable)/total cells (viable and non-viable) X 100. 
2.1.2.2. Chronic treatment of EC with DL-Hcy  
HUVEC were cultured for a period of 5-9 days in complete M199 medium 
containing 1mM DL-Hcy allowing cells to undergo at least one passage in the presence of 
DL-Hcy. Following the period of exposure to DL-Hcy or Cys, HUVEC were subjected to 
different kinds of treatment depending on the experiment which will be conducted as 
described in the following sections.  
2.1.2.3. Negative controls 
Cells were treated with Cys in the same way as they were treated with Hcy using 
similar concentrations (1mM for 5-9 days). Cys served as an osmotic control to ensure that 
the observed effects were due to Hcy and not due to osmotic stress which might have 
activated EC. Cys has a similar structure to Hcy with a similar free thiol group and 
therefore, it has also been used as a negative control to check that the observed effects with 
Hcy were specific to Hcy and not nonspecific effects from a free thiol group.  Therefore, 
two negative controls were used in all the experiments: non-treated cells, which were 
grown in complete M199 media with no treatment and Cys-treated cells. These negative 
controls were used in the experiments in this chapter and all the following chapters. Due to 
89 
 
the limited availability of HUVEC, a smaller number of experiments using the negative 
control Cys were carried compared to those using Hcy or non-treated controls. 
2.1.2.4. Cell proliferation rate (MTT assay) 
To determine the HUVEC growth rate, an MTT assay was conducted. A solution of 
3-[4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) is colourless or 
yellowish. However, mitochondrial dehydrogenase of viable cells cleaves the tetrazolium 
ring of MTT, yielding purple MTT formazan crystals. These crystals can be dissolved in 
DMSO and the resulting colour read spectrophotometrically giving absorbance proportional 
to cell number. HUVEC were seeded in triplicate into gelatin-coated 96 well plates (1x10
4
 
or 2x10
4
 cells per well). Complete M199 was added to three wells of the plate to act as a 
cell blank control. Plates were incubated at 37°C and 5% CO2 in a humidified atmosphere 
for 96h. Culture media was changed once after 48h. Following incubation, MTT solution 
(5mg/ml) was added aseptically in an amount equal to 10% of the culture volume and 
plates were incubated for 3-4h at 37°C and 5% CO2 in a humidified atmosphere. 
Subsequently, media was discarded and the crystals formed were dissolved in 150µl 
DMSO. Within 1h absorbance was measured using Microplate reader MRX II (Dynex 
technologies, Chantilly, USA) at a wavelength of 570nm and blank readings were 
subtracted from those of samples. This technique was also carried out every 24h for 4 days 
to measure the daily proliferation rate of non-treated and treated HUVEC.  
2.1.2.5. Assessment of HUVEC and their CAM expression by Enzyme-linked 
immunosorbent assay (ELISA)  
96 well plates were seeded with a concentration of 2x10
5
 DL-Hcy-treated or control 
cells per ml (2x10
4
 cell/well). Plates were incubated at 37°C and 5% CO2 in a humidified 
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atmosphere overnight. Cells were fixed with 100µl of 2% w/v paraformaldehyde (in PBS) 
and then incubated with 1% w/v BSA in PBS (100µl per well) for 60min at room 
temperature to block non-specific binding. The mouse anti-human primary antibodies to 
ICAM-1, E-selectin and P-selectin were optimally diluted (2µg/ml) with 0.125% w/v BSA 
in PBS. The blocking buffer was removed and replaced with diluted antibodies. Plates were 
incubated overnight at 4°C. Excess antibody was removed by multiple washes (at least 3x) 
with the wash buffer, 0.05% v/v Tween 20 in PBS. The plate was inverted and blotted 
gently on paper tissue to remove as much wash buffer as possible before proceeding to the 
next step. The secondary antibody, rabbit anti-mouse immunoglobulin conjugated to 
horseradish peroxidase (RAM-HRP), was diluted 1:1000 with the diluent buffer (0.125 % 
w/v BSA in PBS) and 100µl/well was added to all wells. Plates were incubated for 60min 
at RT, and then the washing steps repeated to remove any excess antibody. Substrate 
solution consisting of 50ml of 50mM phosphate-citrate buffer (pH 5.0), with o-
phenylenediamine (OPD) dihydrochloride (3.7mM) and 20µl of 30% hydrogen peroxide 
was prepared fresh. 100µl/well of substrate was added and the soluble coloured end-
product allowed to develop for 30min in the dark at RT. 50µl/well of 1M sulphuric acid 
was the last addition to stop the reaction and the absorbance was read at 490nm using a 
multiwell ELISA plate reader. Blank wells were used in this experiment and treated in the 
same way the sample wells were treated except that they did not have cells in them. All 
samples were tested in triplicate and the mean absorbance of the blank wells was then 
subtracted from the mean absorbance of each set of sample wells incubated with the 
different antibodies to exclude any nonspecific measurement.  
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2.1.2.6. Assessment of HUVEC and their CAM expression by immunofluorescence  
Chamber slides (Nunc, Roskilde Denmark) were seeded with a concentration of 2 x 
10
5
 cells per ml (500µl/chamber). Confluent monolayers of HUVEC with treatments 
described previously (section 2.1.2.2) were fixed using ice cold 100% methanol for 10min 
at -20°C and then washed thoroughly with PBS. The cells were blocked with donkey serum 
(10% in PBS, 90min) and then they were incubated with 100µl mouse monoclonal anti-
human E-Selectin/CD62E FITC (50μg/ml), anti-human P-Selectin/CD62P FITC (50μg/ml) 
or anti-human ICAM-1/CD54 FITC (75μg/ml) (R&D systems, Minneapolis, MN, USA) 
overnight at 4°C. Vectashield with 4’,5-Diamidino-2-phenylindole (DAPI) (Vector 
laboratories, Burlingame, CA, USA) was used to counter stain nuclei. Cells were viewed on 
an Eclipse TE2000 inverted research microscope (Nikon, Tokyo, Japan) and photographed 
with a cooled Hamamatsu digital camera (Hamamatsu, Japan) using 20x objective.  
Photos of four randomly chosen fields were taken in each experiment using the 
FITC- filter and DAPI- filter and the results were quantified using ImageJ software after 
adjusting the threshold. As DAPI counterstains nuclei, these images were used to make sure 
that roughly equal numbers of cells are present in each chosen field and hence any 
difference between FITC filter-captured photos were due to different intensity of FITC 
rather than different densities of cells. 
2.1.2.7. Assessment of EC:neutrophil interactions under flow conditions 
A flow chamber was used to subject cultured HUVEC treated and non-treated 
monlayers to laminar flow shear stress and mimic blood flow through a human blood 
vessel. To study the effects of DL-Hcy on the expression of the individual adhesion 
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molecules under flow conditions, HUVEC were cultured as indicated in section 2.1.2.2. 
Subsequently, HUVEC were subjected to flowing neutrophils. 
2.1.2.8. Isolation of neutrophils 
Neutrophils were isolated from whole blood obtained from consented healthy 
donors according to the regulations of the University of Bradford.  
Blood was collected into sodium citrate (0.1M, pH: 6.5) 1:10. The blood was 
diluted with an equal volume of HEPES HBSS (Hanks Balanced Salt Solution, Invitrogen: 
14025-050) (0.08M dextran and 0.025M HEPES in HBSS). Tubes containing the blood and 
HEPES HBSS solution were left to stand at room temperature for 45min. The top layer was 
taken carefully and added to universal tubes containing an equal amount of lymphoprep 
(Axis Shield: NYC-1114545). These tubes were centrifuged at 400g for 30min at 4°C then 
kept on ice. The supernatant was discarded carefully and the remaining RBC were lysed by 
the addition of 1ml ice-cold water per each neutrophil pellet and agitation for 1min. All 
pellets, including the sterile water were combined in one tube and mixed with DPBS 
(BioWhittaker: BE17-513F and BE17-512F) containing 0.5% v/v human serum. The 
suspension was re-centrifuged at 400g for 15min at 4°C.  Then the pellet was resuspended 
in 10ml ice-cold DPBS/0.5% human serum and the neutrophil concentration was adjusted 
to 1×10
6 
cells/ml. Neutrophil viability was routinely assessed using Trypan blue dye 
exclusion.  
2.1.2.9. Flow chamber assay 
Sterile 35mm cell culture dishes (BD Falcon, cat No. 351008) were coated with 
10% v/v gelatine solution (in PBS) for at least 30min and rinsed with PBS prior to addition 
93 
 
of cells. 2ml EC suspension (2x10
5
cell/ml) were seeded onto the dishes. Dishes were 
incubated overnight at 37°C in an atmosphere of 95% air and 5% CO2 in order for the cells 
to form confluent monolayers. The 35mm dish was fitted with a gasket where removal of a 
5.0 x 50.0mm rectangular section from gasket provided a flow channel, with a height of 
0.25mm (the gasket thickness). The chamber has a vacuum outlet, and two ports (appendix 
1). The neutrophil solution was fed through the first port while the other port was connected 
to syringe pump (Harvard apparatus, south Natick, MA) which pulled the neutrophil 
solution at a rate of 0.5ml/min which is equivalent to a shear stress equal to 1.1dyne/cm
2
. 
The vacuum helped in holding the chamber to the 35mm cell culture dish on which the EC 
had been cultured.  
The shear stress applied in the flow an experiment reflected a shear rate in venules in vivo 
and it was calculated using this formula (Lawrence et al., 1987): 
 
When,  = shear stress (dyne/cm2); Q = volumetric flow rate (ml/sec);  = viscosity of the 
liquid (poise); w = width of the flow field (cm); h = height of the flow field (cm). 
Medium covering confluent cells was removed and the chamber containing the gasket was 
put on the dish and held in place by vacuum. Existing air bubbles were carefully removed 
from the system, via a bubble port. The flow chamber was placed onto the stage of an 
inverted microscope (appendix 1). EC were visualized at 10x and 20x magnification using 
phase contrast microscopy. The clear dishes allowed direct live time microscopic 
observation of the EC in the dish under exposure to flow. The entire period of perfusion 
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was recorded via a charge coupled device camera and video recorder equipped with a time-
date generator and millisecond clock and a black and white television monitor (appendix 1 
photo B), then the film was converted into digital image in order to be quantified on the 
computer. Tethering, rolling, adherent and transmigrated cell were counted.  
2.1.2.10. Classification of EC:neutrophil interactions: 
2.1.2.10.1. Tethering 
Neutrophil tethering on EC was detected within the first 6min of the flow using the 
x10 objective. Two kinds of tethering have been distinguished, primary and secondary 
tethering. Primary tethering interactions are weak reversible interactions which occur 
quickly between neutrophils and EC. Secondary tethering interactions are similar to the 
primary ones however, they occur between adherent and flowing neutrophils. Tethering 
interactions are characterised as such when the duration of the interaction is <1s. 
2.1.2.10.2. Rolling 
After the first 6min, neutrophils rolling on EC were detected for a further 8min of 
flow using the x20 objective. Rolling neutrophils were classified when they remained in 
contact with the EC for longer than the tethering time (>1s) and could be easily observed 
rolling on the EC monolayer. Rolling neutrophils have a greatly decreased velocity when 
compared to other flowing neutrophils and were easily distinguished from both tethering 
and fixed neutrophils. 
2.1.2.10.3. Fixed 
Neutrophils were considered as fixed when they made firm contact with EC and 
stayed there for the whole period of flow (14min). Fixed neutrophils were counted at the 
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start of the second phase of flowing (after the initial 6min) and the end of the whole flow 
process (14min) using x20 objective. Fixed neutrophils were distinguishable from other 
neutrophils as they exhibited no movement for the whole 14min duration of the experiment. 
2.1.2.10.4. Transmigration 
During this stage, neutrophils underwent morphological changes and they could be 
seen flattening and spreading. Their shape changed from bright field to a duller shade and 
had a characteristic “halo” appearance as they transmigrated through the EC monolayer. 
Transmigrated neutrophils were counted at the end of the 14min flow period. 
2.1.2.11. Counting of EC:neutrophil interactions 
All of the above described interactions were counted manually. A grid on 
transparent paper was designed to divide the computer screen into 9 portions. Therefore, 
counting was done within all areas of the screen in one time. Therefore, each grid was 
screened frame by frame for a given time point and for a one type of interaction only. This 
was repeated for the same time point and interaction type in all of the 9 grids on the screen. 
The same quantifying method was repeated for all of the remnant interactions. The results 
were presented graphically using the mean values of each type of interaction, +/- SD, 
counted in each flow experiment. A complete flow experiment usually contained between 
4-12 35mm dishes depending on the types of stimulation. 
The counting method was developed by Eccles (2006), where for each period of 
6min during which both primary and secondary tethering were counted, just 10s at the end 
of each minute was counted and the figure multiplied by 6 to give the result for the whole 
minute. The same procedure was applied in counting rolling and a 10s of each minute of 
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the 8min was counted. Again the figure was multiplied by 6 to give a figure of the whole 
minute. The numbers of fixing and transmigration interaction were counted by the end of 
each minute. 
2.1.2.12. Statistical analysis 
Excel and SPSS software packages were used for the statistical analysis of the data 
in all chapters. We tested normal distribution using Kolmogorov–Smirnov test and values 
were assumed to follow normal distribution if p value was more than 0.05. For normally 
distributed values, all data analysis was carried out using paired t-test unless specified. The 
differences were considered significant if p values were < 0.05. The same statistical 
analysis was carried on in this chapter and all the following chapters unless specified. 
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2.2. RESULTS 
2.2.1. Isolation and culture of primary HUVEC 
The length of the cord sections was on average 15-30cm with a diameter of nearly 
3-6mm. HUVEC were isolated as described in section 2.1.2.1.2. Under phase contrast 
microscopy, newly isolated HUVEC looked like small floating dots, they adhered within 
12h to the gelatin coating the flask and they had a small irregular cigar shape (Figure 12A). 
These cells proliferated and became confluent within 24-48h in T25 flasks and 2-3days in 
T75 flasks (Figure 12B). The growth rate was variable between cells from different donors. 
Upon confluence, cells were passaged at ratio of 1:3 up to passage number 4. HUVEC 
which were not able to adapt to culture conditions were discarded. Total contact inhibition 
was not observed. However, cells proliferated very slowly when they reached confluence 
and the number of floating dead cells was higher in confluent flasks then non-confluent 
ones. 
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Figure 12: HUVEC in culture, A: primary HUVEC 24h after harvesting. B: 
confluent monolayer of HUVEC. (Original magnification is 100x). 
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2.2.2. Characterization of isolated EC 
The endothelial phenotype was confirmed using phase-contrast microscopy and 
immunostaining for vWF and CD31 (PECAM-1) in addition to the distinct cobblestone like 
arrangement of the cells at confluence. FITC-tagged antibodies against vWF and CD31 
were used to visualise their expression on the HUVEC surface. Both molecules gave high 
fluorescence in HUVEC indicating a basal expression of these molecules (Figure 13) while 
cells which have been treated with FITC-tagged rabbit anti-mouse immunoglobulin 
antibody showed no fluorescence (data not shown). Cells which did not show cobblestone 
like arrangement or did not express vWF and CD31 on their surface were excluded and not 
used in the experiments. 
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Figure 13: Representative images of the expression of vWF and CD31 on HUVEC 
surface. HUVEC were grown in complete M199 medium and then were fixed and 
immunostained with FITC-tagged antibodies against CD31 or vWF. The upper row 
is immunofluorescence microscopy detection of FITC, the middle raw is 
immunofluorescence microscopy detection of DAPI and the bottom one is merge of 
the two. (Original magnification 200x). 
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2.2.3. Characterization of chronic DL-Hcy effects on HUVEC 
2.2.3.1. Morphological changes in HUVEC cultured in DL-Hcy 
DL-Hcy appeared to affect the growth rate of the HUVEC when compared with 
non-treated HUVEC from the same donor. The effects seem to have an inverse relationship. 
There were also alterations in the phenotypic appearance of the cells. The difference was 
very obvious between HUVEC which had been grown in normal complete M199 media 
(Figure 14A) and those which had been grown in complete M199 media containing DL-
Hcy at either 1mM or 5mM (Figure 14B, C respectively). The DL-Hcy-treated cells were 
elongated in shape and showed slower proliferation. In contrast, Cys did not seem to have 
negative effects on either growth rate or phenotypic appearance of the HUVEC when added 
to the media compared with non-treated HUVEC from the same donor (data not shown). 
Furthermore, individual differences could be noticed between cells from different donors in 
response to exposure to DL-Hcy. Photos in Figure 14B represent cells typically used in 
experiments to produce results in this thesis.   
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Figure 14: Morphological changes in HUVEC cultured in DL-Hcy, A: HUVEC 
grown in normal complete M199 media (5 days after passaging), B: HUVEC grown 
in complete M199 media containing 1mM DL-Hcy (5 days after passaging), C: 
HUVEC grown in complete M199 media containing 5mM DL-Hcy (5days after 
passaging). Arrows indicate elongated cells which are affected by high DL-Hcy 
treatment. (Original magnification: left column: 100x, right column: 200x.) 
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2.2.3.2. Characterization of chronic DL-Hcy effects on HUVEC viability  
There have been previously published reports that 1mM DL-Hcy causes decreased 
EC viability (Lee et al., 2005). Therefore, Trypan blue dye exclusion was used to 
distinguish between live and dead cells and this test was performed on cells without 
treatment and on those treated with 1mM DL-Hcy or Cys. The percentage of live cells was 
more than 95% in all treated and non-treated cells indicating that neither DL-Hcy nor Cys 
had toxic effects on HUVEC leading to reduced cell viability. 
2.2.3.3. Characterization of chronic DL-Hcy effects on HUVEC proliferation 
To evaluate the effects of DL-Hcy on HUVEC proliferation, the MTT assay was 
used. However, it was first necessary to determine the correlation between HUVEC cell 
number and the formed colour after carrying out the MTT assay and also to establish the 
best cell seeding density. HUVEC were seeded at different concentrations (2.5x10
3
, 5x10
3
, 
1x10
4
, 2x10
4
 and 4x10
4
 cells/well) in triplicate and incubated overnight. The MTT assay 
was then conducted and the relationship between cell number and absorbance was 
determined (Figure 15). The linear relationship demonstrated in Figure 15 shows that 
absorbance values are proportional to the number of the cells in each well. HUVEC were 
then seeded at two different densities, 1x10
4
 and 2x10
4
 cells per well in a 96-well plate and 
incubated for 96h. When a density of 1x10
4
 cells/well was used, there was a significant 
difference in the proliferation rate between non-treated cells and DL-Hcy-treated cells 
(p<0.01) (Figure 16) while no significant difference was observed between Cys-treated 
cells and non-treated cells. On the other hand, when a cell seeding density 2x10
4
 cells/well 
was used, there was no significant difference in the proliferation rate between either DL-
Hcy or Cys compared to non-treated cells (p>0.05) (Figure 16). Furthermore, the MTT 
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assay was conducted on another set of cells every 24h for 4 days at the same densities used 
above (1x10
4
 cells/well and 2x10
4
 cells/well). When the cell seeding density 1x10
4
 
cells/well was used, results showed a significant difference in proliferation rate only on the 
fourth day (Figure 17) while no significant difference was observed at any time once 2x10
4
 
cells/well seeding density was used. The percentile increase of cell numbers was calculated 
for each seeding density (Figure 18) and shows a daily increase in the cell numbers when 
1x10
4
 cells/well seeding density was used. However, the percentage increase in cell 
numbers was lower once the highest seeding density was used.  
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Linear relationship between cell number and absorbance in the MTT assay 
 
 
 
Figure 15: HUVEC cells were seeded in 96-well plate at different concentrations in 
triplicate and MTT assays were conducted after 24h. Linear relationship was 
observed between the numbers of the cells and the absorbance values. The results 
are expressed as mean (+/- SEM) from 3 different donors (n=3).  
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The effects of chronic exposure to DL-Hcy on cell proliferation rate 
 
 
 
Figure 16: DL-Hcy (1mM) and Cys (1mM) -treated HUVEC cells were seeded in 
96-well plate (A: 1x10
4
 cells/well and B: 2x10
4
 cells/well) in triplicate and MTT 
assays were conducted after 96h. Non-treated and Cys-treated HUVEC from the 
same donor were used in each experiment as negative controls. The results are 
expressed as mean (+/- SEM) from 9 different donors (n=9). Non-treated values 
were defined as 100% and other values were adjusted accordingly. (*) p < 0.01 for 
DL-Hcy versus non-treated cells. 
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The effects of DL-Hcy on cell proliferation rate over 4 days 
 
 
Figure 17: DL-Hcy-treated HUVEC (1mM) were seeded in 96 well plates (A: 1x10
4
 
cells/well and B: 2x10
4
 cells/well) in triplicate and MTT assays were conducted 
every 24h for 4 days. Non-treated and Cys-treated (1mM) HUVEC from the same 
donor were used in each experiment as negative controls. The results are expressed 
as mean (+/- SEM) from 4 different donors (n=4). (*) p < 0.05 for DL-Hcy and non-
treated cells. 
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The effects of chronic exposure to DL-Hcy on cell proliferation rate 
 
 
Figure 18: DL-Hcy -treated HUVEC (1mM) were seeded in 96-well plates (1x10
4
 
and 2x10
4
 cells/well) in triplicate and MTT assays were conducted every 24h for 4 
days. Non-treated and Cys-treated HUVEC from the same donor were used in each 
experiment as negative controls. The results are expressed as percentile increases of 
the mean of the numbers of live cells every 24h from 4 different donors (n=4). 
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2.2.3.4. The effects of chronic exposure to DL-Hcy on the expression of cellular 
adhesion molecules 
Using antibodies against ICAM-1, E-selectin and P-selectin, ELISA detected a 
slight increase in expression of these CAMs in response to DL-Hcy compared to non-
treated cells. However, these increases were not significant (data not shown). Subsequently, 
immunofluorescence tagged antibodies against these CAMs were used to visualise their 
expression on the HUVEC surface. All three CAMs gave high fluorescence in response to 
DL-Hcy treatment compared to non-treated and Cys-treated cells (Figures 20, 21 and 22).  
In DL-Hcy-treated cells both E-selectin and ICAM-1 showed cell surface 
localization in addition to paranuclear and Golgi localization (Figure 19). However, it was 
difficult to identify the localization of P-selectin in those cells. Therefore, histamine-treated 
cells were used to illustrate the localization of P-selectin after appropriate stimuli and 
Figure 19 shows that P-selectin was mainly localized in paranuclear locations in addition to 
showing cell surface expression. 
Quantifying these results using ImageJ software (Figure 23) revealed that neither 
non-treated cells nor Cys-treated cells showed any significant expression for P-selectin or 
E-selectin. ICAM-1 expression was detectable in non-treated and Cys-treated cells. On the 
other hand, DL-Hcy induced significant expression of ICAM-1 and E-selectin compared to 
non-treated controls (P<0.05) but did not significantly increase P-selectin (P>0.05) on the 
HUVEC surface. 
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The effects of chronic exposure to DL-Hcy on CAM expression and their cellular 
localization
 
Figure 19: The cellular localization of each E-selectin, ICAM-1 after (1mM DL-Hcy, 5-9 
days) and for P-selectin after (10
-5
M histamine, 18min). The upper row is 
immunofluorescence microscopy detection of FITC, the middle raw is immunofluorescence 
microscopy detection of DAPI and the bottom one is merge of the two. The cellular 
localization of different molecules are indicated by arrows: (↑): cell surface localization, 
(↓): Golgi localization and (←): paranuclear localization.  
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The effects of chronic exposure to DL-Hcy on E-selectin expression 
 
Figure 20: Representative images of the effect of DL-Hcy on E-selectin expression 
on HUVEC surface of 6 different experiments. HUVEC were grown in complete 
M199 medium and either left non-treated or treated with DL-Hcy (1mM; 5-9 days), 
Cys (1mM; 5-9 days) or TNF-α (120U/ml; 4h). Then, fixed cells were 
immunostained with FITC-tagged antibodies against E-selectin. A: non-treated 
HUVEC, B: DL-Hcy-treated HUVEC, C: TNF-α (120U/ml; 4h) treated HUVEC, D: 
Cys treated HUVEC. (Original magnification: 200x). 
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The effects of chronic exposure to DL-Hcy on ICAM-1  expression 
 
Figure 21: Representative images of the effect of DL-Hcy on ICAM-1 expression 
on HUVEC surface of 8 different experiments. HUVEC were grown in complete 
M199 medium and either left non-treated or treated with DL-Hcy (1mM; 5-9 days), 
Cys (1mM; 5-9 days) or TNF-α (120U/ml; 24h). Then, fixed cells were 
immunostained with FITC-tagged antibodies against ICAM-1. A: non-treated 
HUVEC, B: DL-Hcy-treated HUVEC, C: TNF-α (120U/ml; 24h) treated HUVEC, 
D: Cys treated HUVEC. (Original magnification: 200x). 
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The effects of chronic exposure to DL-Hcy on P-selectin expression 
 
Figure 22: Representative images of the effect of DL-Hcy on P-selectin expression 
on HUVEC surface of 7 different experiments. HUVEC were grown in complete 
M199 medium and either left non-treated or treated with DL-Hcy (1mM; 5-9 days), 
Cys (1mM; 5-9 days) or histamine (10
-5
M; 18min). Then, fixed cells were 
immunostained with FITC-tagged antibodies against P-selectin. A: non-treated 
HUVEC, B: DL-Hcy-treated HUVEC, C: histamine (10
-5
M; 18min) treated 
HUVEC, D: Cys treated HUVEC. (Original magnification: 200x). 
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The effects of chronic exposure to DL-Hcy on CAM expression 
 
 
 
Figure 23: Fluorescence density of the immunostaining experiments of 4 randomly 
chosen fields for each experiment was quantified using ImageJ software. The results 
are expressed as mean (+/- SEM) from 6 different donors (E-selectin), 8 different 
donors (ICAM-1) and 7 different donors (P-selectin) for DL-Hcy and non-treated. 
Non-treated values were defined as 100% and other values were adjusted 
accordingly. (*) p < 0.05 for DL-Hcy versus non-treated cells. 
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2.2.3.5. Characterization of isolated neutrophils 
2.2.3.5.1. Characterization of neutrophil viability  
Neutrophil viability was tested using Trypan blue dye exclusion and cell viability 
was routinely found to be over 98%. 
2.2.3.5.2. Characterizing the efficiency of the neutrophil isolation procedure  
Neutrophils from each donor were counted and adjusted to the volume of donated 
blood and the range was 1.3-1.6 x 10
6
 cells per ml of blood. Considering that the neutrophil 
count in a healthy person is 1.5 x 10
6
 cells/ml, we can conclude that the efficiency of the 
isolation method was at least 94%. 
2.2.3.6. The effects of chronic exposure to DL-Hcy on HUVEC:neutrophil interactions 
EC were treated as described in section 2.1.2.2 and the effects of these treatments 
on the EC:neutrophil interactions are shown in Figure 24.  The results are shown as mean 
number of interactions from 5 different experiments +/- SD. The numbers of all interactions 
in the negative controls remained negligible suggesting that the non-treated EC were not 
activated. However, cells which were cultured in complete M199 media containing 1mM 
DL-Hcy showed significant interactions. Both primary and secondary tethering interactions 
were significantly increased, as were the number of rolling, fixed and transmigrated 
neutrophils (p<0.05 in all cases). In contrast, stimulation with Cys had no effect on 
interactions and numbers were equal to or less than those for non-treated cells. Once these 
cells were treated with histamine (10
-5
M; 18min), TNF-α (120U/ml; 4h) or TNF-α 
(120U/ml; 24h), all different sorts of interactions were induced and that was described 
previously by Eccles et al (2008). Figure 25 represents images taken from the flow 
experiments (CD containing movies of the flow experiments is included); Figure 25A and 
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B shows adhered and transmigrated neutrophils on DL-Hcy-treated HUVEC, while Figure 
25C shows no neutrophils interacted with non-treated HUVEC.  
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The effects of chronic exposure to DL-Hcy on HUVEC:neutrophil interactions 
 
 
Figure 24: The effects of chronic exposure to DL-Hcy on HUVEC:neutrophil 
interactions. HUVEC were stimulated with DL-Hcy (1mM; 5-9 days), or Cys (1mM; 
5-9 days). HUVEC from the same donor were grown in complete M199 media 
without any stimulation and considered with Cys-treated cells as negative controls. 
The effects on EC:neutrophil interactions under flow conditions were observed and 
quantified. The results are expressed as mean (+/- SD) from 5 different donors 
(n=5). (*) p < 0.05 for DL-Hcy and non-treated cells. 
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Representative images for the effects of DL-Hcy on HUVEC:neutrophil interactions 
under flow conditions 
 
Figure 25: Representative images for the effects of DL-Hcy on HUVEC:neutrophil 
interactions under flow conditions of 5 different experiments. A (100x) and B (200x): 
neutrophils (white dots) adhered (arrow) and transmigrated (circle) through DL-Hcy-
treated HUVEC. C (200x): non-treated HUVEC with no adhered neutrophils. 
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2.3. DISCUSSION 
The inflammatory response is a series of local cellular and vascular responses to 
harmful stimuli, body injury, or bacterial infection. This inflammatory response includes 
the local vascular system, the immune system and various cells within the injured tissue 
(Galkina and Ley, 2009). A prolonged and uncontrolled inflammatory response (termed 
chronic inflammation) can develop into fatal diseases, e.g. atherosclerosis and autoimmune 
diseases. Atherosclerosis is defined as a chronic inflammatory response in the walls of 
arteries (Galkina and Ley, 2009; Lusis, 2000). Arterial EC represent the primary site for the 
initiation of atherosclerosis. Due to the fact that human arterial EC are not easy to obtain, 
different in vitro studies have used EC from a variety of sources to study the mechanisms 
behind atherosclerotic plaque formation (Dalal et al., 2003; Ferretti et al., 2004; Lee et al., 
2002; Zhang et al., 2001a). HUVEC represent one easily accessible in vitro model to study 
atherosclerosis progression mechanisms and they have been used successfully in several 
studies (Dong et al., 2005; Outinen et al., 1999; Xu et al., 2000).  Even though HUVEC are 
venous EC, they still represent a more relevant model than murine or bovine arterial EC 
which have been used by some groups (Jin et al., 2007; Weiss et al., 2002). HUVEC are 
human EC which have been exposed to human blood containing the same growth factors, 
cytokines and other factors to which arterial EC are exposed.  
Characterization of HUVEC isolated in this study showed that these cells retain important 
endothelial characteristics until at least passage number four as defined by adhesion 
molecule expression in response to classical acute inflammatory stimuli, staining with EC 
markers and growth characteristics and also by their basal expression of vWF and CD31 on 
their surface. Similar data has been previously published and it is likely that EC lose this 
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characteristic features once grown in culture for a longer time (Kaushal et al., 2001). Since 
further characterisation had not been carried out on higher passage numbers, cells were not 
used beyond this number of passage in culture.  
hHcy, which has a prevalence of 5-7% in the population, is considered an 
independent risk factor for cardiovascular disease (Lawrence de Koning et al., 2003) 
(Section 1.1.5.4.1). It is therefore important to establish what effects high concentrations of 
Hcy have on EC function to determine its role in atherogenesis and atherosclerotic 
progression. Ranges of Hcy concentration that have been measured in clinical studies are 
not as high as those cultured cells have been exposed to. However, previous studies found 
that EC isolated from normal donors can adapt to stress conditions in culture and are 
relatively resistant to the effects of Hcy and require high concentration to induce 
intracellular uptake and to overcome cellular mechanisms responsible for Hcy metabolism 
and/or clearance (Dalal et al., 2003; Hajjar, 1993; Outinen et al., 1999; Rodgers and Kane, 
1986). Therefore, EC in culture might require exposure to higher concentrations to increase 
intracellular uptake and overcome the cellular factors that influence the metabolism of Hcy 
(Hajjar, 2001; Werstuck et al., 2001). In early experiments of this chapter, two different 
concentrations of DL-Hcy were used, 1mM and 5mM. The highest concentration 
significantly inhibited HUVEC proliferation in addition to changing their typical 
cobblestone shape (Figure 14) and these findings are consistent with those of Dalal et al 
(2003) who reported elongated shape of HSVEC after treatment with 5mM Hcy and also 
with Rodriguez-Nieto et al (2002) who showed that Hcy inhibits in a dose-dependent 
manner the proliferation of BAEC. It was decided not to carry out further experiments 
using this supra pathological concentration. Instead, 1mM DL-Hcy was used in all 
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subsequent experiments. Since the only commercially available Hcy is D/L mixture and 
only the L isomer is biologically active, the effective Hcy concentration was 0.5mM rather 
than 1mM. This was thought to be high enough to be pathologically relevant without being 
toxic to the cells because this concentration is within a similar range to patients with 
homozygous CBS deficiency. Most previous studies exposed cells to Hcy for only short 
periods (acute exposure; ≤ 24h). However, Hcy is a risk factor for chronic, rather than 
acute, inflammatory EC dysfunction. Therefore, in this chapter HUVEC were grown in the 
presence of DL-Hcy for at least one passage to ensure that all stages in the cell cycle during 
EC proliferation were exposed to the stressing agent.  
Even though Hcy has been shown to alter different signaling pathways, its toxicity is still in 
debate and there is uncertainty whether activation of these pathways induces cell apoptosis 
or not. Therefore, this chapter initially determined effects on HUVEC viability and growth 
of 1mM DL-Hcy. Trypan blue exclusion results showed clearly that the concentration of 
DL-Hcy used in this study (1mM) was not cytotoxic to cells since the viability of DL-Hcy-
treated cells was always greater than 95% with the number of dead cells similar to that 
observed in non-treated or Cys-treated cells. This finding are consistent with other studies 
which suggest that EC are resistant to Hcy cytotoxicity even at levels as high as 10mM 
(Outinen et al 1999), 5mM (Stangl et al., 2001) or 3mM (Zhang et al., 2001a). Although 
cell viability was not negatively affected, exposure to chronic DL-Hcy did slow down 
proliferation as measured by MTT. Firstly, a linear relation between cell numbers and 
absorbance of formed formazan was established (Figure 15) which means the absorbance 
values were proportional to the number of live cells and therefore demonstrates that the 
MTT results reflect cellular proliferation rate. Two different seeding densities were used in 
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the MTT assay (1x10
4
 and 2x10
4
 cells/well). The data in Figure 16 shows that DL-Hcy 
significantly decreased the proliferation rate of HUVEC seeded at the lowest density. The 
measurement of proliferation rate after 24h showed that there was no difference between 
non-treated and DL-Hcy-treated cells until the 4
th
 day of DL-Hcy treatment when cells 
were seeded at 1x10
4
 cells/well (Figure 17). This highlights the fact that in hHcy patients, 
where EC are exposed to high levels of Hcy for years, EC proliferation may be reduced 
compared to EC in normal people. EC proliferate at a low rate normally but start 
proliferating quickly in response to a lesion or in angiogensis. Therefore, it could be said 
this Hcy-induced slow in proliferation might accelerate lesion development. This data 
indicates changes in gene expression that might make cells less responsive to growth 
factors. That might make the cells more primed for atherosclerosis and could be responsible 
for other Hcy-induced effects. When higher numbers of HUVEC were used to assess 
proliferation (2x10
4
 cells/well), the difference between proliferation rate of DL-Hcy-treated 
and non-treated cells was not significant (Figure 16). Plating this cell density allowed them 
to reach confluence in each well prior to day 4 resulting in their proliferation rate being 
suppressed by contact inhibition (Figure 18). Therefore, non-treated and DL-Hcy-treated 
cells, at such high plating density, might have reached confluence within less than 96h and 
thus ended up with no difference between numbers of live cells after 96h. When fewer cells 
were plated (1x10
4
 cells/well) a significant reduction in proliferation in response to DL-Hcy 
was recorded after 96h. On the other hand, Cys did not affect HUVEC proliferation and 
their proliferation rate was similar to non-treated cells. Mitochondrial dehydrogenase of 
viable cells converts the tetrazolium into formazan which has a purple colour and the 
intensity of the colour is proportional to the number of live cells. However, this enzyme 
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could be altered by Hcy treatment and therefore, that might result in inaccurate results. 
Therefore, it might have been useful to measure the proliferation rate with other techniques 
in addition to the MTT such as [
3
H]thymidine incorporation or the inhibition of expressions 
of gene which are known to be involved in regulating cell cycle (Wang et al., 2002; Wang 
et al., 1997). 
These findings are in line with the findings of other groups like Nagai et al who 
found that Hcy (within 5 days) inhibited the proliferation of bovine aortic endothelial cells 
(BAECs) in a dose-dependent manner and there was almost no cell proliferation in the 
presence of 10mM homocysteine (Nagai et al., 2001). Similar to the results with Cys-
treated cells in this chapter, the proliferation of BAECs was not inhibited by cysteine. Other 
studies showed also that treatment with Hcy for 24h, even at the low concentration of 
20µM, decreases [
3
H]thymidine incorporation into HUVEC by 50% (Wang et al., 2002; 
Wang et al., 1997) and the cell line SVEC4-10 (mouse lymph node endothelial cell line) 
(Ohashi et al., 2006), which supports the results in this chapter  showing that Hcy has 
inhibitory effects on EC proliferation. Wang’s group found that mRNA expression and 
protein levels of Cyclin A, which is a key regulatory cyclin regulating G1 and G1/S 
transition of cell cycle, were significantly decreased by both homocystine and Hcy (25-
50µM/30h). They also showed that overexpression of cyclin A was sufficient to overcome 
the G1/S phase block caused by Hcy. They believe that suppression of this cyclin was 
responsible for Hcy-induced cell growth arrest and suggested these effects to happen in 
very late G1 or at the G1/S transition (Wang et al., 2002). Furthermore, Hcy was reported 
to have cell-type specific proatherogenic effects as it suppresses EC growth (the results of 
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the current chapter), Ohashi et al (2006) and Wang et al (1997), while inducing VSMC 
proliferation (Tsai et al., 1994).  
Endothelial activation has been proposed to be one of the initiating events of 
atherosclerosis and it is characterized by the induction of several intracellular signaling 
pathways leading to up-regulation of several proteins like CAMs which will be mobilized 
and expressed on the activated EC surface (Galkina and Ley, 2009; Lusis, 2000). To 
investigate whether DL-Hcy induces EC activation, specific monoclonal antibodies against 
ICAM-1, E-selectin and P-selectin were used to detect the expression of these CAMs on the 
EC surface in response to chronic treatment with DL-Hcy under static conditions. Firstly, 
an established ELISA technique was used. However, the results were not encouraging and 
no significant CAM expression was detected even after stimulation with proinflammatory 
mediators as positive controls (histamine and TNF-α). The antibodies which were used in 
the ELISA were capture antibodies that detect soluble proteins. Despite the fact these 
soluble proteins should be similar to surface expressed adhesion molecules, it was difficult 
to explain how these capture antibodies were not able to detect the surface expressed CAM. 
As an alternative experimental approach, HUVEC were immunostained with FITC-tagged 
antibodies against these CAM to directly visualize alterations in expression. Both ICAM-1 
and E-selectin showed significant up-regulation of expression in DL-Hcy-treated cells 
compared to non-treated cells or Cys-treated cells (Figures 20, 21 and 23). Furthermore, 
both molecules showed in addition to cell surface localization, paranuclear and Golgi 
localization which indicate de novo synthesis of these two molecules (Figure 19) and that 
means after 5-9 days treatment with DL-Hcy, E-selectin and ICAM-1 synthesis was still 
going on in addition to sustained cell surface expression. Collectively that means the cycle 
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of synthesizing and mobilizing these molecules to cell surface was taking place as long as 
the DL-Hcy was present. ICAM-1 was detectable in non-treated and Cys-treated cells 
because it is well known that HUVEC express ICAM-1 under basal conditions. Even 
though P-selectin expression on DL-Hcy-treated EC appeared to increase as detected by 
eye (Figure 22), the increase was not quite statistically significant (Figure 23). Localization 
of P-selectin in DL-Hcy-treated cells was difficult to study as the staining was not strong 
enough. Therefore, positive control cells were used in Figure 19 to illustrate P-selectin 
localization and this CAM showed in addition to the cell surface staining mainly 
paranuclear localization which is typical for P-selectin as this adhesion molecule is usually 
stored in WPB (McEver et al., 1989) before being mobilized to the cell surface.  
Previous studies have demonstrated that acute exposure to Hcy induced expression 
of P-selectin in murine venular EC (5mM DL-Hcy/150min) (Pruefer et al., 1999), E-
selectin in HAEC (100µM/20h) (Koga et al., 2002) and ICAM-1 in HUVEC and in murine 
venular EC (200µM/6h and 5mM DL-Hcy/150min) (Postea et al., 2006; Pruefer et al., 
1999). Although the findings of this chapter do not totally agree with Pruefer et al (1999), 
this may well reflect differences between responses of murine endothelium and HUVEC or 
that acute effects may be different from chronic effects and might induce increases in the 
expression of the CAM which then decreases to basal levels. Furthermore, Mansoor et al 
found after methionine loading in healthy subjects, increased plasma levels of circulating 
ICAM-1 and E-selectin and to lesser extent P-selectin (Mansoor et al., 2004). Their results 
correlate with the immunostaining results of this chapter except that they studied the 
soluble form of these CAMs while this chapter investigated the surface expressed CAM. It 
has been described previously that cytokines induce peak expression of surface E-selectin 
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followed by decrease which was associated with a peak of soluble E-selectin (Wyble et al., 
1997). This means that the only source of soluble CAM is the shed receptors and in the case 
of chronic Hcy treatment, the CAM synthesis pathway might be continuously activated 
which leads to replacement of the shed receptors. On the other hand, some other studies 
have found that acute treatment with Hcy (5mM/15min) was not able to induce significant 
expression of CAM in HUVEC (Stangl et al., 2001) and that could be explained by the 
short incubation time. Furthermore, Dudman and Hale (1997) and Dudman et al (1999) 
found that 200µM Hcy was not able to induce E-selectin, ICAM-1, or P-selectin in 
HUVEC. Dudman’s group co-cultured neutrophils (indirectly) and HUVEC and treated the 
neutrophils with Hcy assuming that Hcy might induce them to release cytokines which 
might induce CAM up-regulation on HUVEC. However, this treatment failed to induce any 
expression of CAM on HUVEC (Dudman et al., 1999). 
Most of the previous studies which investigated EC:leukocyte interaction and the 
expression of CAMs were conducted under static conditions (Dudman et al., 1999; Lin et 
al., 2008; Postea et al., 2006; Silverman et al., 2002). Static studies results are not 
particularly relevant to the interactions in the blood vessels because they don’t consider the 
flow forces and shear stress. Therefore, the in vitro flow model, which was used in this 
study, made it easy to study the different sorts of interactions between the two cell types 
under conditions which represent binding with discrete adhesion molecules e.g. tethering 
with P-selectin and rolling with E-selectin. The in vitro flow model allows the study of the 
expression of these CAM under flow conditions through studying different sorts of 
interactions between HUVEC and neutrophils which are mediated by these adhesion 
molecules in real time.  
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Neutrophils, which represent approximately 60% of all leukocytes, are widely used 
in different in vitro models to study inflammatory responses (Dudman et al., 1999; Jones et 
al., 1996; Woolhouse et al., 2005). Furthermore, adhesion of neutrophils to EC, as well as 
being the main event in acute inflammation, has also been shown to play a role in early 
atherosclerotic lesion development (Jia et al., 2005; Zernecke et al., 2008). While it is 
accepted that adhesion of monocytes and lymphocytes to EC appears to be important in the 
later stages including the formation of fatty streaks (reviewed by Lusis (2000)), this study 
focuses on roles of Hcy in initiation of atherosclerosis and thus neutrophils were used in the 
in vitro model. 
The data in Figure 24 demonstrate that DL-Hcy induced up-regulation of 
EC:neutrophil interactions under flow conditions: tethering, rolling, adhesion and 
transmigration (p<0.05 in all cases). Mayadas et al (1993) have previously demonstrated in 
genetically modified mice that P-selectin, on the level of EC, is the main mediator of the 
first contact between leukocyte and EC which was later termed tethering. However, the 
results from the static immunostaining experiments in this chapter did not give evidence of 
significant DL-Hcy-induced P-selectin up-regulation. Despite this, the number of tethered 
neutrophils on DL-Hcy-treated HUVEC as quantified in the flow model was significantly 
higher than that of non-treated or Cys-treated cells. Collectively, it could be concluded that 
DL-Hcy up-regulated P-selectin expression to a level high enough to mediate tethering 
between neutrophils and HUVEC and thus initiate the first step in the inflammatory 
response or atherosclerotic plaque formation. P-selectin density on activated EC in vivo is 
still unknown but thought to be much lower than E-selectin on also on the activated 
platelets surface (less than 10,000 per cell) (Blann et al., 2003). This level of expression 
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could be below the limit of detection for both ELISA and immunostaining and might 
explain why these technique used on static cells was not able to reveal significant 
expression of P-selectin. This data are in line with several previous studies which also 
failed to detect a significant expression of soluble P-selectin by HUVEC (Blann et al., 
2003). However, another study showed that Hcy induced up-regulation of both soluble P-
selectin and in aortic sections of hHcy mice (CBS deficient) (Weiss et al., 2002). This study 
used arterial EC which might express P-selectin at a higher level than venous EC which 
were used in this study. Collectively, these data suggest that it is difficult to detect P-
selectin even after appropriate stimulation. However, the flow model provided strong 
indirect evidence of DL-Hcy-induced P-selectin up-regulation (Figure 24). One study 
suggested that P-selectin can mediate rolling (Lawrence and Springer, 1991). However, this 
study was conducted on artificial lipid membranes containing different levels of 
immobilized E-selectin and P-selectin. Our lab has previously investigated role of P-
selectin in Hcy-mediated response under flow using specific blocking P-selectin antibodies 
and shown that blocking P-selectin inhibited tethering without affecting rolling and the 
following stages which means P-selectin is the main mediator of tethering (unpublished 
data). Immunostaining experiments in this chapter revealed that DL-Hcy induced 
significant expression of E-selectin (p<0.05). Furthermore, under flow conditions, the 
number of rolling neutrophils on DL-Hcy-treated HUVEC significantly increased which 
suggests that DL-Hcy treatment induced EC activation resulting in expression of the 
specific CAMs which mediate neutrophil rolling. Several studies have shown that E-
selectin is the main mediator of leukocyte rolling on activated EC and its level is negatively 
correlated with rolling velocity (Abbassi et al., 1993; Jung and Ley, 1999; Kunkel et al., 
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2000). Therefore, the significant increase in the number of rolling neutrophils in the flow 
model reflects an up-regulation of E-selectin expression under flow conditions. Therefore, 
the experiments in this chapter suggest that DL-Hcy-induced continued up-regulation of E-
selectin was responsible for mediating neutrophil rolling on EC.  
Immunostaining experiments gave strong evidence that DL-Hcy induces ICAM-1 
expression on HUVEC surface (p<0.05 compared to non-treated cells). It has been shown 
previously that members of the immunoglobulin superfamily, like ICAM-1 (Sligh et al., 
1993) and VCAM-1 (Carlos and Harlan, 1994) act as receptors for integrins on the 
leukocyte surface to mediate the firm adherence of leukocytes to EC. The results from the 
flow experiments strongly support these findings and collectively with the immunostaining 
results, it could be said that DL-Hcy induced ICAM-1 expression under static conditions. 
ICAM-1 expression was high enough to mediate the firm adhesion of neutrophils to 
HUVEC under flow conditions. On the other hand and despite the basal expression of 
ICAM-1 by non-treated cells which is seen in the immunostaining images (Figure 21), that 
was not enough to induce significant EC:neutrophil interactions under physiologically 
relevant flow conditions. 
Several previous studies have been conducted to investigate the effects of Hcy on 
EC:leukocyte interactions. An in vivo study on murine vein using intravital microscopy 
demonstrated that 1mM Hcy induced significant increases in leukocyte rolling within 1h of 
treatment (Pruefer et al., 1999). Despite their finding about CAM, Dudman’s group found 
that Hcy treatment induced enhanced neutrophil endothelial interactions in cultured human 
cells and in rat venules in vivo but they believe Hcy induces HUVEC to release appropriate 
cytokines like IL-8 and MCP-1 which will mediate such interactions (Dudman et al., 1999). 
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Hcy was shown also to enhance HAEC adhesion to activated mononuclear cells from 
patients with coronary artery diseases (Lin et al., 2008). Furthermore, treatment with 
200µM Hcy for 6h induced significant increases in monocyte adhesion to EC cell line 
(EA.hy 926) (Postea et al., 2006). Monocytes were also shown to adhere to Hcy-treated 
HAEC (100µM/18h) under static conditions and they demonstrated that VCAM-1 and 
ICAM-1 were involved in this step (Silverman et al., 2002). Dudman’s group demonstrated 
also that neutrophils adhered to Hcy-treated HUVEC. Furthermore, these neutrophils 
managed to migrate through the monolayer of HUVEC (Dudman et al., 1999).  
All of the above mentioned studies are consistent with the findings of this chapter 
although most of them were conducted under static conditions and studied only one type of 
EC:leukocyte interaction. Therefore, they do not provide a complete picture of what 
happens in humans with hHcy. Therefore, this study is the first to show that chronic 
exposure to DL-Hcy alone induces continuous up-regulation of these three CAMs up to 9 
days and also induces all types of interactions between DL-Hcy-treated EC and leukocytes 
under flow conditions in the absence of any additional cytokine stimulation. It is possible 
that chronic treatment with DL-Hcy will generate and maintain proinflammatory conditions 
by inducing the production of proinflammatory cytokines and that may augment the effects 
of DL-Hcy on CAM expression and leukocyte interaction with EC. These findings are 
different to the findings of pro-inflammatory cytokine effects on CAM expression e.g. 
cytokine-induced up-regulation of E-selectin which returns to basal within 24h (Bevilacqua 
et al., 1989) or histamine-induced up-regulation of P-selectin which peaks within 20min 
(McEver et al., 1989) then return to basal levels demonstrating differences in EC responses 
to chronic inflammatory mediator Hcy compared to TNF-α/histamine. 
131 
 
All the experiments conducted in this chapter found that results of Cys-treated cells 
were similar to non-treated cells which means that all of the observed effects with Hcy-
treated cells were specific to Hcy and were not reproducible with its metabolite Cys. These 
findings match with previous studies which confirmed the unique properties of Hcy-
induced EC damage (Carmel and Jacobsen, 2001; Jacobsen, 2000; Sengupta et al., 2001; 
Wang et al., 1997). This data also confirms that the relatively high Hcy concentrations are 
not affecting the cells through osmotic/nonspecific mechanisms. 
In summary, the static in vitro experiments showed that DL-Hcy-induced significant 
expression of E-selectin and ICAM-1 and to a lesser extent P-selectin on HUVEC cell 
surfaces. The direct demonstration of up-regulation is further enhanced by results in the 
flow model showing significant tethering (P-selectin), rolling (E-selectin) and firm 
adhesion (ICAM-1) in response to DL-Hcy. Collectively, chronic treatment with DL-Hcy 
had several vital consequences in EC. It significantly deceased proliferation rate and 
induced changes to genetic expression causing up-regulation of different CAM. These 
CAM in turn mediated different sorts of interactions between EC and leukocytes which 
represent the first step in atherosclerosis plaque formation.  
2.4. CONCLUSION 
Chronic exposure to high levels of DL-Hcy (1mM) did not kill HUVEC in culture. 
However, it caused a decrease in cellular proliferation rate. Furthermore, DL-Hcy induced 
changes in cell morphology and induced sustained gene expression in the EC which led to 
up-regulation of CAM as demonstrated both statically (immunofluorescence) and under 
flow. These DL-Hcy-induced CAM mediated the recruitment of leukocytes to the activated 
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EC and promoted significant interactions between the two cell types which can be 
considered to represent the first step in atherosclerosis lesion initiation. 
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CHAPTER 3 
3. JNK ROLE IN HCY-MEDIATED EC ACTIVATION 
EC activation has different consequences and might lead to cell apoptosis and/or 
cell involvement in inflammatory interactions. JNK involvement in this activation and 
cellular effects has been studied intensively. Various previous studies reviewed by Sumara 
et al (2005) reported a role for JNK in mediating TNF-α-induced apoptosis in different cell 
types. The downstream effects of JNK pathway activation includes phosphorylation of a 
number of transcription factors, including the c-Jun component of the activation protein-1 
(AP-1) transcription factor family (Sumara et al., 2005) in addition to other AP-1 proteins, 
including JunB, JunD and ATF2 (Davis, 2000). These transcription factors have functional 
binding sites on different genes including ICAM-1 (Voraberger et al., 1991), E-selectin 
(Hoefen and Berk, 2002; Min and Pober, 1997), VCAM-1 (Ahmad et al., 1998) and IL-8 
(Roebuck, 1999). All the products of these previous genes are reported to be involved in 
mediating interactions between leukocytes and endothelial cells and hence mediating the 
inflammatory response. This highlights the key role of JNK in inflammation and thus 
potentially in the chronic inflammatory disease atherosclerosis. Further evidence comes 
from experiments with knocked down JNK which induced up-regulation of other MAPK-
mediated pathways such as ERK1/2 (Hoefen and Berk, 2002) or other pathways involved in 
the development of atherosclerosis (Ricci et al., 2004). 
Chapter 2 indicates clearly that Hcy induced EC activation characterized by up-
regulation of several adhesion molecules in addition to increased numbers of 
HUVEC:neutrophil interactions. However, the signalling pathway through which Hcy 
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induces such effects is still unclear. Previously published work in cultured EC 
demonstrated that acute Hcy exposure induced activation of the stress activated MAP 
kinase family member JNK  and its downstream substrate c-Jun (Dong et al., 2005; Zhang 
et al., 2001b). Therefore, this chapter aimed to demonstrate whether chronic treatment with 
Hcy induces sustained activation of the JNK pathway and whether this pathway is 
responsible for the up-regulation of CAM already demonstrated in Chapter 2 under static 
and flow conditions.  
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3.1. MATERIALS and METHODS 
3.1.1. Materials 
3.1.1.1. Reagents  
All reagents used for SDS-PAGE and western blotting were of electrophoresis 
grade. Sodium dodecyl sulfate (SDS, L3771), glycine (G-8898), sodium pyrophosphate (S-
9515), bromophenol blue (B-5525), N,N,N′,N′-tetramethylethylenediamine (TEMED, T-
9281), DL-dithiothreitol (D-0632), polyoxyethylene-sorbitan monolaurate (Tween 20, P-
1397), bovine serum albumin (BSA, A-4503), ammonium persulfate (APS, A-3678), 1,9-
Pyrazoloanthrone (SP600125, S5567), Kodak GBX developer and replenisher (P7167) and 
Kodak fixer and replenisher (P7042), were all purchased from Sigma-Aldrich (Poole 
Dorset, UK). Acrylamide/Bis Solution (30%) was obtained from BioRad Labs (161.0156, 
Bio-Rad Laboratories, Hercules, California, USA). X-ray film was obtained from 
Amersham (Amersham hyperfilm ECL, RPN3114K) and PVDF membrane (Hybond-P, 
RPN303F) was purchased from GE healthcare, Buckinghamshire, UK. Reagents for 
enhanced chemiluminescence (ECL) were purchased from Amersham Life Sciences, Little 
Chalfont, Bucks, UK. 
3.1.1.2. Antibodies 
Mouse monoclonal antibodies against phospho-SAPK/JNK (catalog No. 9255) were 
purchased from Cell Signaling Technology Inc, Danvers, MA, USA. Rabbit polyclonal 
antibodies against phospho-SAPK/JNK (catalog No. V7931) were obtained from Promega, 
Southampton, UK. ECL anti rabbit IgG horseradish peroxidase linked whole antibody 
(NA934V) and ECL anti mouse IgG horseradish peroxidase linked whole antibody 
(NA931V) were obtained from GE healthcare UK limited, Buckinghamshire, UK. 
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Prestained protein marker broad range (P7707S) was purchased from New England 
Biolabs. Biotinylated protein ladder (catalog No. 7727) and HRP conjugated anti biotin 
antibodies (catalog No. 7075) were purchased from Cell Signalling Technology. The 
diluent which has been used to dilute all antibodies was TBS-T including 2% w/v BSA. 
3.1.1.3. JNK inhibition 
SP600125 was used to inhibit the activity of phosphorylated JNK. It was added to 
the media with the DL-Hcy to a final concentration of 3μM, which has been previously 
shown to selectively inhibit JNK without affecting any other MAPK family members 
(Bennett et al., 2001). Media was changed every 24h during the treatment with SP600125 
to avoid any possible degradation of the inhibitor. 
3.1.2. Methods 
3.1.2.1. Detection of phospho-JNK by sodium dodecylsuphate polyacrylamide gel 
electrophoresis (SDS-PAGE) and western blotting 
3.1.2.1.1. Preparation of samples for analysis by SDS-PAGE 
Following the appropriate stimulation, the reaction was stopped by placing the 
plates containing cells on ice and rinsing twice with ice-cold HPFEV buffer (50mM Hepes, 
10mM sodium pyrophosphate, 100mM sodium fluoride, 4mM EDTA, 2mM 
orthovanadate). Integrity of the confluent monolayers was confirmed by microscopic 
observation. 300μl of hot (65°C) Laemmli buffer (0.048M Tris-HCl, pH 6.8 containing 
0.8mM sodium pyrophosphate, 5mM EDTA, 2% w/v SDS, 10% glycerol, 001% w/v 
bromophenol blue, 50mM DTT) (Laemmli, 1970) was then added. A cell scraper was used 
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to harvest the cells and the cell lysate homogenized through a fine 23G needle several 
times. Samples were boiled for 5min and then stored at -20°C until analysis.  
3.1.2.1.2. Determination of protein concentration 
Protein assay was applied on cell lysate (without bromophenol blue) using BioRad 
protein assay kit (500-0120). The protocol supplied by the manufacturer was followed. 
Serial dilutions of BSA in PBS (0.2mg/ml – 1.5mg/ml) were prepared and used as 
standards. 5µl of all of the standards and the cell lysate were added to a 96 well plate in 
triplicate. 25µl reagent A
*
 (2% v/v reagent S in reagent A) was added to each well and then 
200µl reagent B was added to each well. The plate was incubated for 15min at room 
temperature with gentle agitation. Within an hour, absorbance was read at 750nm. The 
volume of sample containing 30µg of protein was then calculated and used in the following 
steps.  
3.1.2.1.3. Resolution of protein by SDS PAGE 
A Biorad mini protean gel electrophoresis kit was used to run all gels. Tris buffers 
were prepared and stored at room temperature for both resolving gel (1.5M Tris and 0.4% 
w/v SDS, pH 8.4) and stacking gel (0.5M Tris and 0.4 
 
w/v SDS, pH 6.8). 10% resolving 
gel (appendix 2) was prepared and poured in-between glass plates and spacers (1.5mm 
thick) to a level 1cm below the bottom of the combs when inserted and overlaid with 1% 
w/v SDS solution. Once the resolving gel polymerized, a 3% stacking gel (appendix 2) was 
poured on the top and a 1mm comb was inserted. Following gel polymerization, they were 
connected to an electrode and placed in a Perspex tank containing electrophoresis buffer 
(25mM Tris base, 192mM glycine and 0.1% w/v SDS, pH 8.3). Appropriate volume 
containing 30µg were loaded per well and also 5µl of control pre-stained protein ladders 
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and of biotinylated standards were uploaded into two of the wells. Samples were 
electrophoresed at a constant voltage of 100V for 2h. 
3.1.2.1.4. Western Blotting 
A Biorad mini transfer kit was used for the transfer of proteins to PVDF membrane. 
PVDF membranes were pre-wet in methanol for 5min and then washed with distilled water 
and blotting buffer (25mM Tris base, 192mM glycine and 20% v/v methanol) for 15 min 
each. A transfer sandwich was prepared containing sponge, blotter paper, resolving gel and 
the pre-wet PVDF membrane. This sandwich was inserted into a transfer tank filled with 
blotting buffer. The whole tank was engulfed with ice and connected to the power supply at 
100V for 2h. 
3.1.2.1.5. Detection of protein 
Once transfer was completed, PVDF membrane was placed in blocking solution of 
10% w/v BSA in tris buffer saline-Tween (TBS-T) (150mM sodium chloride, 20mM Tris 
base pH 7.4) containing detergent (Tween 20) at a concentration of 0.1% v/v. The 
membrane was then incubated with phospho-SAPK/JNK mouse mAb (1:2000) or phospho-
SAPK/JNK rabbit pAb (1:5000) overnight with agitation at RT. The following day, the 
membrane was washed 4x for 15min with 20ml TBS-T and then incubated with either 
horseradish peroxidase (HRP)-conjugated sheep anti-mouse IgG (1:10000) or horseradish 
peroxidase (HRP)-conjugated sheep anti-rabbit IgG (1:10000) for 1h at room temperature 
depending on which primary Ab was used. Membrane was washed as previously described. 
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3.1.2.1.6. Detection of protein by enhanced chemiluminescence (ECL) 
Following the final wash, membrane was incubated in equal amount of ECL 
solution 1 and 2 for 90s with gentle agitation and then placed in developing cassette, 
covered with saran wrap excluding air bubbles. Amersham X-ray film was exposed to the 
membrane in the dark for up to 10min. Film was immersed in developing solution until 
bands were visible, then it was washed with tap water before immersing it in fixing solution 
until the film became translucent. Film was rinsed thoroughly with tap water and left to air 
dry. 
All western blotting experiments were performed on at least 3 independent samples 
and densitometric analysis of ECL exposure was performed using ImageJ software. 
3.1.2.2. JNK activity assay  
Ready kit (catalog # 9810) from Cell Signaling Technology Inc, Danvers, MA, 
USA was used:  
3.1.2.2.1. Antibodies 
Rabbit polyclonal IgG phospho-c-Jun (Ser63) antibody was obtained from Cell 
Signaling Technology Inc, Danvers, MA, USA (unique to the kit #9810) and used after 
diluting (1:10000). ECL anti rabbit IgG horseradish peroxidase linked whole antibody 
(NA934V) was obtained from GE healthcare UK limited, Buckinghamshire, UK and used 
after diluting (1:5000). The diluent which has been used to dilute all antibodies was TBS-T 
including 2% w/v BSA. 
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3.1.2.2.2. Preparation of cell lysate for JNK activity assay  
Following the appropriate stimulation, cells were harvested under nondenaturing 
conditions. The reaction was stopped by placing the plates on ice and rinsing twice with 
ice-cold PBS. 500µl of ice-cold cell lysis buffer (20 mM Tris (pH 7.4), 150mM NaCl, 1mM 
EDTA, 1mM EGTA, 1% Triton, 2.5mM sodium pyrophosphate, 1mM b-
glycerolphosphate, 1mM Na3VO4, 1μg/ml leupeptin) was then added. A cell scraper was 
used to harvest the cells and the cell lysate was sonicated on ice for 5s, 3 times. The cell 
lysates were then microcentrifuged at 14000g for 10min at 4°C. The supernatant (cell 
lysate) was collected and stored at -80°C until analysis. 
3.1.2.2.3. Immunoprecipitation with immobilized c-Jun fusion protein 
20µl of immobilized c-Jun fusion protein beads slurry was added to 200µl cell 
lyasate and incubated with gentle rocking overnight at 4°C. 
3.1.2.2.4. Kinase assay 
Cell lysate/immobilized c-Jun fusion protein was microcentrifuged at 14000g for 
30s at 4°C. The pellet then was washed twice with 500µl cell lysis buffer with 
microcentrifuging after each wash (14000g for 30s at 4°C). The washing steps were 
repeated using 500µl Kinase buffer (25mM Tris (pH 7.5), 5mM b-glycerolphosphate, 2mM 
DTT, 0.1mM Na3VO4, and 10mM MgCl2). Samples were kept on ice between and during 
washes. Following washing steps, the pellet was suspended in 50µl kinase buffer 
supplemented with 200µM ATP and incubated for 30min at 30°C. The reaction was then 
terminated by adding 25µl 3x SDS sample buffer (187.5mM Tris-HCl (pH6.8 at 25°C), 6% 
w/v sodium dodecyl sulfate (SDS), 30% v/v glycerol, 150mM dithiothreitol (DTT), 0.03% 
w/v bromophenol blue). Samples then were vortexed and microcentrifuged for 30s.  
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3.1.2.2.5. Western immunoblotting 
Samples were heated to 95-100°C for 2-5min then loaded on 10% SDS-PAGE gel 
and electrophoresis and western blotting carried out as detailed in section 3.1.2.1.  
Other techniques which have been used in this chapter to detect the 
HUVEC:neutrophil interactions and CAM expression have been previously described in 
section 2.1.   
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3.2. RESULTS 
3.2.1. The effects of chronic exposure to DL-Hcy on the activation of JNK  
HUVEC were cultured in media containing 1mM of DL-Hcy for a period of 5-9 
days, including at least one passage. Cells were also stimulated with TNF-α (120U/ml; 
20min) as a positive control. Antibodies against phosphorylated JNK were used to detect 
JNK activation in the cell lysates. Results from repeated protein assays showed the protein 
concentration in the cell lysates from confluent 35mm dishes was reproducibly just below 
1mg/ml (Figure 26). 
 
The protein assay of cell lysis from 35mm culture dish 
 
Figure 26: Representative graph showing the results of one protein assay. A serial 
dilution of BSA in PBS was prepared and absorbance was read at 750nm. The 
absorbance of this sample was 0.14 and when it is plotted on the graph, protein 
concentration showed to be nearly 1mg/ml. 
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Western blotting was conducted to verify if treatment with DL-Hcy resulted in 
detectable phosphorylated JNK protein. Figure 27A shows protein bands of 46kD and 
54kDa representing phosphorylated JNK1 and JNK2 respectively for both DL-Hcy- and 
TNF-α-treated cells. Figure 27A is representative of 4 different experiments with samples 
from 4 different donors. The band densities were quantified using ImageJ and the results 
are shown as the mean number from 4 different experiments +/- SD (Figures 27B and 27C 
for JNK1 and JNK2 respectively). HUVEC grown in complete M199 media showed less 
intense bands suggesting that JNK was not phosphorylated in non-treated cells. However, 
HUVEC grown in media containing DL-Hcy (1mM), showed significantly activated JNK1 
presented by the bands of p-JNK1 (46kDa) (p<0.05) (Figure 27A) and quantified in Figure 
27B. DL-Hcy-treated HUVEC also showed some increase in phosphorylation of JNK2 
(54kDa) compared to non-treated cells (Figure 27A) however, this increase was 
insignificant (p>0.05) indicating that chronic treatment with DL-Hcy did not significantly 
activate the JNK2 isoform (Figure 27C). Furthermore, Figure 27A shows that TNF-α 
induced activation of both isoforms, JNK1 and JNK2. 
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The effects of chronic exposure to DL-Hcy on the activation of JNK isoforms 
 
 
 
 
  
 
Figure 27: A: Representative blot showing the effects of chronic exposure to DL-Hcy on 
the activation of different JNK isoforms in HUVEC. HUVEC were cultured in media 
containing DL-Hcy (1mM) for 5-9 days until confluence and then lysed. TNF-α (120U/ml, 
20min) was used as a positive control. 30µg protein from each sample was used in the 
western blot. Phosphorylated JNK was detected using specific antibodies and was identified 
as a band of approximately 46kDa (JNK1) and 54kD (JNK2). B and C: Density of both 
46kDa (JNK1) and 54kDa (JNK2) bands represented in Figure 27A and from 3 further 
experiments with independent samples were quantified using ImageJ software. These 
graphs represent the results for non-treated and DL-Hcy-treated HUVEC which are 
expressed as mean (+/- SD) from 4 different donors for DL-Hcy and non-treated (n=4). 
Non-treated values were defined as 100% and DL-Hcy values were adjusted accordingly. 
(*) p < 0.05 for DL-Hcy versus non-treated cells. 
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3.2.2. The effects of chronic exposure to DL-Hcy and SP600125 on the activation of c-
Jun 
The activation of JNK in response to stimulation with DL-Hcy alone or in 
combination with SP600125 was assessed by measuring the activation of the downstream 
substrate of JNK, c-Jun. Figure 28A shows a protein band of 48kD representing 
phosphorylated c-Jun for both DL-Hcy- and TNF-α-treated cells (positive control). Figure 
28A is representative of 3 different experiments with 3 different donors. The band densities 
were quantified, and are shown as the mean number from 3 different experiments +/- SD 
(Figure 28B). Cells which were grown in media containing 1mM DL-Hcy alone showed 
significantly activated c-Jun represented by bands of phosphorylated c-Jun (approximately 
5-fold increase) (p<0.05). However, cells which were treated with DL-Hcy (1mM) along 
with SP600125 (3µM) did not show activated c-Jun. Cells from the same donors were 
treated with 1mM Cys and those showed no activation of JNK. SP600125 alone was not 
able to induce any activation of c-Jun.  
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The effects of chronic exposure to DL-Hcy on the activation of c-Jun 
 
 
 
  
 
 
 
Figure 28: A: Representative blot showing the effects of chronic exposure to DL-Hcy on 
the activation of c-Jun in HUVEC. HUVEC were cultured in media containing 1mM of 
DL-Hcy, 1mM DL-Hcy and 3µM SP600125, or 1mM Cys for 5-9 days until confluence 
and then lysed. TNF-α (120U/ml, 20min) was used as a positive control. Non-treated and 
Cys-treated HUVEC from the same donor were used in each experiment as negative 
controls. 30µg protein from each sample was used in western blot. Phosphorylated c-Jun 
was detected using specific antibodies and was identified as a band of approximately 48kD. 
B: Density of the bands represented in Figure 28A and from 2 further experiments with 
independent samples were quantified using ImageJ software. These graphs represent the 
results for non-treated, DL-Hcy alone or with SP600125, and Cys-treated HUVEC which 
are expressed as mean (+/- SD) from 3 different experiment (n= 3). Non-treated values 
were defined as 100% and other values were adjusted accordingly. (*) p < 0.05 for DL-Hcy 
versus non-treated cells, (**) p < 0.05 for DL-Hcy versus DL-Hcy/Sp600125-treated cells. 
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3.2.3. The role of JNK in mediating DL-Hcy-induced CAM expression 
Specific FITC-tagged antibodies against E-selectin, ICAM-1 and P-selectin were 
used to study the expression of these CAM on DL-Hcy-treated HUVEC as described in 
section 2.1.2.6. Both E-selectin and ICAM-1 showed high fluorescence in response to DL-
Hcy treatment (Figures 29B and 30B) compared to non-treated (Figures 29A and 30A). 
However, such fluorescence was not evident in response to DL-Hcy/ SP600125 for both E-
selectin and ICAM-1 (Figures 29C and 30C). Quantifying these results using ImageJ 
software revealed that DL-Hcy induced significant expression of E-selectin (Figure 29D) 
and ICAM-1 (Figure 30D) compared to non-treated controls (p<0.05). On the other hand, 
SP600125 prevented the effects of DL-Hcy on E-selectin and ICAM-1 expression to a level 
similar to non-treated controls (p>0.05) and significantly lower than DL-Hcy-treated cells 
(p<0.05) (Figure 29D and 30D).  
P-selectin did not show high fluorescence in response to DL-Hcy treatment (Figure 
31B) or DL-Hcy/SP600125 treatment (Figure 31C) compared to non-treated controls 
(Figure 31A). Quantifying these results using ImageJ software revealed that DL-Hcy 
induced slight increase in P-selectin expression compared to non-treated controls and this 
increase was prevented by SP600125 treatment (Figure 31D). However, there were no 
significant differences in the level of P-selectin expression between the three groups 
(p>0.05). 
3.2.4. The role of JNK in mediating DL-Hcy effects on EC:neutrophil interactions 
Compared with non-treated cells, cells treated with DL-Hcy showed a significant 
increase in their interactions with flowing neutrophils (as explained in section 2.2.3.6). 
When HUVEC were treated with DL-Hcy and the JNK/SAPK inhibitor SP600125, the 
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numbers of tethered, rolled, fixed and transmigrated neutrophils were decreased 
significantly to a level similar to the numbers of interactions of non-treated cells (Figure 
32). Vehicle samples were prepared where cells were treated with SP600125 alone and 
those cells showed no activation and the numbers of different interactions were similar to 
those of non-treated cells (data not shown). 
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The role of JNK in mediating DL-Hcy effects on E-selectin expression 
 
 
Figure 29: Representative images showing the effect of DL-Hcy on E-selectin expression 
on HUVEC surface in the presence and absence of SP600125. HUVEC were grown in 
complete M199 medium and either not treated or treated with DL-Hcy (1mM) alone or with 
SP600125 (3µM) for 5-9 days. Then, fixed cells were immunostained with FITC-tagged 
antibodies against E-selectin. A: non-treated HUVEC, B: DL-Hcy-treated HUVEC, C: DL-
Hcy and SP600125-treated HUVEC, D: Fluorescence density of the A, B and C was 
quantified using ImageJ software. These graphs represent the results for DL-Hcy- and DL-
Hcy/SP600125-treated HUVEC which are expressed as mean +/- SEM (n = 4). Non-treated 
values were defined as 100% and other values were adjusted accordingly. (*) p < 0.05 for 
DL-Hcy versus non-treated cells and DL-Hcy/SP600125-treated cells. 
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The role of JNK in mediating DL-Hcy effects on ICAM-1 expression 
 
 
Figure 30: Representative images showing the effect of DL-Hcy on ICAM-1 expression on 
HUVEC surface in the presence and absence of SP600125. HUVEC were grown in 
complete M199 medium and either not treated or treated with DL-Hcy (1mM) alone or with 
SP600125 (3µM) for 5-9 days. Then, fixed cells were immunostained with FITC-tagged 
antibodies against ICAM-1. A: non-treated HUVEC, B: DL-Hcy-treated HUVEC, C: DL-
Hcy and SP600125-treated HUVEC, D: Fluorescence density of the A, B and C was 
quantified using ImageJ software. These graphs represent the results for DL-Hcy- and DL-
Hcy/SP600125-treated HUVEC which are expressed as mean +/- SEM (n = 4). Non-treated 
values were defined as 100% and other values were adjusted accordingly. (*) p < 0.05 for 
DL-Hcy versus non-treated cells and DL-Hcy/SP600125-treated cells. 
 
50μM
A
B
C
D
152 
 
The role of JNK in mediating DL-Hcy effects on P-selectin expression 
 
 
Figure 31: Representative images showing the effect of DL-Hcy on P-selectin expression 
on HUVEC surface in the presence and absence of SP600125. HUVEC were grown in 
complete M199 medium and either not treated or treated with DL-Hcy (1mM) alone or with 
SP600125 (3µM) for 5-9 days. Then, fixed cells were immunostained with FITC-tagged 
antibodies against P-selectin. A: non-treated HUVEC, B: DL-Hcy-treated HUVEC, C: DL-
Hcy and SP600125-treated HUVEC, D: Fluorescence density of the A, B and C was 
quantified using ImageJ software. These graphs represent the results for DL-Hcy- and DL-
Hcy/SP600125-treated HUVEC which are expressed as mean +/- SEM (n = 3). Non-treated 
values were defined as 100% and other values were adjusted accordingly. 
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The role of JNK in DL-Hcy-mediated interactions 
 
Figure 32: The effects of the JNK inhibitor, SP600125, on HUVEC:neutrophil 
interactions under flow conditions. HUVEC were stimulated with DL-Hcy (1mM; 5-
9 days) alone or with 3µM SP600125 and the effects on EC:neutrophil interactions 
under flow conditions were observed and quantified. HUVEC from the same donor 
were grown in media without any stimulation and were considered as negative 
control (non-treated) in each experiment. The results are expressed as mean (+/- SD) 
from 5 different donors (n=5). (*) p < 0.05, (**) p < 0.01 for DL-Hcy versus DL-
Hcy/SP600125 treated cells. 
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3.3. DICUSSION 
While the activation of HUVEC by sustained exposure to Hcy has been clearly 
shown in Chapter 2, the mechanisms responsible require characterisation. JNK is a signal 
transducer that has been implicated in both cell survival and cell apoptosis (Barr and 
Bogoyevitch, 2001). The functional cellular outcome downstream of JNK activation 
depends on the cell type, stimulation type and environmental circumstances (Hoshino et al., 
2005). JNK activation is regulated by upstream kinases MKK4/7 and by dual specificity 
phosphatases that dephosphorylate and inactivate JNK. Therefore, either activation of 
MKK4/7, decreased JNK phosphatase activity or combination of both can lead to JNK 
activation (Chen et al., 2001a). Previous studies have shown that JNK is activated in 
response to acute treatment with Hcy (up to 24h) in HUVEC (Cai et al., 2000; Dong et al., 
2005; Zhang et al., 2001b). No studies have been carried out to demonstrate if the 
activation of JNK is sustained in EC over longer periods of time in response to Hcy. 
Therefore, in this chapter, HUVEC were exposed to DL-Hcy chronically (5-9 days) and the 
effects of this extended treatment in HUVEC were investigated to determine whether this 
treatment induces sustained activation of JNK. DL-Hcy induced a 2-fold increase in the 
level of phosphorylated JNK1 compared to non-treated control cells (p<0.05) on continual 
stimulation for 5-9 days (Figure 27). It has been suggested that only the large isoform of 
JNK (54kD) gets phosphorylated in murine atherosclerotic lesions (Ricci et al., 2004). 
However these authors were not able to specify in which cell type of the lesion the 54kDa 
JNK isoform was phosphorylated. This chapter’s results clearly indicate that only JNK1 
(46kDa) was phosphorylated in chronically Hcy-treated HUVEC.  
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The antibodies used in this chapter recognize the active forms of JNK1, JNK2, and 
JNK3 isoforms. Therefore, these antibodies were able to recognize both JNK1 (46kDa) and 
JNK2 (54kDa) which are known to be expressed in EC. The data of this chapter clearly 
indicate that Hcy preferentially activated the JNK1 isoform which was suggested by 
Sabapathy et al (2004) to play a major role in activating c-Jun. However, TNF-α activated 
both JNK1 and JNK2 isoforms which means different other substrates will be activated in 
addition to c-Jun. This will lead to amplifying TNF-α effects compared to Hcy and might 
explain the robust effects of TNF-α compared to Hcy in inducing EC activation, such as the 
effects observed in CAM up-regulation in Chapter 2 (Figures 20C and 21C). 
Several published acute studies have demonstrated similar findings, however none 
of them have identified which JNK isoform was activated. Cai’s group treated HUVEC 
with 3mM Hcy which induced significant and rapid phosphorylation of JNK within 30min 
and this phosphorylation was sustained for the duration of the experiment (8h) (Cai et al., 
2000). Zhang’s group gave evidence that JNK was still activated after 12h of treatment 
with 3mM Hcy (Zhang et al., 2001b). Furthermore, Dong et al showed that JNK remained 
activated after 24h treatment with 1mM Hcy (Dong et al., 2005). Therefore, it could be said 
that JNK stayed activated for the duration of exposure to Hcy (up to 24h). However, 24h 
treatment was not enough to ensure that cells were exposed to Hcy through all stages of 
cellular proliferation. Therefore, this chapter confirms the previous findings and 
additionally has given strong evidence that a longer exposure to DL-Hcy induces 
continuous activation of JNK after up to 9 days treatment indicating that JNK was always 
activated in the presence of DL-Hcy (Alkhoury et al., 2009a). This is in contrast to data 
obtained with other cellular stresses implicated in atherosclerosis such as TNF-α. JNK is 
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activated in response to TNF-α in HUVEC and peaks after 15min but decreases sharply 
after 60min with a maximum activation at 30min (Zhou et al., 2007) due to action of JNK 
phosphatase (Cavigelli et al., 1996). This chapter along with the previously described more 
acute studies (Cai et al., 2000; Dong et al., 2005; Zhang et al., 2001b) gives evidence for a 
continuous up-regulation of JNK at all time points measured in response to continuous 
treatment with Hcy. Therefore, these findings might indicate that chronic exposure to Hcy 
in patients with hHcy could induce sustained activation of JNK pathway. Despite the clear 
results in Figure 27, the antibodies used in the western blotting experiments produced 
variable results from different batches of antibody. Due to the unreliability of the antibodies 
used from both NEB and Promega, a JNK assay kit was also used to quantify the activation 
of JNK downstream substrate, c-Jun. In DL-Hcy-treated cells, activated JNK induced 
approximately a 5-fold increase in the activation of its downstream substrate c-Jun (Figure 
28). On the other hand, Cys was not able to induce c-Jun activation which means these 
effects are not non-specific but are mediated by Hcy.  
JNK isoforms have been suggested to interact differently with different substrates 
such as c-Jun and ATF-2 (Gupta et al., 1996). JNK2 was found to have 10-times and 25-
times higher affinity to c-Jun than JNK1 in COS-1 cells  (Sluss et al., 1994) and in Jurkat 
cells (Kallunki et al., 1994) respectively.  Both studies suggested that JNK2 preferentially 
phsphorylates c-Jun due to its high binding affinity compared to JNK1. However, 
Sabapathy et al (2004) suggested that this binding affinity represents a mechanism by 
which JNK2 works as a negative regulator of c-Jun stability and that, in unstimulated 
fibroblasts, most c-Jun is found bound to JNK2. Once these cells are stimulated, JNK2 
leaves the c-Jun therefore, giving more access to activated JNK1 leading to c-Jun 
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phosphorylation (Sabapathy et al., 2004). Therefore, Sabapathy’s group suggested JNK1 to 
be the main contributor to c-Jun activation. Furthermore, the same group found JNK1 to 
preferentially bind and activate ATF2 (Sabapathy et al., 2004). Collectively, it is very clear 
that different JNK isoforms interact differently with different substrates. DL-Hcy was 
shown to preferentially activate JNK1 which might preferentially activate c-Jun compared 
to JNK2. Even though activated JNK1 was able to induce significant activation of the 
downstream c-Jun in this chapter, this activation was less than that induced by TNF-α and 
that was clearly because TNF-α was able to induce more activation of JNK1 in addition to 
activating JNK2. 
Cumulatively, this chapter shows that chronic treatment of HUVEC with DL-Hcy 
activated JNK1 isoform (46kDa) and although it is yet unknown whether the activity of 
JNK would be affected by which isoform is being phosphorylated, this chapter also 
demonstrates that DL-Hcy-induced activation of the JNK1 was efficient enough to induce 
activation of its substrate c-Jun and mediated cellular effects on CAM expression. 
However, it is not currently clear whether Hcy effects are via activating MKK4/7 and/or 
decreasing in JNK phosphatase activity.  
It was demonstrated in Chapter 2 that DL-Hcy induced P-selectin, E-selectin and 
ICAM-1 expression which in turn mediates different sorts of HUVEC:neutrophil 
interactions. However, a little is known about the pathway through which Hcy induces 
CAM up-regulation. Therefore, to study to which extent JNK is implicated in mediating 
Hcy effects on CAM expression, the JNK specific inhibitor SP600125 was used and cells 
were incubated with SP600125 and DL-Hcy together for 5-9 days. SP600125 has been 
previously shown to selectively inhibit JNK with an IC50 of 40nM and to have no 
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significant effects on other MAP kinase activities (Bennett et al., 2001; Bogoyevitch, 
2005). SP600125 has been used as a JNK specific inhibitor by several in vivo studies 
reviewed by Sumara et al (2005) and in vitro studies (Ennis et al., 2005; Miho et al., 2005; 
Zhou et al., 2007). SP600125 showed a higher selectivity for the JNK pathway over other 
inflammatory response mediators in Jurkat T cells (Bennett et al., 2001). 3µM SP600125 
was used in this chapter and gave a strong inhibition of JNK activation. The results of the 
JNK activity assay in Figure 28 show that DL-Hcy-mediated c-Jun activation was totally 
reversed by SP600125 thus showing effective blockade of DL-Hcy-induced JNK pathway 
activation. Thereafter, the role of JNK in mediating DL-Hcy induced CAM expression was 
studied under both static and flow conditions. Using FITC-tagged antibodies against P-
selectin, E-selectin and ICAM-1 as explained in Chapter 2 it was revealed that SP600125 
suppressed DL-Hcy-induced E-selectin and ICAM-1 expression (Figures 29 and 30). 
Quantifying the images from 4 independent experiments on cells from different donors 
using ImageJ showed that there was no significant difference in expression between DL-
Hcy/SP600125-treated cells and non-treated cells (P>0.05), while significant difference in 
expression was observed between DL-Hcy-treated cells and DL-Hcy/SP600125-treated 
cells (p<0.05) (Figure 29D and 30D). On the other hand, P-selectin expression showed no 
significant differences between all types of treatment and non-treated cells (Figure 31). 
Therefore, blocking the JNK pathway inhibited DL-Hcy-induced E-selectin and ICAM-1 
expression while results of P-selectin were not interpretable as the immunofluorescence 
technique was not able to reveal significant P-selectin expression in response to Hcy alone 
(as explained in Chapter 2). Further experiments to determine the functional significance of 
the alterations in adhesion molecule expression were carried out under flow conditions 
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where neutrophil recruitment was quantified. HUVEC treated with DL-Hcy and SP600125 
were subjected to flowing neutrophils and interactions were counted. DL-Hcy alone 
induced significant increases in all types of interactions between HUVEC and neutrophils 
compared to non treated controls (p<0.05 in all cases) (as explained in Chapter 2). 
However, blocking JNK pathway activation by SP600125 was able to reverse all of these 
effects. Numbers of tethered, rolled, adhered and transmigrated neutrophils dramatically 
decreased and were similar to non-treated cells (p values were ranging from 0.2 to 0.8) 
(Figure 32). The dramatic decrease in the number of rolling and adhered neutrophils is 
likely to reflect a down-regulation of the expression of E-selectin and ICAM-1 respectively 
which are known to mediate these interactions. Therefore, it could be said that JNK plays a 
key role in mediating DL-Hcy effects on E-selectin and ICAM-1 expression on the 
HUVEC surface. The immunofluorescence results confirm that JNK is mediating the up-
regulation of E selectin and ICAM-1 on the EC surface in response to DL-Hcy. These 
findings match with other studies which showed that JNK mediates TNF-α-induced E-
selectin up-regulation in HUVEC (Min and Pober, 1997). The results in this chapter are 
also in agreement with the findings of Miho’s group, who showed that thrombin-induced 
ICAM-1 up-regulation is mediated by JNK in both HUVEC and BAEC by a mechanism 
that is dependent on G proteins (Miho et al., 2005). However, different mechanisms by 
which Hcy induces JNK activation were suggested like induction of oxidative stress (to be 
discussed in Chapter 4). Miho’s group used the same JNK inhibitor which has been used in 
this chapter SP600125 but at a higher concentration (10 and 30µM) and it showed 
inhibition of thrombin up-regulation of ICAM-1 in HUVEC. However, once they used 
equivalent concentrations of SP600125 to those used in this chapter, there was no 
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significant inhibition of thrombin-induced ICAM-1 up-regulation. It might be that thrombin 
induced robust activation of JNK compared to that induced by Hcy in this chapter. 
Therefore, higher concentrations of the JNK inhibitor SP600125 were needed to overcome 
this thrombin-induced JNK robust activation than those used to overcome Hcy-induced 
JNK activation. 
Zhou’s group found that 30µM SP600125 significantly inhibited TNF-α-induced 
JNK activation in HUVEC by 75% (Zhou et al., 2007). However, they found that JNK was 
not involved in TNF-α-induced ICAM-1 up-regulation as 30µM SP600125 was not able to 
significantly reverse TNF-α effects and they suggested it to be NF-κB-mediated instead. 
SP600125 was recommended to be specific for JNK inhibition at concentration of 3µM 
which was enough to totally inhibit the JNK pathway activation as this chapter shows. 
Furthermore, this concentration of SP600125 totally reversed Hcy-induced ICAM-1 up-
regulation under static and flow conditions. Collectively, that suggests a strong 
involvement of JNK in ICAM-1 Hcy-mediated expression; Zhou’s study however suggests 
that TNF-α-mediated ICAM-1 expression happens mainly through NF-κB-mediated 
pathway. These data together suggest that ICAM-1 expression could be mediated by 
different pathways depending on the stimuli. 
While immunofluorescence studies on P-selectin could not confirm up-regulation of 
this adhesion molecule, the flow data strongly suggests that some up-regulation is going on 
and this is confirmed by the tethering reactions in response to Hcy under flow. The 
inhibition of tethering when the JNK pathway is blocked strongly implicates a role for JNK 
in P-selectin expression, a previously unreported phenomenon. P-selectin is presynthesized 
and stored in WPB in the EC and will be mobilized to the cell surface once appropriate 
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stimuli are present (Hattori et al., 1989). Chronic exposure to certain appropriate stimuli, 
like TNF-α, induces continuous expression of P-selectin on mouse EC surface (Hahne et 
al., 1993). Half of the expressed P-selectin will be shed by proteolysis (Hartwell et al., 
1998) and the other half internalised and recycled to WPB (Arribas and Cutler, 2000). 
Therefore, there must be a synthesizing mechanism for new P-selectin to guarantee its 
continuous expression. TNF-α was shown previously to induce P-selectin in mice in a 
mechanism similar to TNF-α-induced E-selectin synthesis (Hahne et al., 1993). JNK in this 
chapter was shown to play a role in DL-Hcy-mediated P-selectin expression measured by 
number of tethered neutrophils under flow conditions; however, P-selectin expression could 
result from WPB exocytosis or from de novo synthesis. The flow experiments from the first 
chapter provided evidence that DL-Hcy induced continuous expression of P-selectin on 
HUVEC and this chapter provided evidence that JNK activation is required for this 
expression. These results together indicate for the first time that JNK is involved in 
mediating synthesis of P-selectin and/or WPB exocytosis in HUVEC. Therefore, the 
question which remains unresolved is whether JNK mediates WPB exocytosis or de novo 
synthesis of P-selectin.  
The use of MAP kinase inhibitors like SP600125 has been criticized in several 
reports reviewed by Bain et al (2003). It is argued that it might not be very specific and 
might interfere with other proteins which might give misleading results. In fact, another 
technique may be used to confirm the findings of this chapter, small interfering (siRNA) 
could be used to down-regulate the expression of JNK in HUVEC and then study whether 
P-selectin synthesis and/or expression is affected. On the other hand, the mechanism by 
which Hcy is inducing JNK pathway activation is still unknown and the next chapter will 
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focus on the ability of Hcy to induce ROS generation and whether those radicals are 
involved in mediating the JNK pathway activation. 
3.4. CONCLUSION 
The JNK MAP kinase pathway is a key pathway in DL-Hcy-mediated HUVEC 
activation and potential damage. JNK mediates DL-Hcy-induced CAM up-regulation which 
in turn mediates the HUVEC:neutrophil interactions under flow conditions. Blocking this 
pathway with a specific JNK inhibitor (SP600125) reversed all the effects of DL-Hcy and 
provided an evidence of potential therapeutic benefit of JNK specific inhibitors in 
preventing unwanted inflammatory responses.  
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CHAPTER 4  
4. THE ROLE OF OXIDATIVE STRESS IN HCY-MEDIATED EC 
ACTIVATION 
Oxidative stress is a cellular condition which results from high levels of ROS and/or 
impaired defective function of antioxidant defence systems (Sies, 1997) and it has been 
shown in many studies to be associated with cardiovascular diseases (Cai and Harrison, 
2000; Dimmeler et al., 1997; Kanani et al., 1999; Loscalzo, 1996; Sorescu et al., 2002).  
Hcy contribution to the onset of cardiovascular disease has more recently been 
explained by several pathogenic mechanisms including generation of reactive oxygen 
species (ROS)(Loscalzo, 1996), endoplasmic reticulum stress (Ji and Kaplowitz, 2004), 
genetic disruption (Kokame et al., 1996) and abnormal fibrinolysis (Hajjar et al., 1998). 
The majority of evidence from previous reports indicates that oxidative stress could be 
responsible for Hcy atherogenic effects (Papatheodorou and Weiss, 2007). Several possible 
theories have been suggested for Hcy-induced oxidative stress including auto-oxidation of 
the free thiol group in Hcy (Misra, 1974), inhibition of different enzymatic antioxidant 
systems such as glutathione peroxidase (Handy et al., 2005), the activation of NADPH 
oxidases (Dong et al., 2005) in addition to decreasing NO bioavailability through direct 
disruption of eNOS (Zhang et al., 2000) and/or inducing eNOS uncoupling (Heydrick et 
al., 2004). 
From the results of chapters 2 and 3, it is clear that Hcy induces EC activation via a 
JNK mediated pathway. However, the mechanism by which chronic Hcy induces such 
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activation is still unclear. Therefore, this chapter investigates the role of oxidative stress in 
inducing activation of Hcy-treated HUVEC by measurement of oxidant stress and 
assessment of intracellular signalling pathways involved as well as examining the effects of 
anti-oxidant treatment on leukocyte recruitment by endothelial cells under flow conditions. 
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4.1. MATERIALS and METHODS 
4.1.1. Materials 
N-acetyl cysteine (NAC) (A7250), Vitamin C (A4544), pyridine (184527) and 2′,7′-
Dichlorofluorescin diacetate (DCHF-DA) (D6883) were purchased from Sigma-Aldrich 
Chemical Company (Poole Dorset, UK). 2′,7′-Dichlorofluorescin diacetate (DCHF-DA) 
(287810) and nitrotetrazolium blue (NBT) (484235) were supplied by Calbiochem (La 
Jolla, USA). Phenol red-free M199 media (11043-023) was supplied by Invitrogen 
(Paisley, UK). 
4.1.2. Treatment with antioxidants 
HUVEC were cultured for a period of 5-9 days in complete M199 medium 
containing 1mM DL-Hcy alone or with either 5mM NAC or 100µM vitamin C. HUVEC 
from same cell line were cultured for a period of 5-9 days in complete M199 medium alone 
or containing 1mM Cys and considered as negative controls. 
4.1.3. Measurement of oxidative stress 
4.1.3.1. Measurement of intracellular superoxide anion 
NBT reduction was used to measure the intracellular production of superoxide 
anions. The protocol recommended by Eligini et al (2005) was used with slight 
modification after personal communications with  Susanna Colli, University of Milan, 
Italy. Treated HUVEC were seeded into gelatin coated 35mm cell culture dishes (BD 
Falcon, cat No. 351008) and grown until confluence. Media was aspirated and replaced 
with Phenol red-free M199 media containing the same treatment for each well in addition 
to 1mg/ml NBT and cells were incubated at 37°C and 5% CO2 for 90min. Subsequently, 
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media was discarded and cells were washed twice with DPBS. Cells were harvested in 1ml 
PBS by gentle scraping using a sterile scraper. The cell pellet was collected by centrifuging 
at 2300g for 5min. Pellets were lysed vigorously in 500µl 100% pyridine and then cell lysis 
vortexed thoroughly before heating in a heating block at 95°C for 20min. Absorbance was 
measured immediately using a spectrophotometer at a wavelength of 570nm after the 
machine was blanked using 100% pyridine alone. Intracellular superoxide anion production 
was proportional to the absorbance values (Au-Yeung et al., 2004; Eligini et al., 2005). 
Concentration of super oxide anions was measured using the absorbance values and the 
extinction coefficient: 7200 M
-1
xcm
-1
. All samples were prepared and analysed in 
duplicate.  
4.1.3.2. Detection of total ROS 
Treated HUVEC were seeded into gelatin coated chamber slides (Nunc, Roskilde 
Denmark) and grown until confluence. Media was aspirated and cells were washed twice 
with DPBS. Media containing 100µM DCFH-DA was added and cells were incubated at 
37°C and 5% CO2 for 45min. DCFH-DA is membrane-permeable and once it gets into the 
cell, it is converted into non-fluorescent DCFH through the action of cellular esterases. 
However, in the presence of ROS, DCFH is oxidized to its fluorescent derivative 2’, 7’-
dichlorofluorescin (DCF). Fluorescence intensity of DCF was read at 525nm emission 
when exited at 488nm by confocal microscope (Leica, TCS SP-2, Heidelberg, Germany). 
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4.2. RESULTS 
4.2.1. Measurement of intracellular superoxide anion 
To investigate whether DL-Hcy induced generation of superoxide anions 
intracellularly, the NBT reduction assay was used. NBT is water soluble and will be taken 
up intracellularly where it will be converted in the cytoplasm by the action of superoxide 
anions to a water insoluble blue formazan crystal (Baehner et al., 1976). The formed 
crystals are trapped within the cell but can be released by solubilising in solvent solution 
e.g. pyridine and then formation can be monitored spectrophotometrically at 550-560nm 
(Tarpey and Fridovich, 2001). Figure 33 shows clearly that there are detectable levels of 
superoxide anions in non-treated cells. Cys-treated cells also showed detectable levels of 
superoxide anion but they were not significantly different compared to non-treated cells 
(p<0.05), while cells treated with 1mM DL-Hcy for 5-9 days showed significant increases 
in superoxide anions compared to non-treated cells (1.5-fold, p<0.01).  
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The effects of chronic exposure to DL-Hcy on superoxide anion production 
 
 
Figure 33: HUVEC were grown in complete medium and either not treated or treated 
with DL-Hcy (1mM) or Cys (1mM) for 5-9 days. Cys-treated and non-treated cells were 
considered as negative controls. Media was replaced with phenol read-free media 
containing NBT (1mg/ml) and incubated at 37°C in 5% CO2 for 90min. Cells were lysed 
in pyridine, heated at 90°C for 20min and absorbance was measured immediately at 
570nm. Extinction coefficient: 7200 M
-1
xcm
-1
. The results are expressed as mean (+/- 
SD) from 10 different donors for DL-Hcy and control (n=10) and 5 different donors for 
Cys. (*) p < 0.01 for DL-Hcy versus non-treated cells. 
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4.2.2. Detection of total ROS and the effects of NAC on the ROS generation 
Different ROS can be produced intracellularly in addition to superoxide anions by 
EC including peroxides and hydrogen peroxide (Droge, 2002). To investigate whether Hcy 
might induce increase in the generation of total ROS generated intracellularly the DCFH-
DA probe was used. DCFH-DA is a lipid permeable nonfluorescent compound is taken up 
by cells, where intracellular esterase cleaves the molecule to DCFH which remains trapped 
inside the cells (Tarpey and Fridovich, 2001). DCFH is oxidized by intracellular ROS to 
form the lipid-impermeable and fluorescent compound 2’, 7’ dichlorofluorescin (DCF) 
(Royall and Ischiropoulos, 1993) (Figure 34).  
Even though non-treated and Cys-treated cells produced small amounts of ROS 
(Figure 35A and 35B), DL-Hcy-treated cells showed a much higher production of the 
fluorescent dye (Figure 35C) which reflects significant accumulation of ROS. Cells which 
had been treated with DL-Hcy and NAC together showed very low expression of ROS 
(Figure 35D) similar to the level of non-treated cells. Data in Figure 35 are representative 
of two individual experiments using HUVEC from two different donors.  
 
 
Figure 34: The mechanism of DCFH-DA assay. 
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The effects of chronic exposure to DL-Hcy and NAC on ROS production 
 
Figure 35: Representative images showing the effect of DL-Hcy and NAC on ROS 
generation in HUVEC. HUVEC were grown in complete medium and either not treated 
or treated with DL-Hcy (1mM) alone or in combination with NAC (5mM) for 5-9 days. 
Cells from the same donor were treated with Cys (1mM) for 5-9 days. Non-treated and 
Cys-treated cells were considered as negative controls. These cells were washed with 
DPBS then incubated with 100µM DCFH-DA for 45min. Fluorescence intensity of DCF 
was read at 525nm emission when exited at 488nm by confocal microscope. A: non-
treated, B: Cys, C: DL-Hcy, D: DL-Hcy/NAC. 
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4.2.3. Oxidative stress and JNK pathway 
The results in Chapter 3 demonstrated that chronic treatment with DL-Hcy induced 
JNK activation. However, it was unclear from these experiments if this activation was 
dependent on generation of ROS in response to DL-Hcy treatment. Therefore, NAC was 
used to prevent oxidative stress generation which has been shown in the previous section 
(section 4.2.2) and thereafter, the JNK activity assay (as described in section 3.1.2.2) was 
used to study the effects of NAC on DL-Hcy-induced JNK activation and determine if JNK 
activation was oxidative stress dependent. Figure 36A shows a protein band of 48kD 
representing phosphorylated c-Jun for both DL-Hcy- and TNF-α-treated cells (positive 
control). However, no bands were observed for cells which were treated with DL-Hcy and 
NAC. Figure 36A represent 3 different experiments with 3 different donors. These band 
densities were quantified as means of 3 different experiments +/- SD (Figure 36B). NAC 
alone was not able to induce any effects. 
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◄48kDa: c-Jun 
◄48kDa: c-Jun 
The effects of antioxidants on DL-Hcy-induced c-Jun activation 
 
 
 
 
                 
 
 
Figure 36: A: Representative blot showing the effects of chronic exposure to DL-Hcy on 
the activation of c-Jun in HUVEC. HUVEC were cultured in media containing 1mM DL-
Hcy, 1mM DL-Hcy and 5mM NAC, or 1mM Cys for 5-9 days until confluence and then 
lysed. TNF-α (120U/ml, 20min) was used as a positive control. Non-treated and Cys-
treated HUVEC from the same donor were used in each experiment as negative controls. 
30µg protein from each sample was used in westernblot. Phosphorylated c-Jun was 
detected using specific antibodies and was identified as a band of approximately 48kD. B: 
Density of the bands represented in Figure 36A and from 2 further experiments with 
independent samples were quantified using ImageJ software. These graphs represent the 
results for non-treated and DL-Hcy alone or with NAC-treated HUVEC which are 
expressed as mean (+/- SD) from 3 different experiment (n= 3). Non-treated values were 
defined as 100% and other values were adjusted accordingly. (*) p < 0.05 for DL-Hcy 
versus non-treated cells, (**) p < 0.05 for DL-Hcy versus DL-Hcy/NAC-treated cells. 
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4.2.4. The effects of antioxidants on DL-Hcy-induced HUVEC:neutrophil interactions 
Since oxidative stress activates JNK, this may be the sole mechanism by which 
adhesion molecule expression is up-regulated and therefore, antioxidants may prevent 
adhesion molecule up-regulation. In order to investigate this possibility, the effects of 
antioxidants and Hcy on EC:neutrophil interactions were determined as a measure of 
dynamic adhesion molecule expression. Results in Chapter 2 demonstrated that 1mM DL-
Hcy alone induced significant increases in all different sorts of interactions between EC and 
neutrophils. Therefore, this chapter investigates whether these effects are mediated by ROS. 
The flow experiments were repeated using two different antioxidants, NAC and vitamin C, 
in order to confirm that any effects were due to the ROS scavenging properties of each 
antioxidant. 
4.2.4.1. NAC 
In the first set of experiments, different concentrations of NAC (1mM, 5mM and 
10mM) were used along with DL-Hcy and Figure 37 shows the effects of all of these 
different treatments. NAC (1mM) did not have measurable reduction on DL-Hcy induced 
HUVEC:neutrophil interactions while 10mM dramatically blocked all interactions and 
reduced interactions to below non-treated control level which might mean that NAC at such 
high concentration might have affected the cellular response to stimuli. 5mM NAC 
inhibited the effects of DL-Hcy on HUVEC:neutrophil interactions. Although different 
concentrations of NAC were used by other studies ranging from 1-30mM in cultured EC 
cell lines (Gu et al., 2002; Xia et al., 2006), 5mM NAC was used in all of the following 
experiments in this chapter. 
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Compared to non-treated cells, cells treated with DL-Hcy (1mM) showed a 
significant increase in their interactions with flowing neutrophils (already described in 
Chapter 2). When HUVEC were treated with DL-Hcy (1mM) and NAC (5mM), the 
numbers of tethered, rolled, fixed and transmigrated neutrophils decreased significantly to a 
level similar to the numbers of interactions in negative control cells (Figure 38). Cells 
treated with NAC (5mM) alone showed similar numbers of interactions to non-treated 
control (data not shown). 
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The effects of different doses of NAC on DL-Hcy-induced interactions 
(NAC dose response) 
 
 
Figure 37: HUVEC were stimulated with DL-Hcy (1mM; 5-9 days) alone or in 
combination with different concentrations of NAC (1mM, 5mM or 10mM) and the 
effects on EC:neutrophil interactions under flow conditions were observed and 
quantified. HUVEC from the same donor were grown in complete M199 media without 
any stimulation and were considered as negative control in each experiment (n=1). 
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The effects of antioxidants on DL-Hcy-induced interactions (NAC) 
 
 
Figure 38: HUVEC were stimulated with DL-Hcy (1mM; 5-9 days) alone or with 5mM 
NAC and the effects on EC:neutrophil interactions under flow conditions were observed 
and quantified. HUVEC from the same donor were grown in media without any 
stimulation and were considered as negative control in each experiment. The results are 
expressed as mean (+/- SD) from 6 different donors (n=6). (*) p < 0.001 for DL-Hcy 
versus non-treated cells, (**) p < 0.001 for DL-Hcy versus DL-Hcy/NAC treated cells. 
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4.2.4.2. Vitamin C 
Vitamin C was used at concentration of 100µM as this concentration has been 
previously used as an antioxidant by a number of different groups (Ryu et al., 2007; 
Takaishi et al., 2003). Compared with non-treated cells, cells treated with DL-Hcy showed 
a significant increase in their interactions with flowing neutrophils (as already described in 
Chapter 2). When HUVEC were treated with DL-Hcy and vitamin C, the numbers of 
tethered, rolled, fixed and transmigrated neutrophils decreased significantly to a level 
similar to the numbers of interactions in negative control cells (Figure 39). 
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The effects of antioxidants on DL-Hcy-induced interactions (vitamin C) 
 
 
Figure 39: HUVEC were stimulated with DL-Hcy (1mM; 5-9 days) alone or with 
100µM vitamin C and the effects on EC:neutrophil interactions under flow conditions 
were observed and quantified. HUVEC from the same donor were grown in media 
without any stimulation and were considered as negative control in each experiment. The 
results are expressed as mean (+/- SD) from 4 different donors. (*) p < 0.05 and (**) 
p<0.01 for DL-Hcy versus non-treated cells, (#) p< 0.05 for DL-Hcy versus DL-
Hcy/vitamin C treated cells (n=4). 
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4.3. DISCUSSION 
Generation of oxidative stress is the most accepted theory to account for Hcy effects 
or at least a major part of them (Papatheodorou and Weiss, 2007; Weiss et al., 2003). These 
reviews have listed many studies which investigated different possible pathways through 
which Hcy induces oxidative stress in the endothelium which leads to atherosclerosis 
initiation. 
Different methods reviewed by Tarpey and Fridovich (2001) have been used and 
published to detect and measure ROS production in the cells. However, measuring vascular 
production of ROS is a difficult process because intracellular steady-state O2
•−
 tends to be 
very low due to the continuous scavenging by cytoplasmic and mitochondrial SOD. 
Furthermore, some of this O2
•−
 might leak to extracellular spaces via anion channels (Rosen 
and Freeman, 1984). Therefore, the relatively short half-life (seconds) of ROS in addition 
to the efficient systems involved in scavenging them, require techniques to measure 
intracellular ROS to be very efficient and sensitive (Tarpey and Fridovich, 2001). 
Therefore, in this chapter, different direct and indirect methods were used to detect whether 
chronic treatment with DL-Hcy induces oxidative stress. NBT reduction has been used by 
several studies to measure the production of superoxide anions (Au-Yeung et al., 2004; 
Eligini et al., 2005; Patterson et al., 1999) which all indicated that the amount of formed 
formazan was proportional to the concentration of superoxide anions. Superoxide anions 
reduce NBT to monoformazan (NBT
+
) which can be detected spectrophotometrically. This 
chapter’s results indicate that non-treated and differently treated cells show detectable 
levels of superoxide anions. These data are in line with other studies which proposed that 
intact EC express small amount of superoxide anions which play an essential role as a 
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second messenger mediating different signalling pathways (Kunsch and Medford, 1999; 
Ullrich and Bachschmid, 2000; Zhang and Gutterman, 2007). Even though all cells showed 
detectable levels of superoxide anions, DL-Hcy-treated cells showed higher levels (1.5-
fold) compared to non-treated cells. This increase was significant (p<0.01), indicating that 
DL-Hcy induced an increase in superoxide anion generation intracellularly. This data match 
with Au-Yeung et al (2004) who used NBT reduction and found that treating HUVEC with 
100µM Hcy for 15min induced 1.5-fold increase in intracellular superoxide anions in spite 
of using only 100µM Hcy. However, in this chapter the generation of superoxide anions 
was studied after chronic treatment with DL-Hcy (5-9 days) which induced sustained 
intracellular production of superoxide anions and therefore, the high concentration of DL-
Hcy used in this chapter compared to Au-Yeung’s study might be required to overcome 
cellular antioxidant systems and therefore to induce the sustained production of the anions. 
In contrast, Cys had no effects on producing superoxide anions and their level was similar 
to non-treated cells indicating that the effect was specific to Hcy and not due to any osmotic 
effects or non specific due to the free thiol group. The NBT reduction assay could have 
been done with and without including SOD which would have made the results more 
relevant and reflect only the superoxide generation. To confirm these findings, a specific 
nonfluorescent probe DCFH-DA was used to detect the generation of ROS which, if 
present oxidize DCFH-DA into its fluorescent derivative DCF. DCFH-DA was shown to be 
oxidized by different ROS like H2O2 in BAEC (Royall and Ischiropoulos, 1993; Tampo et 
al., 2003) and by oxidants produced
 
during the respiratory burst in inflammatory cells 
(Tarpey and Fridovich, 2001). Photos in Figure 35 show that non-treated cells and Cys-
treated cells showed a very low level of fluorescence compared to DL-Hcy-treated cells. 
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These results clearly indicate that DL-Hcy treatment induced ROS accumulation and thus 
oxidative stress in HUVEC. These findings match those of Tyagi et al (2005) who used the 
same probe DCFH-DA and found significant increases in ROS generation in Hcy-treated 
rat cardiac microvascular EC (40µM Hcy for 24h). 
The DCFH-DA probe is very sensitive to aerobic conditions so stock solutions were 
purged with nitrogen immediately after preparation and stored in -80°C. However, within a 
few days, the dye was bleached and stopped working. Even though different studies 
managed to get reproducible results using this probe (Tampo et al., 2003; Tyagi et al., 
2005), and despite using two different batches of the dye from two different suppliers 
(Sigma Aldrich and Calbiochem) in this chapter, it was very hard to get reproducible 
results. Therefore, the photos in Figure 35 represent only two experiments. Collectively, the 
results of the NBT reduction assay and DCFH-DA probe together give strong evidence that 
chronic treatment with DL-Hcy induced oxidative stress in HUVEC. These findings match 
with previously published studies that confirmed Hcy-induced oxidative stress in vascular 
EC using different techniques: both Handy et al (2005) and Upchurch et al (1997) showed 
that Hcy induces dose dependent inhibition of glutathione peroxidase in cultured BAEC 
and thus accumulation of H2O2. Zhang et al (2000) also demonstrated that 50µM Hcy for 
24h induced significant generation of ROS in HUVEC. Furthermore, patients with acute 
coronary syndromes showed elevated levels of Hcy and malondialdehyde, a marker for 
oxidative stress, in addition to decreased expression of SOD (Wang et al., 2004). However, 
there is still controversy as an early study reported that Hcy does not induce oxidative stress 
but induces reductive stress which leads to ER stress and induces EC damage (Outinen et 
al., 1998). These authors built their conclusion on their findings that Hcy (1-5mM for 18h) 
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was not able to induce expression of heat shock proteins but induced expression of stress 
response genes which are known to be induced by reducing agents in HUVEC. However, 
they showed also that Hcy inhibited the expression of antioxidant enzymes like glutathione 
peroxidase which enhances the cytotoxic effects of ROS. Other techniques could have been 
used to establish which species of ROS are mediating Hcy-induced oxidative stress such as 
L-band electron spin resonance with nitroxyl probes and magnetic resonance imaging spin 
trapping (Halliwell and Whiteman, 2004). 
The next set of experiments were designed to detect whether scavenging DL-Hcy-
induced ROS by antioxidants would disrupt DL-Hcy effects on JNK pathway and the 
activation of the JNK substrate c-Jun, in addition to characterizing the effects of antioxidant 
treatment on DL-Hcy-induced HUVEC:neutrophil interactions. Firstly and to check the 
efficiency of NAC as a ROS scavenger, DCFH-DA dye was used. Figure 35 indicates that 
cells treated with DL-Hcy/NAC-treated cells show a very low level of fluorescence 
compared to DL-Hcy-treated cells which indicates that NAC was an efficient ROS 
scavenger and was able to overcome DL-Hcy-induced ROS production. DL-Hcy has 
already been shown in Chapter 3 to activate the JNK pathway and subsequently to induce 
phosphorylation of its substrate c-Jun leading to up-regulation of CAM. However, once 
these cells were treated with DL-Hcy and NAC, JNK pathway activation was blocked and 
c-Jun was not phosphorylated (Figure 36) which indicates that NAC inhibited DL-Hcy 
effects on JNK pathway. It is likely that NAC scavenging of ROS inhibited DL-Hcy-
induced JNK activation. The involvement of ROS in mediating MAP kinase pathway 
activation has been suggested in VSMC in response to angiotensin II (Ushio-Fukai et al., 
1998) and in neutrophils in response to Hcy (Alvarez-Maqueda et al., 2004). Our lab is the 
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first to demonstrate that ROS play a role in mediating chronic Hcy-induced MAPK JNK in 
EC (Alkhoury et al., 2009b). NAC (20mM) also blocked TNF-α-induced activation of 
JNK1 in human monocyte cell line (U937) (Gu et al., 2002). Furthermore, ROS in 
fibroblasts (Kamata et al., 2005) and in human embryonic kidney 293 cells (Chen et al., 
2001a) were reported to inhibit JNK phosphatase, which is responsible for 
dephosphorylating activated JNK, and therefore ROS induced sustained activation of JNK. 
Results in Chapter 3 clearly showed that chronic DL-Hcy induced sustained activation of 
JNK (Figures 27 and 28) and the current results (Figure 36) show that scavenging ROS by 
NAC inhibited this JNK activation indicating that ROS mediate Hcy-induced JNK 
activation under static conditions in HUVEC in culture. One study found that 20mM NAC 
(1h pre-treatment followed by 4h of 3mM Hcy) was not able to reverse Hcy-induced JNK 
activation in HUVEC (Cai et al., 2000). The high concentration of Hcy used in this study 
might have induced huge ROS production that was not able to be scavenged totally with 
NAC and that might explain why NAC was not able to reverse Hcy-induced JNK 
activation. 
In this chapter, treatment with antioxidants NAC (Figure 38) or vitamin C (Figure 
39) managed to reverse the effects of DL-Hcy on HUVEC:neutrophil interactions under 
flow and the number of all different sorts of interactions were similar to those of non-
treated cells. These effects of antioxidants are definitely due to their ROS scavenging 
properties as the results were reproducible with two different antioxidants, NAC and 
vitamin C. That means ROS mediate the DL-Hcy effects on HUVEC:neutrophil 
interactions under flow and that they are involved in the signalling pathways that lead to 
up-regulation of different CAMs and/or chemokines which mediate different types of 
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interactions between EC and leukocytes. This chapter provides clear evidence that chronic 
treatment with Hcy induced EC dysfunction by a ROS-mediated mechanism that is 
characterized by activation of the JNK pathway and increased EC:neutrophil interactions 
under flow conditions which all were reversible by antioxidant treatment.  Vitamin C has 
been previously used successfully in a few studies and managed to reverse Hcy-induced EC 
dysfunction (Chambers et al., 1999; Nappo et al., 1999) and to reverse Hcy coronary 
effects in patients with experimentally induced hHcy (Yamashita et al., 2005). NAC and 
vitamin C also reversed Hcy inhibitory effects on L-arginine intracellular uptake in BAEC 
(Jin et al., 2007). This chapter is the first study to confirm that ROS accounts for most Hcy 
effects on EC in vitro in addition to the efficiency of antioxidants in reversing these effects 
under static and flow conditions. 
Tyagi (1998) showed, using fluorescence labelled homocystine, that homocystine 
binds to receptors on human vascular SMC membrane and some of this homocystine 
managed to become intracellular. However, the group could not explain whether results 
were due to diffusion or transport of homocystine into the cell through receptor 
internalization or redox channel mechanisms. On the other hand, Tyagi showed that NAC 
reversed homocystine binding but they could not explain whether these reversing effects 
were due to antioxidant activity of NAC or due to interaction between the two compounds 
which might prevents homocystine from binding to its proposed receptors (Tyagi, 1998). 
Furthermore, Ewadh et al (1990) showed that including Cys in the media inhibited Hcy 
cellular uptake by HUVEC and they suggested this inhibition to be due to the formation of 
mixed disulphides between Hcy and Cys. NAC has a free thiol group similar to Hcy and 
Cys, which is readily available to form disulphide bonds with other thiol containing groups. 
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Data provided by both Tyagi and Ewadh et al suggest that NAC might interact with Hcy 
forming mixed disulphides thus preventing Hcy intracellular uptake. Thus, presenting 
another possible mechanism for NAC by which it inhibits Hcy effects in addition to its 
ROS scavenging activity. Moreover, further studies could be used to detect the presence of 
such mixed disulphides by using techniques, such as mass spectroscopy (MS). Preliminary 
data using MS (appendix 3) showed that Hcy and NAC might interact to form a mixed 
disulphide. However, this intermediate compounds is likely to be instable in physiological 
pH. Further studies are required to optimize a protocol using the appropriate buffer to 
evaluate the efficiency of NAC in preventing Hcy cellular uptake (appendix 3). 
NAC was shown to decrease cell apoptosis and restore balance redox status in a 
TNF-α-treated EC cell line (ECV304) (Xia et al., 2006) and also was shown to inhibit, in a 
dose dependent fashion, LDL oxidation in vitro (in a test tube) (Rattan and Arad, 1998). 
Furthermore, NAC inhibited endothelin-1-induced JNK activation in VSMC (Fei et al., 
2000) and was shown to inhibit cytokine-induced expression of VCAM-1 and MCP-1 in 
EC (Kunsch and Medford, 1999). All of these studies indicate that NAC is an effective 
antioxidant and this data, collectively with the results of this chapter, provide strong 
evidence that DL-Hcy-induced EC dysfunction and the subsequent chronic inflammatory 
response are mediated by oxidative stress.  
Despite that, a study by Frank et al (2007) suggested that Hcy did not induce ROS 
generation and did not induce cytotoxicity to human microvascular endothelial cell lines. 
Furthermore, they found that adhesion of monocytes to Hcy-treated EC was not significant 
and they suggested that Hcy was not able to induce oxidative stress, inflammation or EC 
dysfunction. Frank’s group results contradict those of this chapter and different reasons 
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might account for this contradiction. Firstly, they used endothelial cell lines which might 
respond in a different way from primary EC to Hcy treatment and they might be more 
resistant to Hcy treatment. Secondly, they exposed EC to Hcy for only 4h which may not 
enough to induce significant expression of some CAM such as ICAM-1 whose expression 
requires 6-12h to peak and which is essential for monocyte adhesion. Finally, they carried 
out their adhesion assay under static conditions where involvement of NO generated under 
shear stress cannot be taken into account and is therefore less relevant to the in vivo 
situation. 
Although different in vitro studies have provided evidence of the efficiency of 
antioxidants in reducing the inflammatory conditions and to have anti-atherosclerotic 
effects (Gu et al., 2002; Kamata et al., 2005; Kyaw et al., 2004; Rattan and Arad, 1998; 
Siow et al., 1998; Xia et al., 2006), several clinical studies have failed to provide clear 
evidence of the benefits of antioxidants in reducing risk of different cardiovascular diseases 
(Paolini et al., 2003; Stanner et al., 2004) as already highlighted in section 1.3.4. It is still 
unclear why antioxidants clear beneficial effects in vitro, while less satisfying results were 
observed in clinical studies (Kyaw et al., 2004).  
The mechanism by which Hcy induces ROS overproduction is not clear and this 
chapter does not include any experiments to attempt to resolve this. However, other studies 
have suggested and provided evidence of different mechanisms which could mediate Hcy-
induced ROS production. NADPH oxidase is the major source of O2
•−
 in EC (Ullrich and 
Bachschmid, 2000) and different studies have provided evidence of Hcy-induced activity of 
NADPH oxidase (Dong et al., 2005; Ungvari et al., 2003). Furthermore, Dong’s group 
showed that inhibition of NADPH oxidase with apocynin prevented Hcy-induced ROS 
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generation. Other researchers believe that eNOS under certain conditions might produce 
O2
•−
 in the expense of NO (this hypothesis will be discussed in more details in Chapter 5). 
NADPH oxidase could be upstream of other (O2
•−
)-producing enzymes because superoxide 
anions produced by NADPH oxidase appear to be implicated in the activation of other O2
•−
 
producing enzymes like eNOS uncoupling (Landmesser et al., 2003).  
4.4. CONCLUSION 
This chapter demonstrates that Hcy induces oxidative stress in EC and this is 
required for their activation. This has been indicated by JNK activation with the subsequent 
functional effects of increasing EC:neutrophil interactions under flow which indirectly 
indicates downstream CAM expression. Furthermore, this chapter presents clear evidence 
of the efficiency of two different antioxidants in protecting EC from Hcy damage, 
implicating oxidative stress as the mechanism by which HUVEC are activated in response 
to chronic Hcy.  
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CHAPTER 5 
5. THE ROLE OF NITRIC OXIDE AND NITRIC OXIDE SYNTHASE 
IN HCY-MEDIATED ATHEROGENIC EFFECTS 
The health of the vascular system depends on the balance between anti-
inflammatory and anti-thrombotic nitric oxide together with levels of pro-inflammatory 
superoxide and other radicals like peroxynitrite, and the hydroxyl radical (reviewed by 
Forstermann (2008), Naseem (2005) and Tomasian et al (2000). Disturbances to this 
balance, leading to reduced nitric oxide (NO) bioavailability result in induction of a pro-
inflammatory phenotype within endothelial cells (EC) lining the blood vessels, with up-
regulation of CAM and chemokine production. Recruitment of leukocytes which contribute 
to atherosclerotic plaque development then occurs (Lusis, 2000). 
It is known that a lack of either the substrate L-arginine or the cofactor BH4 leads to 
uncoupling of the eNOS leading to superoxide anion production at the expense of NO (Xia 
et al., 1998). Hcy has been suggested to induce eNOS uncoupling either via reducing levels 
of BH4 (Zhang et al., 2000) or decreasing intracellular uptake of L-arginine (Jin et al., 
2007). Therefore, uncoupled eNOS could represent a major source of ROS in Hcy-treated 
EC. 
It is clear from the previous chapters that chronic Hcy induced sustained oxidative 
stress inducing prolonged activation of the JNK pathway and therefore EC activation. 
Furthermore, scavenging ROS by different antioxidants reverseed all of these effects. 
However, the questions which remain unanswered are how DL-Hcy induces ROS 
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generation and would restoring NO bioavailability restore the EC quiescence. Therefore, 
this chapter investigated the possibility of uncoupled NO as a major source of ROS in 
chronically treated Hcy. Furthermore, we investigated the efficiency of restoring NO 
bioavailability on reversing Hcy-induced HUVEC:leukocyte interaction. 
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5.1. MATERIALS and METHODS 
5.1.1. Materials 
Two NO donors were used GSNO (0603) was purchased from Tocris biosciences 
(Bristol, UK) and DPTANONOate (ALX430066) was purchased from Alexis 
Biochemicals. Two eNOS inhibitors were used, L-NAME (483125) and L-NIO (400600) 
were purchased from calbiochem (La Jolla, USA). ODQ (1H-[1,2,4]Oxadiazolo[4,3-
a]quinoxalin-1-one) (495320) was also purchased from Calbiochem, (La Jolla, USA). DL-
dithiothreitol (D-0632) was purchased from Sigma-Aldrich (Poole Dorset, UK). 
5.1.2. HUVEC culture and treatment 
5.1.2.1. NO donors  
HUVEC were cultured in the presence of DL-Hcy chronically as in section 2.1.2.2 
and then subjected to flow as described in section 2.1.2.7. However, 10min prior to flow, 
DL-Hcy-treated cells were exposed to either GSNO (20µM) or DPTA (20µM). 
Furthermore, some of the DL-Hcy treated cells were pre-treated with 40µM ODQ for 
30min followed by treatment with 20µM GSNO for 10min. Subsequently, these cells were 
subjected to flowing neutrophils as explained in section 2.1.2.7. Some HUVEC (DL-Hcy-
treated and non-treated cells) were also treated with different concentrations of the reducing 
reagent DTT (0.1mM and 1mM) for 20min prior to flow or prior to NO donor treatment. 
4.7.2.2. eNOS inhibitors 
HUVEC were cultured for a period of 5-9 days in complete M199 medium 
containing 1mM DL-Hcy alone or with 1mM L-NAME. HUVEC were then subjected to 
flow as described in section 2.1.2.7. The same experiments were repeated with another 
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eNOS inhibitor L-NIO (1mM). Furthermore, NBT reduction was used to measure 
superoxide anions generation in the treated-cells as described in section 4.1.3.1.  
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5.2. RESULTS  
5.2.1. NO reverses DL-Hcy-induced HUVEC:neutrophil interactions  
To study the effects of DL-Hcy on NO bioavailability and whether restoring NO 
bioavailability might reverse the effects of DL-Hcy on EC:neutrophil interactions, two NO 
donors were used separately to flood the EC with NO. As before (section 2.2.3.6) DL-Hcy 
significantly induced EC:neutrophil interactions. Despite the short incubation period 
(10min), DPTANONOate was able to reverse all types of HUVEC:neutrophil interactions: 
tethering, rolling, adhesion and transmigration, to levels similar to those of non treated cells 
(Figure 40A). The difference between numbers of interactions of DL-Hcy alone treated 
cells and those pre-treated with DPTA were significant (p<0.05). Similar results were 
obtained with the second NO donor GSNO (Figure 40B). Some DPTA was exposed to light 
at room temperature to stop its ability to generate NO. Therefore, this “broken” DPTA was 
used as a negative control to make sure that the observed effects were due to NO and not to 
any chemical property of the NO donor. “Broken” DPTA was not able to reverse the effects 
of DL-Hcy on HUVEC:neutrophil interactions (data not shown). Furthermore and to study 
whether these effects were occurring via a cGMP mediated pathway, the cGMP inhibitor 
ODQ was used to inhibit this pathway prior to treatment with NO donors. Inhibiting cGMP 
caused no alteration to the effects of the NO donor in reversing DL-Hcy-mediated 
interactions. Cells treated with DL-Hcy/GSNO/ODQ showed significant decreases in their 
interactions with neutrophils to a level similar to those treated with DL-Hcy/GSNO and to 
the non-treated cells (Figure 41).  
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Figure 40: The effects of the NO donors DPTA (A) or GSNO (B), on 
HUVEC:neutrophil interactions. HUVEC were stimulated with DL-Hcy (1mM; 5-9 days) 
and some of these DL-Hcy-treated cells were exposed to DPTA (20µM) or GSNO 
(20µM) for10min and the effects on EC:neutrophil interactions under flow conditions 
were observed and quantified. HUVEC from the same donor were grown in media 
without any stimulation and were considered as negative controls in each experiment. 
The results are expressed as mean (+/- SD) from 3 different donors for DPTA and 6 
different donors for GSNO. (*) p < 0.05 for DL-Hcy versus DL-Hcy/NO donor treated 
cells, (**) p < 0.05 for DL-Hcy versus non-treated cells. 
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The role of cGMP in NO donor effects on DL-Hcy-induced interactions 
 
 
Figure 41: HUVEC were stimulated with DL-Hcy (1mM; 5-9 days) and some of these DL-
Hcy-treated cells were pre-treated with 40µM ODQ for 30min followed by treatment with 
20µM GSNO for 10min. The effects on EC:neutrophil interactions under flow conditions 
were observed and quantified. HUVEC from the same donor were grown in media without 
any stimulation and were considered as negative controls in each experiment. The results 
are expressed as mean (+/- SD) from 3 different donors. (*) p < 0.05 for DL-Hcy versus 
DL-Hcy/GSNO treated cells, (**) p < 0.05 for DL-Hcy treated cells versus DL-
Hcy/ODQ/GSNO treated cells. 
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5.2.2. The effects of reducing agents on DL-Hcy-stimulated HUVEC:neutrophil 
interactions 
NO was shown in the previous section to inhibit DL-Hcy-induced 
HUVEC:neutrophil interactions under flow via a cGMP-independent mechanism. 
Nitrosylation of some proteins might explain these effects of NO treatment. Reducing 
reagents like DTT have previously been shown to reverse nitrosylation of some proteins 
(Park et al., 2006; Park et al., 2000a). Therefore, DTT was used in this chapter to check 
whether it could reverse NO effects on DL-Hcy-treated cells. Firstly, DTT effects on non-
treated and DL-Hcy-treated HUVEC were investigated. In the first experiment, HUVEC 
were treated with 1mM DTT alone for 20min and then subjected to flowing neutrophils. 
These cells did not interact with the flowing neutrophils (Figure 42), and furthermore, cell 
phenotype was affected and they lost their normal phenotype. Following that, DL-Hcy-
treated cells were treated with either 1mM or 0.1mM DTT for 20min before being 
subjected to flowing neutrophils. DTT appeared to have a dose-dependent response on the 
cells and number of interactions decreased compared to DL-Hcy-treated cells. 1mM DTT 
reduced HUVEC:neutrophil interactions more than 0.1mM DTT (Figure 42). However, 
HUVEC in both cases looked abnormal as well and lost their normal cobblestone 
arrangement.  
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The effects of reducing reagents (DTT) on DL-Hcy-induced interactions 
 
 
Figure 42: HUVEC (1mM DL-Hcy-treated and non-treated cells) were also treated with 
different concentrations of the reducing reagent DTT (0.1mM or 1mM) for 20min prior to 
flow. These results represent only one experiment for each concentration of DTT. 
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5.2.3. The role of eNOS in DL-Hcy-induced effects 
DL-Hcy was shown previously (Chapter 4) to induce ROS generation in EC which 
mediated DL-Hcy-induced EC:neutrophil interactions however, the source of these ROS is 
still unclear. Uncoupled eNOS represent a major source of ROS and therefore this chapter 
investigates the role of eNOS in mediating the DL-Hcy-induced oxidative stress in HUVEC 
and whether it is responsible for generating superoxide anions at the expense of NO. eNOS 
in HUVEC was inhibited and then the consequences of such inhibition were studied under 
static and flow conditions. 
5.2.3.1. Effects of inhibition of eNOS on superoxide generation 
NBT reduction was used to measure the generation of intracellular superoxide 
anions in differently treated cells (as explained in section 4.1.3.1). As already demonstrated 
in section 4.2.1, 1mM DL-Hcy induced significant generation of superoxide anions. 
However, once these cells were treated with 1mM DL-Hcy and 1mM L-NAME together, 
superoxide anion production decreased significantly (Figure 43) (p<0.05). L-NAME alone 
had no effects on superoxide anion production with levels generated being similar to that in 
non-treated cells. 
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The role of eNOS in DL-Hcy-induced oxidative stress 
 
 
Figure 43: HUVEC were grown in complete medium and either not treated or treated 
with DL-Hcy (1mM) alone or with L-NAME (1mM) for 5-9 days. Non-treated cells were 
considered as negative controls. Media was replaced with phenol red-free media 
containing NBT (1mg/ml) and incubated at 37°C and 5% CO2 for 90min. Cells were 
lysed in pyridine, heated at 90°C for 20min and absorbance was measured immediately at 
570nm. Extinction coefficient: 7200 M
-1
xcm
-1
. The results are expressed as mean (+/- 
SD) from 7 different donors (n=7). (†) p < 0.05 for DL-Hcy versus non-treated cells. (*) 
p < 0.05 for DL-Hcy versus DL-Hcy/L-NAME-treated cells. 
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5.2.3.2. The role of eNOS in DL-Hcy-induced HUVEC:neutrophil interactions 
As eNOS was shown in the previous section to be responsible for producing ROS in 
response to chronic DL-Hcy treatment, the effects of inhibiting eNOS on DL-Hcy-induced 
HUVEC:neutrophil interactions was investigated. HUVEC were treated with DL-Hcy with 
and without the specific eNOS inhibitor L-NAME (1mM) for 5-9 days and then subjected 
to flowing neutrophils. As before (section 2.2.3.6) DL-Hcy induced significant 
HUVEC:neutrophil interactions. L-NAME managed to reverse all the effects of DL-Hcy 
(p<0.05) and numbers of tethering, rolling, adhesion and transmigration interactions of DL-
Hcy/L-NAME-treated cells were similar to those of non-treated cells (Figure 44). These 
results were reproducible with another eNOS inhibitor L-NIO (1mM) (data not shown). L-
NAME alone showed not to have any effects on HUVEC:neutrophil interactions. 
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The effects of eNOS inhibition on DL-Hcy-induced interactions 
 
Figure 44: HUVEC were stimulated with DL-Hcy (1mM; 5-9 days) alone or with 1mM 
L-NAME and the effects on EC:neutrophil interactions under flow conditions were 
observed and quantified. HUVEC from the same donor were grown in media without any 
stimulation and were considered as negative controls in each experiment. The results are 
expressed as mean (+/- SD) from 4 different donors (n=4). (*) p < 0.05 for DL-Hcy 
versus DL-Hcy/L-NAME treated cells. 
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5.3. DISCUSSION 
The importance of nitric oxide in CVD has been investigated intensively and NO 
has been strongly implicated in protecting against the initiation and progression of different 
CVD (reviewed by Naseem (2005)). NO is also involved in regulating different CAM 
expression on EC and leukocytes (Takahashi et al., 1996). Furthermore, NO can inhibit 
LDL oxidation by reacting with lipid peroxyl radicals (Rubbo et al., 1994). Collectively it 
suppresses the inflammatory response via these effects. Hcy as a risk factor in CVD has 
been demonstrated in published work and in the data obtained in Chapter 4 of this thesis 
since it induces oxidative stress which mediates inflammatory interactions between 
activated EC and neutrophils. eNOS uncoupling might be mediating these effects in hHcy 
patients through generating superoxide. Therefore, experiments in this chapter were 
designed to study whether restoring NO bioavailability might reverse Hcy inflammatory 
effects and also to investigate whether Hcy induces eNOS uncoupling which could account 
for the generated oxidative stress.  
There is accumulating evidence from the past few decades about the involvement of 
NO in regulating CAM expression but most of these studies have used exogenous donors 
for the same period of CAM-inducing stimuli (Kosonen et al., 2000; Spiecker et al., 1998; 
Takahashi et al., 1996; Zampolli et al., 2000). Cytokine treatments in all the previous 
studies were acute (up to 12h) and therefore they used the NO donors for the same length of 
time as the CAM inducing stimuli. In this chapter, even though NO donor treatment was 
very short (10min after 5-9 days of DL-Hcy exposure) there was still full reversal of each 
type of interaction which had been induced by chronic DL-Hcy alone treatment under flow 
conditions (Figure 40). Two different NO donors were used to determine conclusively that 
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the effects were due to NO release. The fact that broken DPTA, which is not able to 
generate NO, was not able to induce similar effects to DPTA further strengthens the 
evidence. There have been conflicting reports as to whether NO-stimulated effects on CAM 
are sGC and cGMP dependent (Marshall and Stamler, 2001; Takahashi et al., 1996; 
Zampolli et al., 2000). To check whether the observed effects of NO happened through a 
cGMP mediated pathway, cells were treated with the cGMP specific inhibitor ODQ prior to 
GSNO treatment. ODQ has been suggested to selectively inhibit the haem site of sGC 
inducing irreversible inactivation of the enzyme and therefore inhibiting cGMP production 
(Schrammel et al., 1996). However, inhibiting cGMP did not reverse GSNO effects which 
means all of these effects were occurring through a cGMP-independent pathway (Figure 
41). As de novo synthesis requires 3h for P-selectin in mice (Weller et al., 1992), 4-8h for 
E-selectin (Bevilacqua and Nelson, 1993) and up to 12h for ICAM-1 (Dustin et al., 1986), 
this 10min treatment with NO donors was too short to induce changes at the transcriptional 
level and to disturb synthesis of any of these adhesion molecules. Therefore, it could be 
said that the NO-mediated dramatic decrease of DL-Hcy-induced EC:neutrophil 
interactions was unlikely to be due to inhibition of CAM synthesis.  
Within the literature NO donor treatment was shown to have contradicting effects 
on CAM de novo synthesis using different mechanisms. Cytokine-induced ICAM-1 
expression in HSVEC (Spiecker et al., 1998) and HUVEC (Takahashi et al., 1996) was 
inhibited by NO donors in a cGMP-independent manner when cells were treated with NO 
donor prior to cytokine treatment. Furthermore, NO donor exposure inhibited E-selectin 
expression after stimulation with cytokines or lipopolysaccharide in both HSVEC and 
HUVEC (Kosonen et al., 2000; Zampolli et al., 2000). However, Kosonen’s and 
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Zampolli’s groups found that pre-treatment with NO donors in HSVEC did not attenuate 
cytokine-induced ICAM-1 expression and they explained that by the high constitutive 
expression of ICAM-1 under basal conditions (Kosonen et al., 2000; Zampolli et al., 2000).  
Published findings about NO donor effects on P-selectin are more consistent. P-
selectin mRNA was increased significantly in human iliac vein EC treated with eNOS 
inhibitor L-NAME (Armstead et al., 1997) and reached a maximum level after 4h of 
treatment. The same group used NO donors to demonstrate a significant decrease in mRNA 
level of P-selectin with a maximum effect after 4h. Furthermore, NO donors were shown to 
decrease ischemia-reperfusion-induced P-selectin expression in murine endothelial sections 
(Gauthier et al., 1994). On the other hand another study in HUVEC found that a sGC 
activator (BAY 41-2272) was able to reverse both IL-1β-induced and histamine-induced P-
selectin expression suggesting a NO-independent and cGMP-dependent mechanism instead 
(Ahluwalia et al., 2004). Collectively, NO seems to play different roles in regulating the 
expression of different CAM and this regulation seems to happen via different pathways, 
both cGMP- dependent and independent.  
Unlike CAM induction for E-selectin and ICAM-1, P-selectin expression on the cell 
surface requires the exocytosis of WPB to mobilize P-selectin from its storage vesicles to 
the surface and this happens within 2min (Hattori et al., 1989). Different protein 
superfamilies are involved in this process like NSF and SNARE (Lowenstein et al., 2005). 
NSF is composed of N-terminal domain and two homologous ATP binding domains (D1 
and D2). The D1 domain hydrolyzes ATP providing the mechanical force required to 
disassemble SNARE complex (Matsushita et al., 2003). Matsushita’a group found that 
some Cys residues in NSF protein are responsible for its interaction with SNARE while 
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other Cys residues regulate NSF disassembly of SNARE complexes. They also showed that 
some of these Cys residues could be nitrosylated which will inhibit their activity and 
therefore inhibit the disassembling of SNARE leading to blocking the exocytosis. NO has 
been shown to nitrosylate NSF in cultured human EC (Matsushita et al., 2003) and in 
platelets (Morrell et al., 2005). Furthermore, addition of recombinant NSF to EC pretreated 
with NO was shown to restore the exocytosis (Matsushita et al., 2003). While, the same 
group showed that once recombinant NSF was pretreated with NO donor, it was not able to 
restore WPB exocytosis. Therefore, NO inhibits NSF enzymatic activity by nitrosylation 
and thereafter inhibits the whole exocytosis process. Subsequently, no P-selectin will be 
mobilized to the cell surface. Chapter 2 of this thesis showed DL-Hcy induced P-selectin 
expression and it is suggested this expression continues to cycle once DL-Hcy is present 
continuously as illustrated in Figure 45.  
These steps in the continuous presence of DL-Hcy are happening in a cycle. 
However, NO inhibits the WPB exocytosis and thus breaks this cycle and the P-selectin 
which is already present on cell surface will be shed in the first few seconds of exposure of 
the EC to laminar flow and then cannot be replaced and therefore, the tethering step will be 
blocked due to lack of P-selectin the main mediator of this step. There is little likelihood of 
flowing neutrophils starting to roll directly unless they are tethered first on EC to slow them 
down and allow enough time to start the bond formation between E-selectin and its ligand 
and also for ICAM-1 and integrins to bind and mediate adherence of the neutrophils. 
Furthermore, P-selectin has been shown to induce leukocyte activation which is essential 
for the integrin conformational changes from the non-adhesive form to the adhesive one 
(Lawrence and Springer, 1991; Lorant et al., 1993). So, it could be concluded that blocking 
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P-selectin expression and therefore neutrophil tethering led to blockade of all the following 
steps although other CAM expression might not have been affected by NO treatment. 
Furthermore, the chemokine IL-8 which is known to play a major role in neutrophil 
adherence and migration is also stored in WPB. Therefore, blocking WPB exocytosis will 
induce decreases in IL-8 availability and that will amplify the negative effects of NO on 
cell:cell interactions. 
 
 
Figure 45: P-selectin life cycle and how NO can regulate P-selectin surface expression 
through inhibition of exocytosis. 
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Despite the short incubation period with NO, these results are in line with other 
studies which demonstrated that NO inhibits P-selectin expression (reviewed by 
Lowenstein (2007) and Lowenstein et al (2005)). Furthermore, an in vivo study in mice, 
using intravital microscopy, found that Hcy (1-5mM for 150min) induced dose- and time-
dependent increases in the expression of P-selectin and ICAM-1 on venular EC which were 
reversed by including an NO donor (Pruefer et al., 1999). NO donors have been also shown 
to inhibit cytokine-induced E-selectin expression in HSVEC (Zampolli et al., 2000) and 
lipopolysaccharide-induced E-selectin expression in HUVEC (Spiecker et al., 1998).  
Findings using the in vitro flow system used in this chapter (Graham et al., 2009) 
are in line with some other studies which used different techniques to study the effects of 
NO on leukocyte:EC interactions. Static adhesion assays showed that NO donors reversed 
leukocyte adhesion on lipopolysaccharide-treated HUVEC (Kosonen et al., 2000) and on 
IL-1β-treated HSVEC (Zampolli et al., 2000). Furthermore, intravital microscopy studies in 
mice showed that NO donors managed to reverse Hcy-induced (Pruefer et al., 1999) and 
ischemia/reperfusion-induced (Gauthier et al., 1994) increase in rolling and adherence of 
leukocytes on EC surface. Another in vivo study (Ahluwalia et al., 2004) gave evidence 
that eNOS knockout mice showed increased numbers of rolling and adhered leukocytes and 
NO donors were able to significantly attenuate this increase and thus were consistent with 
this chapter’s findings. They showed however that these effects happen through cGMP-
dependent pathway which contradicts the mechanism suggested by this chapter which 
suggests that NO effects are cGMP-independent. That could be due to differences between 
in vivo and in vitro conditions, differences between mouse and human or NO might act via 
different mechanisms in different vessel types. 
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Nitrosylation was suggested to be a reversible process and reducing reagents like 
DTT can de-nitrosylate the nitrosylated Cys residues (Park et al., 2006; Park et al., 2000a). 
These authors demonstrated, in human embryonic kidney cells, that 10mM DTT reversed 
NO-induced JNK-1 suppression. However, this chapter found that DTT, even at much 
lower concentrations than those suggested in literature, affected the EC structure in a way 
that made it difficult to study the interactions between them and neutrophils after different 
sorts of treatments. Surprisingly DTT reversed, at least in part, DL-Hcy effects (Figure 42) 
and the only explanation we can provide is that cells are not normal anymore and possibly 
some of them have died. HUVEC might be highly sensitive to DTT and therefore, it was 
difficult to proceed with these experiments using DTT. However, using different reducing 
reagents which could be less harmful to HUVEC could be very beneficial to study whether 
NO effects depend on nitrosylation reactions or not. Detection of nitrosylation of proteins 
such as JNK and NSF, using techniques like the biotin switch assay or antibodies against 
nitrosylated proteins, would have completed the studies of the nitrosylation effects of NO. 
However, due to the funding and time limitation, these experiments would be 
recommended for future work to complete the findings of this thesis. 
Under normal conditions, eNOS is the main enzyme responsible for catalyzing the 
generation of NO. However, absence of some cofactors like BH4 or the substrate L-arginine 
induces eNOS uncoupling and it will start catalyzing O2
•−
 generation at the expense of NO 
(Xia et al., 1998). Several studies gave evidence of eNOS uncoupling as a major source of 
the oxidative stress in EC (Forstermann and Munzel, 2006; Landmesser et al., 2003; Topal 
et al., 2004; Zhang et al., 2000). Furthermore, NADPH oxidase in EC was suggested to be 
activated by Hcy to start producing O2
•− 
which reduces BH4 (Zhang et al., 2000) thus 
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uncoupling eNOS and leading to more production of O2
•−
. Several studies provided 
evidence that NADPH oxidase in diabetic humans and mice can be a preliminary source of 
O2
•−
 that induces eNOS uncoupling. Furthermore, inhibiting either eNOS or NADPH 
oxidase in human diabetic EC inhibited O2
•−
 production (reviewed by Gao and Mann 
(2009)). Chapter 4 gave clear evidence that DL-Hcy induces oxidative stress in EC which 
was responsible for the DL-Hcy-mediated JNK activation and HUVEC:neutrophil 
interactions. However, the mechanism by which DL-Hcy is inducing ROS generation in 
human EC is unclear. This chapter investigated the role of eNOS in mediating DL-Hcy-
induced ROS generation.  
NBT reduction results showed that inhibiting eNOS reduced the generation of 
superoxide anions in DL-Hcy/L-NAME-treated cells compared to DL-Hcy-treated cells 
(Figure 43). This clearly indicates that eNOS is mediating DL-Hcy induced superoxide 
anion generation intracellularly under static conditions. Furthermore, inhibiting eNOS by 
L-NAME reversed all DL-Hcy induced HUVEC:neutrophil interactions under flow 
conditions to a level similar to those of non-treated cells (Figure 44) suggesting that ROS 
generation is the cause of EC:neutrophil interaction within this study. Furthermore, the use 
of second eNOS inhibitor L-NIO determined conclusively that these effects were specific to 
inhibiting eNOS. Using eNOS inhibitor dramatically reversed Hcy-induced oxidative stress 
under static and flow conditions which indicates a major role of uncoupled eNOS in 
mediating Hcy-induced oxidative stress. However, there might be still other sources of 
oxidative stress in Hcy-treated EC such as NADPH oxidase or xanthine oxidase which still 
need further investigation. 
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Different studies are in line with the results of this chapter and they illustrated that 
Hcy induces eNOS uncoupling. Hcy-induced ROS generation was markedly blocked by the 
NOS inhibitor L-NAME in HUVEC (Topal et al., 2004), in BAEC (Heydrick et al., 2004) 
and in hHcy mice (Cbs
+/–
 mice fed the high methionine
 
diet) (Dayal et al., 2004). However, 
we cannot rule out as a possibility the effects of reduction of BH4 since Topal’s group 
found that Hcy (100µM/24h) decreased by 80% the intracellular amount of BH4 in HUVEC 
leading to eNOS uncoupling (Topal et al., 2004).  
Collectively, it could be concluded that DL-Hcy induced eNOS uncoupling which 
started to produce superoxide anions in excess. These anions were responsible for the 
oxidative stress which in turn was responsible for initiating JNK pathway activation (as 
explained in Chapter 4) which ended with significant CAM expression able to mediate 
HUVEC:neutrophil  interactions under flow conditions. 
5.4. CONCLUSION 
NO bioavailability is essential in protecting from CVD and Hcy induces 
atherosclerotic effects through affecting NO bioavailability. Therefore, increasing NO level 
is one possible therapeutic approach to cure and/or protect from Hcy effects. On the other 
hand, eNOS uncoupling can account at least in part for Hcy effects and could be the 
mechanism through which Hcy induces oxidative stress. Recoupling the enzyme by L-
arginine or BH4 supplement might present other possible therapeutic approaches to protect 
hHcy patients from CVD. 
 
  
210 
 
CHAPTER 6 
6. THE EFFECTS OF CHRONIC EXPOSURE TO DL-HCY ON 
ENDOTHELIAL CELL CYTOKINE PRODUCTION 
EC produce a number of cytokines and chemokines and regulate the production of 
many other cytokines/chemokines in an autocrine or paracrine manner (Galkina and Ley, 
2009). In addition to CAM, increased production of pro-inflammatory cytokines and 
chemokines represent another characteristic feature of activated EC. Prolonged up-
regulation of such cytokines will lead to the chronic inflammatory response. Uncontrolled 
and self-directed inflammatory responses might result in serious diseases such as 
atherosclerosis (Muller, 2002) and any factor that induces overproduction of pro-
inflammatory cytokines and chemokines will favor the development of atherosclerosis. 
The data from previous chapters indicate clearly the role of Hcy in activating EC 
and that most of Hcy effects were reproducible with acute treatment with the pro-
inflammatory cytokine TNF-α (as was used as a positive control) or other pro-inflammatory 
mediators (Ahluwalia et al., 2004; Takahashi et al., 1996; Zampolli et al., 2000). 
Furthermore, several in vivo studies reported a positive correlation between plasma Hcy 
levels and TNF-α levels in atherosclerotic patients (Abdel Aziz et al., 2001; Akalin et al., 
2008). Collectively, if Hcy is shown to induce the synthesis of such pro-inflammatory 
mediators, that might explain all the reported effects of Hcy via a mechanism similar to 
those cytokines. Furthermore, chemokines such as IL-8 have been suggested to play a key 
role in activating leukocyte integrins which in turn mediate the adhesion of leukocytes on 
inflamed EC (Gerszten et al., 1999; Rot, 1992). Therefore, this chapter will expand what is 
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known about the role of IL-8 and TNF-α in Hcy-induced dysfunction through detecting 
their production at both protein and mRNA level in chronically Hcy-treated EC. 
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6.1. MATERIAL AND METHODS 
6.1.1. MATERIALS  
Oligonucleotide primers for IL-8 forward: 5′-ATGACTTCCAA 
GCTGGCCGTGGCT-3′ and reverse: 5′-TCTCAGCCCTCTTCAAAAACTTCTC-3′ and 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) forward: 5′-ACCACAGTTCA 
TGCCATCAC-3′ and reverse: 5′-TCCACCACCCTGTTGCTGTA-3′ were purchased from 
Sigma (www.sigma.com). Agarose (15510-027) was purchased from Invitrogen (Paisley, 
UK) and ethidium bromide (E7637) was purchased from Sigma-Aldrich (Poole Dorset, 
UK). TAE buffer (H5231) was purchased from Promega, Southampton, UK. All other 
materials used in this chapter were provided in ready kits, for total RNA isolation: RNeasy 
Mini Kit (74104) and DNA digestion kit (79254) were bought from Qiagen (Crawley, West 
Sussex, UK); for cDNA synthesis: ImProm-II™ Reverse Transcription System (A3800) 
was bought from Promega, Southampton, UK.  
For PCR reactions, PCR buffer (Y02028) and MgCl2 (Y02016) were purchased 
from Invitrogen Paisley, UK. dNTP mix (U1511), Taq DNA Polymerase, (M2031) 100bp 
DNA ladder (G2101), loading dye (G190A) and RNase free water (P1193) were purchased 
from Promega, Southampton, UK. For real time PCR, Taqman gene expression mastermix 
(4369016) and Taqman primer/probe sets: CXCL-8 (Hs99999034_m1), TNF-alpha 
(Hs00174128_m1) and GAPDH (Hs99999905_m1) were all purchased from Applied 
Biosystems (www.AppliedBiosystems.com). Amplifications of individual genes were 
performed on ABI 7500 Sequence Detection System. 
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6.1.2. METHODS 
6.1.2.1. Assessment of IL-8 and TNF-α protein production by HUVEC using ELISA 
HUVEC cells were seeded into gelatin-coated 96-well plates (as explained in 
section 2.1.2.4) (1x10
4
 cells/well) in triplicate and plates were incubated at 37°C and 5% 
CO2 in a humidified atmosphere for 96h. Culture media was changed once after 48h and at 
the end of incubation time, media was collected from the wells and mixed for each 
triplicate. The media was centrifuged (560g for 15min) to pellet any cellular residue and 
debris. Supernatant was then collected and kept at -80°C until the ELISA experiment could 
be carried out.  
Since DL-Hcy was shown to inhibit the growth of HUVEC (section 2.2.3.3), 
different numbers of cells might be present in differently treated wells and hence those 
wells with higher number of cells will produce a larger amount of IL-8 or TNF-α. 
Therefore, MTT assays were conducted on the cells after collecting the media (as described 
in section 2.1.2.4) and then ELISA results were adjusted according to the MTT results to 
eliminate any difference in IL-8 or TNF-α secretion due to differences in cell numbers. 
6.1.2.1.1. Detection of IL-8 protein 
A commercial kit was used to detect the IL-8 protein level in the culture media 
(DY208, R&D systems, Oxon, UK). The kit included all the reagents used and the assay 
was done as recommended by the manufacturer. Briefly, ELISA immuno 96 MicroWell™ 
plates (Nunc, Roskilde, Denmark) were coated with 100µl of the capture antibody (4µg/ml 
in PBS) and incubated overnight at room temperature. The following day, the remnants of 
the capture antibody were discarded and all wells were washed four times with 400µl wash 
buffer (0.05% v/v Tween 20 in PBS, pH 7.2 - 7.4). Plates were blotted on dry tissue after 
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each wash to get rid of any remaining liquid. Subsequently, 100µl blocking buffer (1% w/v 
BSA, in PBS with 0.05% w/v NaN3) was added to each well and incubated for 1h at room 
temperature to block nonspecific binding sites. Wells were washed in the same way they 
were washed after the capture antibody and then 100µl of the collected media was added to 
each well in duplicate and incubated for 2h at room temperature. Subsequently, washing 
steps were repeated as before and then 100µl of the detection antibody (20ng/ml in reagent 
diluent: 0.1% w/v BSA, 0.05% v/v Tween 20 in Tris-buffered Saline [20 mM Trizma base, 
150 mM NaCl], pH 7.2 - 7.4) was added to each well. Plates were incubated for 2h at room 
temperature. Following the incubation, washing steps were repeated as before and 100µl 
streptavidin-HRP was added after it was prepared to its working concentration (1:200) in 
reagent diluent. Plates were incubated for 20min at room temperature and then washed four 
times as before. 100µl of freshly prepared substrate solution (reagent A and B) were added 
to each well and incubated in dark for 20min at room temperature. The reaction with the 
substrate produced blue colour which was stopped by 50µl of 1M sulphuric acid. The 
formed colour was stable for 30min and absorbance was measured using Microplate reader 
MRX II (Dynex technologies, Chantilly, USA). The microplate reader was set to 450nm 
and then set to 540nm as a correction wavelength and then the reading produced at 
wavelength 540nm was subtracted from the reading produced at wavelength 450nm as 
recommended by the manufacturer. This subtraction will correct for the optical 
imperfections in the plate as readings made directly at 450nm without correction may be 
higher and less accurate.  
Human IL-8 standard was provided with the kit as lyophilized powder which was 
reconstituted in dH2O and for each assay serial dilutions of IL-8 standard were included 
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(2000, 1000, 500, 250, 125, 62.5 and 31.25 pg/ml). Readings of the standards were used to 
generate a standard curve from which the IL-8 concentrations of unknown wells were 
calculated using the software Revalation version 4.02. 
5.1.2.1.2. Detection of TNF-α protein 
A commercial kit was used to detect the TNF-α protein concentration in the culture 
media (DTA00C, R&D systems, Oxon, UK). The kit included all the reagents used and the 
assay was carried out as recommended by the manufacturer. Briefly, 50µL of assay diluent 
RD1F was added to each well of TNF-α Microplate (96-well plate coated with a mouse 
monoclonal antibody against TNF-α) and then 200µl of the collected media was added to 
each well in duplicate and incubated for 2h at room temperature. Subsequently, the 
remnants of the samples were discarded and all wells were washed four times with 400µl 
wash buffer using a squirt bottle. Plates were blotted on dry tissue after each wash to get rid 
of any remaining liquid. Following that, 200µl of HRP-conjugated polyclonal antibody 
against TNF-α was added to each well and incubated for 1h at room temperature. Wells 
were washed as previously following which, 200µl of freshly prepared substrate solution 
(reagent A and B) was added to each well and the plate was incubated in the dark for 20min 
at room temperature. The reaction with the substrate produced a blue colour and was 
stopped by 50µl of 1M sulphuric acid. The formed colour was stable for 30min and 
absorbance was measured using a Microplate reader MRX II (Dynex technologies, 
Chantilly, USA). The microplate reader was set to 450nm and then set to 540nm and 
adjustments were made for optical imperfections as described previously (section, 
6.1.2.1.1.).  
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Human TNF-α standard was provided with the kit as a lyophilized powder which 
was reconstituted in dH2O and for each assay serial dilutions of TNF-α standard were 
included (1000, 500, 250, 125, 62.5, 31.25 and 15.6 pg/ml). Readings of the standards were 
used to generate a standard curve from which the TNF-α concentrations of unknown wells 
were calculated using the software Revalation version 4.02. 
6.1.2.2. Assessment of IL-8 and TNF-α gene expression by HUVEC  
6.1.2.2.1. Extraction of RNA from cultured HUVEC 
Total RNA was isolated from differently treated HUVEC using RNeasy Mini Kit. 
Cells were grown in T25 flasks and treated as described before with 1mM DL-Hcy, 1mM 
Cys or left untreated. Upon confluence, the cells were washed twice with RNase-free PBS 
and then cells were detached from the flask by Trypsin/EDTA (0.05%/0.02%). Afterwards, 
the cells were transferred into RNase-free polypropylene centrifuge tubes and centrifuged 
at 560g for 5min. Supernatant was discarded and the pellet was then washed 3-4 times by 
suspending in RNase-free PBS and centrifuging. The supernatant was discarded completely 
and the cell pellet was disrupted by adding appropriate volume of buffer RLT. The cell 
pellet was then loosened thoroughly by flicking the tube and mixed thoroughly by vortex 
ensuring that no cell clumps were visible. Cells were homogenized by passing the lysate at 
least 5 times through a blunt 20-gauge needle (0.9 mm diameter) (NV-2025R, Terumo, 
Leuven, Belgium) fitted to an RNase-free syringe (BD Plastipak). A volume of 70% v/v 
alcohol (350µl) was added to the homogenized cells and mixed thoroughly by repeatedly 
pipetting the lysate. Afterwards, the lysate including any formed precipitates was moved to 
an RNeasy spin column, which contains a silica-based membrane, and centrifuged for 15s 
at ≥8000g, the flow-through was discarded and collection tube was used in the next step. 
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An appropriate volume of buffer RW1 (350µl) was added to the spin column, centrifuged 
for 15s at ≥8000g and the flow-through was again discarded. Reverse transcriptase PCR is 
highly sensitive to any traces of DNA so at this stage a DNA digestion step was performed 
to eliminate any possibilities of contamination with DNA using RNase-Free DNase set. The 
lyophilized enzyme DNase I was dissolved in 550µl RNase-free water (final concentration: 
2.73Kunitz units/ml), mixed gently and then aliquoted and stored at -20°C. DNase I was 
diluted (1:8) in the buffer RDD and then 80µl of the diluted enzyme were added to the spin 
column membrane, and placed at room temperature for 15min. At the end of the incubation, 
an appropriate volume of buffer RW1 (350µl) was added to the spin column, centrifuged 
for 15s at ≥8000g, the flow-through was discarded and subsequently, 500μl of buffer RPE 
were added to the RNeasy spin column and centrifuged for 15s at ≥8000g, the flow-through 
was discarded and washing with 500µl buffer RPE was repeated again but with 
centrifuging for 2min at ≥8000g. The long centrifugation dried the spin column membrane, 
ensuring that no ethanol was carried over during RNA elution. To eliminate any possible 
carry over of Buffer RPE, the spin column was placed on new 2ml collection tube and 
centrifuged at full speed for 1min. RNeasy spin column was then placed in a new 1.5ml 
collection tube and 40µl of RNase-free water were added directly to the spin column 
membrane and centrifuged for 1min at ≥8000g to elute the RNA. The last step was repeated 
with another volume of RNase-free water (40µl). 40µl of the isolated RNA were used in the 
later step for quantifying and determining the quality of the isolated RNA and the rest was 
kept in -80°C. 
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6.1.2.2.2. Quantification and determination of quality of RNA 
Spectrophotometry  
The quantity of RNA in each sample was checked using spectrophotometry. RNA 
was diluted in RNase-free water (1:20) and then the absorbance of UV was detected using a 
Jenway 6305 UV/vis spectrophotometer (Keison products, Essex, UK) at two different 
wavelengths 280nm for DNA and 260nm for RNA. The spectrophotometer was first 
calibrated to zero using nuclease-free water in a quartz cuvette. RNA purity was evaluated 
by calculating the ratio (absorbance at 260nm/absorbance at 280nm) and RNA quality was 
considered good if the ratio was between (1.8-2.2). RNA concentration was determined 
using the equation where Ab260 is the absorbance at 260nm and DF is the dilution factor:  
RNA concentration (µg/ml) = Ab260 x DF x 40 
Agarose gel electrophoresis 
A 1.5% gel was formed by melting agarose in 1X tris-acetate-EDTA buffer (TAE) 
using a 950W microwave (Proline Microchef ST44) on power 7 for 135s till the agarose 
was completely dissolved. Subsequently, the solution was left at room temperature to cool 
down to approximately 50°C and then ethidium bromide was added to the solution and 
mixed (final concentration of 0.6µM). The solution was poured into plastic gel trays 
containing gel combs to form wells, and left for approximately 45min to set. Subsequently, 
gel combs were removed gently and the gel was placed in an electrophoresis tank 
containing enough 1x TAE buffer with ethidium bromide (0.6µM) to cover the gel. 15µl of 
RNA samples were mixed with 3µl of loading dye in a ratio of 5:1 to assist loading and 
monitoring progression of the total RNA through the gel throughout electrophoresis, and 
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then carefully loaded into the gel. The tank was set to run at 100V for approximately 
30min. Subsequently, the UVitec gel documentation system (UVItec Limited, Cambridge, 
UK) was used to visualise total RNA and the images were captured using software Uvitec 
version 12.06 for windows. 
6.1.2.2.3. Complementary DNA (cDNA) synthesis 
The RNA purified in section 6.1.2.2.1 was reverse transcribed to complementary 
DNA which in turn is ideal for PCR experiments. ImProm-II™ Reverse Transcription 
System was used. The protocol recommended by the manufacturer was followed. Briefly, 
all reagents and RNA samples were thawed on ice and then any unused portion returned to 
the freezer as soon as aliquots were taken. Reaction mix was prepared in 0.5ml eppendorf 
tubes (Alpha Laboratories) on ice and included ImProm-II™ 5X reaction buffer (16µl), 
9.6µl MgCl2 (6mM), 4µl dNTP Mix (10mM of each dNTP), 2µl oligo(dT)15 primer 
(1µM), 4µl ImProm-II™ reverse transcriptase, 18µl RNA samples (up to 2µg/reaction) and 
then volume was made up to 80µl by Nuclease-Free Water (26.4µl). RNA and all reagents 
were mixed thoroughly by carefully vortexing for no more than 5s and were centrifuged 
briefly to ensure all the liquid was collected at the bottom of the tube. Subsequently, tubes 
were placed in the PCR Sprint thermal cycler (Thermo Hybaid, Ashford, UK) and set to run 
the reverse transcription programme which was: incubation at 25°C for 5min for annealing 
followed by incubation at 42°C for up to one hour to allow cDNA synthesis from mRNA 
by reverse transcription. Afterwards, the reactions were stopped and reverse transcriptase 
was inactivated at 70°C for 15min. Produced cDNA was aliquoted and maintained at -20°C 
for long-term storage. 
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6.1.2.2.4. Reverse transcriptase polymerase chain reaction (RT-PCR) 
All reagents were thawed on ice and then, any unused portion returned to the freezer 
as soon as aliquots were taken. PCR reaction mix was prepared in 0.5ml Eppendorf tubes 
(Alpha Laboratories) on ice by mixing all of the following reagents: 5µl PCR buffer, 2.5µl 
MgCl2 (3.125mM), 1µl dNTP mix (10mM each), 0.5µl Taq DNA Polymerase (5u/µl), 
2.5µl forward primer (10µM, IL-8 or GAPDH), 2.5µl reverse primer (10µM, IL-8 or 
GAPDH) and then the volume was made up to 40µl by 26µl RNase free water. After 
preparing the reaction mix, 10µl of the cDNA samples was mixed with 40µl of master 
reaction mix by gently pipetting in PCR tubes. 40µl of the master reaction mix was mixed 
with 10µl of RNase-free water instead of cDNA and this served as a negative control to 
check if there was any DNA contamination. cDNA samples with all reagents were mixed 
thoroughly by carefully vortexing for no more than 5s, and centrifuged briefly to ensure all 
the liquid was collected at the bottom of the tube. Subsequently, PCR was performed in 
PCR Sprint thermal cycler (Thermo Hybaid, Ashford, UK) and PCR conditions for IL-8 
were: initial denaturation at 94°C for 5min and then (denaturation at 94°C for 30s, 
annealing at 65°C for 30s and extension at 68°C for 1min) for 28 cycles with a final 
extension at 68°C for 2 min. PCR conditions for GAPDH were: initial denaturation at 95°C 
for 15min and then (denaturation at 94°C for 1min, annealing at 63°C for 1min and 
extension at 72°C for 1min) for 25 cycles with a final extension at 72°C for 10min. The 
PCR products were placed on ice to be analysed immediately by agarose gel 
electrophoresis as explained in section 6.1.2.2.2. A DNA ladder was loaded in the gel and 
used as a molecular size marker. The PCR products were electrophoresed on a 1.5% w/v 
TAE-agarose gel and visualized by ethidium bromide staining. The PCR product size for 
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amplified IL-8 and GAPDH were 267bp and 450bp respectively. UVitec gel documentation 
system (UVItec Limited, Cambridge, UK) was used to visualise the PCR products and the 
images were captured using software Uvitec version 12.06 for windows. The differences in 
IL-8 expression were estimated by measuring the intensity of the bands using ImageJ 
software and values were normalized against GAPDH bands density for each sample. 
6.1.2.2.5. Real time PCR 
For quantitative PCR, the following mix was prepared (Taqman Universal PCR 
Master Mix: 10µl, Taqman Primer/Probe: 0.5µl, cDNA: 2µl and H2O: 7.5µl) and 20µl of 
this mix was distributed in MicroAmp® optical reaction 96-well plate (4306737, Applied 
Biosystems). Samples were prepared in triplicate and the plates were centrifuged briefly to 
ensure a good mix of reagents. Real-time PCR was performed using the Applied 
Biosystems 7500 Real-Time PCR System. The thermocycler parameters were 50°C
 
for 
2min and 95°C for 10min, followed by 50 cycles of
 
95°C for 15s and 60°C for 30s. The 
threshold cycle (CT), which indicates the fractional cycle number at which the amount of 
amplified target gene reaches a fixed threshold, from each well was determined using the 
Applied Biosystems Sequence Detection Software v2.01. Relative quantification 
representing the change in gene expression from real-time quantitative polymerase chain 
reactions between experimental groups was calculated by the comparative CT method. The 
data was analyzed by calculating the relative quantification (RQ) using the equation: RQ = 
2
−ΔCTx100, where ΔCT= CT of target gene−CT of housekeeping gene. Evaluation of 2
−ΔCT
 
indicates the fold change in gene expression, normalized to the internal control (GAPDH) 
which enabled the comparison between differently treated cells. All results then were 
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logged to the base 10 (Log10x) and a ratio paired t-test was applied to detect the significant 
level of the differences between differently treated cells. 
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6.2. RESULTS 
6.2.1. The effects of DL-Hcy on cytokine protein secretion 
6.2.1.1. IL-8 
The secretion of IL-8 in response to DL-Hcy treatment was detected using ELISA 
and concentrations of IL-8 protein in culture media were adjusted according to the number 
of live cells (assessed by MTT) in each well. Non-treated cells showed basal detectable 
concentrations of IL-8 in the culture media. However, DL-Hcy-treated HUVEC expressed a 
higher concentrations of IL-8 protein (1910 + 65 pg/ml) compared to non-treated cells 
(1613 + 39 pg/ml) (p<0.01). Figure 46 represents results from 6 individual experiments 
using 6 different donors. In contrast, cells treated with Cys showed concentrations of IL-8 
protein (1475 + 122 pg/ml) similar to non-treated cells. 
5.2.1.2. TNF-α 
The secretion of TNF-α in response to DL-Hcy treatment was detected using ELISA 
and concentrations of TNF-α protein in culture media were adjusted according to the 
number of live cells (assessed by MTT) in each well. TNF-α protein was not detectable in 
the culture media of any of the treated or non-treated cells. 
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The effects of chronic exposure to DL-Hcy on IL-8 protein production 
 
 
Figure 46: HUVEC were grown in complete M199 medium with DL-Hcy (1mM; 5-9 
days), or Cys (1mM; 5-9 days). HUVEC from the same donor were grown in complete 
M199 media without any stimulation and considered with Cys-treated cells as negative 
controls. IL-8 protein production was detected in the culture media using ELISA and 
results were adjusted to the numbers of live cells in each well which were estimated using 
MTT. The results are expressed as mean (+/- SEM) from 6 different donors for DL-Hcy, 
Cys and non-treated (n=6). (*) p < 0.01 for DL-Hcy versus non-treated cells. 
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6.2.2. The effects of DL-Hcy on cytokine mRNA expression 
6.2.2.1. RNA isolation efficiency 
Total RNA was isolated from HUVEC as described in section 6.1.2.2.1 and the 
efficiency of the purification method was assessed by running the isolated RNA on 1.5% 
agarose gel (Figure 47). The image in Figure 47 shows RNA isolated from three different 
samples, non-treated, DL-Hcy-treated and Cys-treated HUVEC. Two main bands for each 
sample could be identified representing the two ribosomal RNA (rRNA) components 18S 
and 28S. 28S rRNA band was approximately twice as intense as the 18S rRNA band. This 
indicates that isolated RNA was of a good quality as intact RNA has these two bands with a 
2:1 ratio (28S:18S). On the other hand, degraded RNA will not exhibit 2:1 ratio and will 
appear as a very low molecular weight smear (Skrypina et al., 2003). This experiment was 
repeated after each isolation process and the image displayed in Figure 47 represents results 
of 4 different experiments.  
6.2.2.2. Reverse transcriptase PCR 
The expression of IL-8 mRNA was assessed in differently treated cells using 
reverse transcriptase PCR. GAPDH was used as an endogenous internal control for 
variations in PCR product levels due to any differences in RNA isolation efficiency and 
PCR reaction efficiency. Furthermore, variations in the numbers of cells between 
differently treated flasks due to inhibitory effects of DL-Hcy on cell proliferation were 
adjusted by normalizing the results of each sample against its own level of GAPDH as 
GAPDH is expressed constitutively and not affected by DL-Hcy. Having loaded equal 
amounts of RNA in the PCR reaction, it can be concluded that GAPDH is expressed 
constitutively and is not affected by DL-Hcy treatment (Figure 48). 
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All cells produced PCR products which correspond to the expected amplicon size 
(267bp: IL-8 and 450bp: GAPDH) and Figure 48A shows bands of IL-8 and GAPDH RNA 
from one experiment. There were no bands in the negative control in which the cDNA was 
replaced with nuclease-free water, indicating that the reagents used in the PCR reaction mix 
were free from any contamination. All IL-8 RNA bands had the same density in differently 
treated cells and that was confirmed by quantifying the bands using ImageJ software 
(Figure 48B). Results indicate no changes in IL-8 mRNA expression in HUVEC once these 
cells were treated with DL-Hcy compared to non-treated or Cys-treated cells. 
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Figure 47: Representative image showing the efficiency of RNA isolation. 15µl of purified 
total RNA was loaded on 1.5% TAE-agarose gel, separated by electrophoresis and 
visualized by UVitec gel documentation system. The 28S and 18S ribosomal RNA are clear 
in the total RNA samples with a ratio of approximately 2:1. 
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◄450bp: GAPDH 
◄267bp: IL-8 
The effects of chronic exposure to DL-Hcy on IL-8 mRNA expression 
(RT-PCR) 
 
 
 
                 
 
Figure 48: A: Representative TAE-agarose gel photographs showing ethidium bromide 
stained RT-PCR products of IL-8 mRNA. HUVEC were grown in complete M199 medium 
with DL-Hcy (1mM; 5-9 days), or Cys (1mM; 5-9 days). HUVEC from the same donor 
were grown in complete M199 media without any stimulation and considered with Cys-
treated cells as negative controls. IL-8 and GAPDH mRNA from differently treated cells 
were amplified using RT-PCR as described in section 6.2.2. No bands were observed in the 
negative control. The expected amplicon size is 267bp and 450bp for IL-8 and GAPDH 
respectively. B: Density of the bands represented in Figure 48A and from 2 further 
experiments with independent samples were quantified using ImageJ software. Non-treated 
values were defined as 100% and other values were adjusted accordingly. Results are 
expressed as mean (+/- SD) from 3 different donors (n=3). 
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6.2.2.3. Real time PCR 
Quantitative real time PCR was applied to study the expression of the mRNA of IL-
8 RNA and TNF-α and all results were adjusted to the internal endogenous control 
GAPDH. Figure 49 shows the numbers of PCR amplifying cycles required for each gene to 
reach a fixed threshold.  
To confirm the findings of RT-PCR for IL-8, a quantitative real time PCR was 
applied and the results show that DL-Hcy induced a slight increase in the level of IL-8 
mRNA in DL-Hcy-treated cells compared to non-treated ones. However, this increase was 
not significant even when a ratio paired t-test was applied (Figure 50). On the other hand, 
DL-Hcy-treated cells showed about 5-fold increase in their TNF-α mRNA. Ratio paired t-
test was applied and indicated that the increase in TNF-α mRNA was significant (p<0.05) 
(Figure 51). 
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Figure 49: The number of PCR cycles required for each gene to reach a fixed threshold. 
The genes which were amplified are: GAPDH (black), IL-8 (violet) and TNF-α (blue). 
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The effects of chronic exposure to DL-Hcy on IL-8 mRNA expression 
(real time-PCR) 
 
 
Figure 50: HUVEC were grown in complete M199 medium with DL-Hcy (1mM; 5-9 
days), or Cys (1mM; 5-9 days). HUVEC from the same donor were grown in complete 
M199 media without any stimulation and considered with Cys-treated cells as negative 
controls. IL-8 mRNA was amplified in differently treated cells using real time PCR. Non-
treated values were defined as 100% and other values were adjusted accordingly. Results 
are expressed as mean (+/- SEM) from 4 different donors for DL-Hcy, Cys and non-
treated (n= 4). 
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The effects of chronic exposure to DL-Hcy on TNF-α mRNA expression 
(real time-PCR) 
 
 
Figure 51: HUVEC were grown in complete M199 medium with DL-Hcy (1mM; 5-9 
days), or Cys (1mM; 5-9 days). HUVEC from the same donor were grown in complete 
M199 media without any stimulation and considered with Cys-treated cells as negative 
controls. TNF-α mRNA was amplified in differently treated cells using real time PCR. 
Non-treated values were defined as 100% and other values were adjusted accordingly. 
Results are expressed as mean (+/- SEM) from 4 different donors for DL-Hcy, Cys and 
non-treated (n= 4). (*) p < 0.05 for DL-Hcy versus non-treated cells. 
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6.3. DISCUSSION  
The role of chemokines in mediating the pathology of atherosclerosis was addressed 
in several studies reviewed by Tedgui and Mallat (2006), and different groups have 
previously investigated whether acute administration of Hcy induces synthesis of such 
chemokines (Dalal et al., 2003; Poddar et al., 2001; Zeng et al., 2003). However, none of 
these studies considered whether chronic treatment with Hcy might induce sustained 
expression of such chemokines in EC. Sustained expression of pro-inflammatory cytokines 
and chemokines might represent another mechanism which is involved at least in part in 
mediating Hcy proatherosclerotic effects. Therefore, this chapter focuses on one of the 
major chemokines, IL-8, and its response to chronic treatment with DL-Hcy. Furthermore, 
the ability of EC to produce the key pro-inflammatory cytokine, TNF-α, was investigated in 
this chapter in addition to studying the effects of chronic treatment with DL-Hcy on such 
production.  
All of the cell populations studied expressed detectable levels of IL-8 protein in 
their culture media which indicates a constitutive production of IL-8 in resting HUVEC. 
Cells which were treated chronically with DL-Hcy expressed significantly higher 
concentrations of IL-8 protein in their culture media compared to non-treated and to Cys-
treated cells (p<0.01) (Figure 46). However, amplifying IL-8 mRNA using RT-PCR 
showed no significant difference in its level between the differently treated cells (Figure 
48) and to confirm this finding, quantifiable real time PCR was conducted on the same 
samples and showed that DL-Hcy induced an increase in the mRNA expression compared 
to non-treated. However, this increase was variable and did not reach significance (Figure 
50). Collectively, although DL-Hcy did not have measurable effects on IL-8 gene at the 
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transcriptional level, it did induce a small increase in IL-8 synthesis and release into the 
culture media. Different possibilities might account for these results; mRNA is produced in 
both the presence and absence of DL-Hcy as it was detected by PCR in all samples. 
However, DL-Hcy might activate the translation of the IL-8 mRNA and/or inhibit protein 
turn over and both possibilities would result in the same consequence, production of more 
IL-8 protein. The increase in P-selectin expression in response to chronic DL-Hcy 
treatment, which has been shown in Chapter 2, indicates increase in WPB exocytosis as it is 
the main mechanism for P-selectin to be mobilized to the cell surface. Furthermore, DL-
Hcy might induce WPB exocytosis by decreasing NO level, which is suggested to be a 
negative regulator of WPB exocytosis (as explained in Chapter 5). Meanwhile, IL-8 is 
stored in WPB (Wolff et al., 1998) which means the DL-Hcy-induced WPB exocytosis will 
result in IL-8 being mobilized outside the cells leading to increase in IL-8 protein in culture 
media. Collectively, that might represent a third possibility indicating that IL-8 synthesis 
rate is not affected by DL-Hcy however, DL-Hcy enhances its transport to WPB and the 
WPB exocytosis leading to releasing more IL-8 extracellularly. Furthermore, only 2% of 
the produced IL-8 has previously been shown to present on the EC surface, while the 
remainder will be shed and present in a soluble form (Marshall et al., 2003). Marshall’s 
group illustrated that shedding of IL-8 and release into culture media is mediated by tPA 
activity and this process was suggested as a mechanism to stabilize the IL-8 expression at 
the cell surface. Marshall’s group suggested that soluble IL-8 has anti-inflammatory effects 
in contrast to the proinflammatory effects
 
of cell surface-bound IL-8. Since tPA was 
suggested to be inhibited by Hcy (Hajjar et al., 1998), there will be a decrease in shedding 
IL-8 and therefore less production of soluble IL-8 in response to Hcy treatment. However, 
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this chapter’s results indicate a Hcy-mediated increase in soluble IL-8 despite the expected 
decrease due to tPA inhibition. Therefore, the small increase in soluble IL-8 is likely to 
reflect a more significant increase of IL-8 de novo synthesis and mobilization to the cell 
surface where only a small fraction will be shed. Therefore, our data suggest a large 
increase in cell surface IL-8 which would be able to promote EC activation. ELISA could 
be used to detect the IL-8 expression on the cell surface of Hcy-treated EC. 
ROS has been shown to differentially mediate IL-8 mRNA expression and protein 
production in different EC and epithelial cells (Lakshminarayanan et al., 1997). The same 
group demonstrated that hydrogen peroxide was able to induce an increase in IL-8 gene 
expression in human epithelial cells but not in a human microvessel endothelial
 
cell line. 
Furthermore, they showed that hydrogen peroxide induced IL-8 protein secretion in both 
human epithelial cells and human microvessel endothelial
 
cell line but not in HUVEC. 
Therefore, ROS involvement in mediating IL-8 production varies between different cell 
types. In contrast to Lakshminarayanan’s findings, Kerkeni et al (2006) found that 
antioxidants were able to reverse, at least in part, Hcy-induced-IL-8 production in HUVEC 
which suggests a role for ROS in mediating IL-8 production in HUVEC. The data of 
Kerkeni’s group might suggest that ROS works synergistically with the above suggested 
mechanisms to mediate the chronic DL-Hcy-induced IL-8 production showed in this 
chapter. 
The constitutive production of IL-8 in resting HUVEC presented in this chapter 
matches with other studies that also reported constitutive expression of IL-8 in HUVEC 
(Geisel et al., 2003; Lakshminarayanan et al., 1997; Marshall et al., 2003), HAEC (Poddar 
et al., 2001) and HSVEC (Dalal et al., 2003). Furthermore, the results of this chapter are in 
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line with other studies who found that Hcy induces increase in IL-8 protein synthesis in 
HAEC (50µM for up to 8h) (Poddar et al., 2001) and in HUVEC (1-10mM, 3-24h) (Geisel 
et al., 2003; Kerkeni et al., 2006). On the other hand, Dalal et al (2003) failed to report 
increase in IL-8 production in response to Hcy (0.5-5mM for 4-24h) in HSVEC but even 
found that Hcy inhibited IL-8 production in dose dependent manner. The difference 
between this chapter’s results and Dalal’s group results could be due to different responses 
by different EC types or the short incubation time, which might have induced transient 
expression which then dropped back to basal levels. Furthermore, pre-treatment of 
cytokine-treated human VSMC with Hcy (up to 1mM for 4h) increased cytokine-mediated 
up-regulation of IL-8 protein and mRNA (Desai et al., 2001), while other groups found that 
Hcy alone induced IL-8 mRNA expression in HUVEC (Geisel et al., 2003) and monocytes 
(Zeng et al., 2003). In Desai’s study, Hcy might have worked synergistically with cytokines 
to induce the increase in mRNA level of IL-8 which might be the reason for the contrast to 
our results where Hcy alone was not able to induce IL-8 mRNA expression. Geisel’s group 
incubated EC with Hcy for 20h which might have induced temporarily increase in mRNA 
which has then dropped back to the basal level as measured in this chapter’s results. On the 
other hand, Zeng’s study was conducted on monocytes which might respond differently to 
Hcy treatment from EC and that could explain why IL-8 mRNA was increased in response 
to Hcy alone.  
JNK was shown to be involved in mediating cytokine-induced IL-8 up-regulation in 
cancer cells while p38 was not involved in this up-regulation (Krause et al., 1998). 
Furthermore, the IL-8 promotor has been shown to have binding sites for AP-1, the 
downstream transcription factor of JNK, and binding of AP-1 is required for inducing 
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transcription activity of the L-8 promotor (Wu et al., 1997). In contrast, Zeng et al (2003) 
demonstrated that Hcy induces IL-8 and MCP-1 production in monocytes in a p38 and 
ERK dependent way. This group also illustrated that the Hcy-induced production of these 
cytokines is ROS mediated. Therefore, it could be concluded that the pathway through 
which IL-8 synthesis is up-regulated varies between different cell types and between 
different stimuli.  
The effect of Hcy on IL-8 protein production is specific to DL-Hcy since Cys was 
not able to induce significant increase in IL-8 protein level (Figure 46). This agrees with 
Poddar’s group who  showed in HAEC that induction of IL-8 and MCP-1 expression is 
specific to Hcy and none of the other thiol containing amino acids, like Cys or methionine 
was able to induce such expression (Poddar et al., 2001). On the other hand, the same group 
found that DL-Hcy induced mRNA expression of MCP-1 and IL-8 in HAEC with maximal 
effects at 50µM and IL-8 mRNA remained high at all concentrations above 50µM (up to 
10mM). This concentration was sufficient to induce increases in protein secretion within 
15min of administration. Differences between cell types might account for the difference 
between this chapter’s results and Poddar’s group results concerning mRNA expression. 
They used arterial cells which represent a good model for atherosclerotic lesions and those 
cells might be more sensitive to Hcy treatment on the transcriptional level than the cells 
used in this chapter (HUVEC). 
The second part of this chapter focuses on the TNF-α as a possible mediator for Hcy 
atherogenic effects. The data from real time PCR experiments revealed that HUVEC 
chronically treated with DL-Hcy expressed 5-fold increase in their TNF-α mRNA 
compared to non-treated HUVEC (Figure 51). In spite of this dramatic increase in TNF-α 
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mRNA, a paired t-test showed that this increase was insignificant. The raw data show that 
the differences between the values of non-treated and DL-Hcy treated cells are not very 
consistent. Thus, the ratio paired t-test was used as an alternative to t-test since it studies the 
differences between the ratios of the non-treated to treated values instead of studying the 
differences between the mean values. These ratios are much more consistent, and therefore, 
analyzing their logs can give more persuasive results. The ratio paired t-test showed that the 
increase in TNF-α mRNA noticed in DL-Hcy treated cells was significant compared to 
non-treated cells (p<0.05). Therefore, in contrast to the lack of increases observed in IL-8 
mRNA, DL-Hcy induced transcription of TNF-α gene. On the other hand, none of the cell 
populations studied expressed any detectable concentrations of TNF-α in their culture 
media. Collectively, although DL-Hcy induced increase in the transcription of TNF-α gene, 
it could not induce increase in the synthesis rate of TNF-α protein.  
These results are hard to explain and the literature does not support the ability of EC 
to produce TNF-α (Dalal et al., 2003; Kerkeni et al., 2006; Nikitina et al., 1997). Dalal’s 
group found that neither resting nor Hcy-treated HSVEC expressed detectable levels of 
TNF-α (Dalal et al., 2003); and Kerkeni’s group found also that Hcy (1-10mM, up to 24h) 
was not able to induce TNF-α secretion in HUVEC (Kerkeni et al., 2006). On the other 
hand, one in vitro study (Bai et al., 2007) showed some controversy in their findings as 
they found that HUVEC expressed a constitutive production of TNF-α (less than 100pg/ml) 
and that 100µM Hcy induced 10-fold increase in this production. ELISA used in this thesis 
detected levels of TNF-α as low as 15.6pg/ml so it should have been able to pick up 
equivalent concentrations of TNF-α to those suggested in Bai’s study. This group used 
HUVEC at passage number between 4-6 while in this chapter HUVEC were used at 
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passage 2-4. Therefore, the cells in Bai’s study were grown in culture conditions for longer 
time than those used in this chapter and that could have altered their sensitivity to stimuli or 
changed constitutive gene expression which could explain their production of TNF-α. 
Furthermore, Bai’s group didn’t carry out any characterization of the HUVEC they used, 
such as detecting the constitutive expression of vWF or CD31. This might suggest that 
those HUVEC are no longer normal at such high passage number, which might explain 
their constitutive production of TNF-α and their sensitivity toward Hcy treatment.  
 The increase in mRNA expression in this chapter’s experiments could be explained 
by a low stability of the mRNA transcript, and thus, this synthesized mRNA was not 
translated into protein. One study found that up to 10mM Hcy was not able to induce 
expression of TNF-α mRNA in HUAEC (Poddar et al., 2001) which contradicts the 
findings of this chapter. However, they used a northern blot technique to identify the 
expression of TNF-α mRNA and could not detect any expression in neither non-treated nor 
Hcy-treated cells; while in this chapter real time-PCR has been used to detect the 
expression of TNF-α mRNA and this technique is quantifiable and more sensitive than the 
technique used in Poddar’s study. Furthermore, they used HUAEC in their study which 
might respond differently to Hcy than HUVEC does. 
Surprisingly, some studies found that 5mM Hcy has inhibitory effects on TNF-α-
induced up-regulation of CAM (Roth et al., 2001; Stangl et al., 2001), and chemokines 
(Roth et al., 2001) in HUVEC. Their findings contrast with Desai’s group who found that 
1mM Hcy augmented TNF-α-induced chemokines expression in human VSMC (Desai et 
al., 2001). The high Hcy concentration which Roth’s group has used might have some 
inhibitory effects on the HUVEC and altered their response to different stimuli and 
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therefore their response to TNF-α was affected. Other cell types have been shown to 
respond differently to Hcy as an in vitro study in human monocytes (Su et al., 2005) 
showed that DL-Hcy (185µM-720µM, 3h) induced significant increases in the mRNA 
expression of several different proinflammatory cytokines, TNF-α, IL-1β, IL-6, IL-8 and 
IL-12. Furthermore, all of these cytokine protein concentrations increased after DL-Hcy 
treatment (185µM-2160µM, 3h) indicating that the translation was induced by this 
treatment.  
Very few in vivo studies have addressed the correlation between Hcy and TNF-α 
concentrations. Diabetic patients who have atherosclerotic lesions were shown to have 
elevated concentrations of both TNF-α and Hcy with a significant positive correlation 
between the two markers (Abdel Aziz et al., 2001; Akalin et al., 2008). Furthermore, 
patients with vitamin B12 deficiency showed significant increase in Hcy and TNF-α 
concentrations and their concentrations were significantly correlated (Peracchi et al., 2001). 
Vitamin B12 is an essential cofactor for remethylation of Hcy which explains the high 
concentrations of Hcy in those patients. However, it remains unclear whether the increase 
of TNF-α is due to vitamin B12 being involved in regulating TNF-α synthesis or due to 
direct induction of TNF-α synthesis by accumulated Hcy. Interestingly, a study on patients 
with psoriatic arthritis found that blocking TNF-α function led to a significant decrease in 
Lp(a) and Hcy (Sattar et al., 2007). Sattar’s findings might suggest a possible role of TNF-
α in regulating Hcy metabolism while other in vitro studies (Bai et al., 2007; Su et al., 
2005) suggest a role for Hcy in inducing TNF-α synthesis. Therefore, the actual relation 
between the atherogenic Hcy and the proinflammatory cytokine TNF-α is still controversial 
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and needs more investigation to reveal their effects on each other’s production and their 
effects on each other’s efficiency. 
To sum up, there are some evidence that a positive correlation between Hcy and 
TNF-α is present in atherosclerotic patients or those at risk of developing atherosclerosis, 
and both Hcy and TNF-α might play a key role in atherosclerosis progression. However, 
this observed correlation was recorded in patients. Hence, different cells could participate 
in TNF-α production. Furthermore, it is not clear whether EC produces TNF-α and whether 
this production could be induced by Hcy. Despite the findings of this chapter that Hcy 
induced TNF-α mRNA expression, the protein level of TNF-α was undetectable and 
therefore, these results are hard to explain and are not final. More work is still needed to 
explore the role of TNF-α in Hcy-induced EC damage. Furthermore, there is a need to find 
a positive control that can induce TNF-α production by EC in order to confirm that EC are 
able to produce TNF-α. It might be worth trying the use of lipopolysaccharides, TNF-α 
itself or other proinflammatory cytokines like IL-1 as an inducer of TNF-α production. 
Furthermore, IL-1 has been shown to be produced by EC (Libby et al., 1986) and therefore, 
it could present a possible mediator of Hcy atherogenic effects. Therefore, characterizing 
the expression of IL-1 mRNA and its protein production could be a possible future step to 
characterize the role of pro-inflammatory cytokines in mediating Hcy-induced EC 
activation. 
6.4. CONCLUSION 
This chapter provide strong evidence that DL-Hcy affects the production of the 
chemokine IL-8 which is thought to play a key role in mediating DL-Hcy-induced EC 
activation. These activated EC will express several CAM on their surface which work 
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together with the secreted chemokines to recruit leukocytes and start the inflammatory 
process. Even though, DL-Hcy induced TNF-α mRNA expression it did not affect its 
protein synthesis.  The significance of this finding is therefore not clear. 
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CHAPTER 7 
7. CONCLUSION AND FUTURE STUDIES 
7.1. Conclusion 
The theory of Hcy and atherosclerosis was formulated in the middle of 1970s 
(McCully and Wilson, 1975) and then Hcy was suggested as a primary risk factor in 
cardiovascular diseases by Lentz et al (Lentz et al., 1996). Many studies have been 
conducted to investigate Hcy-mediated atherogenic effects and to study the mechanisms 
behind such effects. Most of these studies have investigated the effects of acute treatment 
with Hcy and also most of them studied Hcy effects under static conditions (Dong et al., 
2005; Postea et al., 2006; Silverman et al., 2002; Stuhlinger et al., 2001). However, acute 
stimulation does not reflect a clinically relevant situation since the EC in patients with 
hHcy will be continuously exposed to high levels of Hcy, which may modulate the EC 
behaviour. Therefore, the current study aimed to characterize the effects of chronic 
treatment with Hcy on EC under both static and flow conditions thus making the study 
more pathologically relevant. 
In all of the experiments carried out in this thesis, DL-Hcy up to 1mM did not kill 
EC. However, DL-Hcy did suppress EC proliferation rate and induced differential gene 
expression which led to sustained up-regulation of a number of endothelial CAM: P-
selectin, E-selectin and ICAM-1. DL-Hcy also induced EC secretion of the 
proinflammatory chemokine IL-8. The expression of E-selectin and ICAM-1 was detected 
under static and flow conditions, while P-selectin expression was characterized by the 
increase in the number of tethered neutrophils under flow. Furthermore, DL-Hcy was 
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shown to increase the production of IL-8, which is known to be stored along with P-selectin 
in WPB. The fact that DL-Hcy induced increase in IL-8 concentration confirms that DL-
Hcy induced the exocytosis of WPB, the storage vesicle of IL-8, to enable the release of 
this protein. WPB exocytosis will also lead to both release of P-selectin and its expression 
on EC surface. Therefore, the increase in IL-8 levels provides another indirect evidence that 
DL-Hcy induced the expression of P-selectin. Furthermore, DL-Hcy has been shown to 
decrease NO bioavailability (Stuhlinger et al., 2001; Upchurch et al., 1997), which is 
known to be a negative regulator of WPB exocytosis. This strengthens the conclusion that 
DL-Hcy might indirectly modulate WPB exocytosis by decreasing NO level. This 
conclusion provides another explanation for DL-Hcy-induced P-selectin up-regulation since 
WPB is the main storage for P-selectin and DL-Hcy enhances the exocytosis of this storage 
vesicle.  
Collectively all of these observations could be considered as markers of EC 
activation/dysfunction. The up-regulation of these CAM and chemokine made the EC 
susceptible to be involved in different interactions with leukocytes, which were observed in 
the in vitro flow system used in this study. Hence, long term treatment with DL-Hcy was 
able to induce the earliest events in atherosclerosis process under flow conditions. This 
reflects to some extent, the in vivo situation in hyperhomocysteinemic patients and 
therefore, indicates a key role for this amino acid as a primary risk factor in atherosclerosis. 
Furthermore, none of the observed effects was reproducible with Cys indicating the 
observed EC atherogenic effects were not due to osmotic stress but specific to the DL-Hcy. 
Furthermore, Cys has a similar structure to DL-Hcy including the same free thiol group and 
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therefore, as Cys was not able to mimic DL-Hcy effects that indicates the effects of DL-
Hcy are not non specific effects due to its free thiol group.  
Different signalling pathways are involved in mediating CAM and cytokine up-
regulation including MAP kinases and strong evidence provided in the literature suggests a 
key role for the JNK pathway in mediating cytokine-mediated E-selectin and ICAM-1 
expression (Miho et al., 2005; Min and Pober, 1997). Published studies have shown that 
acute Hcy treatment induced JNK pathway activation (Cai et al., 2000; Dong et al., 2005; 
Zhang et al., 2001b) and the data of this thesis extended these findings and provided an 
evidence that chronic exposure to DL-Hcy induces sustained up-regulation of the JNK 
pathway and therefore sustained activation of its substrate c-Jun. Interestingly enough, only 
JNK1 of JNK isoforms was activated by chronic DL-Hcy, which is known to preferentially 
activate the substrate c-Jun compared to JNK2 (Sabapathy et al., 2004) while TNF-α 
activated both JNK1 and JNK2. Furthermore, once this pathway was blocked, using a JNK 
specific inhibitor, DL-Hcy was not able to induce E-selectin or ICAM-1 expression and 
therefore interactions between neutrophils and EC under flow conditions were prevented. 
These findings are in line with others (Miho et al., 2005; Min and Pober, 1997) who 
showed that E-selectin and ICAM-1 up-regulation in response to acute treatment with 
proinflammatory mediators happened through the JNK pathway. However, these CAM 
levels dropped back to the basal level after few hours of induction while, in this study E-
selectin and ICAM-1 were still expressed after 5-9 days of DL-Hcy treatment indicating 
that DL-Hcy induced sustained expression of these CAM. This could be due to sustained 
activation of MKKK, the upstream kinase of the JNK pathway, or due to deactivation of 
MAPK phoasphatase, both of which induce a sustained activation of the JNK pathway. 
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Further work is still needed to reveal the mechanism of Hcy-induced sustained EC 
activation. 
Furthermore, the inhibition of P-selectin expression (characterized by the number of 
tethered neutrophils under flow) in response to JNK inhibition was unexpected. 
Considering that P-selectin is presynthesized and stored in WPB, it could be concluded that 
JNK is involved either in de novo synthesis of P-selectin and/or in the WPB exocytosis, a 
process required for P-selectin surface expression. Collectively, this novel data shows that 
DL-Hcy induced up-regulation of different CAM by different mechanisms including the 
activation of the JNK pathway and altering vesicle trafficking within EC.  
These findings suggest a potential therapeutic target for treating and/or protecting 
hyperhomocysteinemic patients from atherosclerosis by targeting the JNK pathway using 
specific inhibitors. However, the limitation would be that blocking such pathway would 
suppress different kinds of inflammatory responses including those which are vital for the 
survival of the whole organism such as those against invading organisms. Therefore, to 
avoid such side effects, these inhibitors would need to target specific cells at specific time 
points. The data illustrated in this study shows that DL-Hcy specifically activated JNK1; 
while TNF-α activated both JNK1 and JNK2. This might suggest that developing specific 
inhibitors against JNK1 might be a potential solution to avoid the side effects of JNK 
general inhibitors and therefore, avoiding blockage vital inflammatory responses.  
It has been suggested that Hcy induces its atherogenic effects leading to EC 
activation/dysfunction via different mechanisms. Hcy was shown to induce the expression 
of several ER stress response genes (Kokame et al., 1996) and also was suggested to induce 
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ER stress by disturbing disulphide bond formation and therefore leading to UPR as a 
cellular survival response (Kokame et al., 1996; Outinen et al., 1998; Outinen et al., 1999). 
However, severe and prolonged ER stress elicited by Hcy and failed or prolonged UPR 
were suggested to have several atherogenic consequences including lipid dysregulation, 
programmed cell death and inflammation. Forming disulphide bonds between Hcy and Cys 
molecules was suggested also to disturb some enzymes which have free Cys groups like 
eNOS or DDAH and therefore disrupting their efficiency leading in both cases to decrease 
in the bioavailable NO (Boger, 2003; Boger et al., 2001; Dayal and Lentz, 2005). 
Furthermore, it has been suggested that Hcy induces the production of ROS and/or disrupt 
antioxidant enzymes leading to cellular oxidative stress which was suggested to account for 
most intracellular Hcy effects (Au-Yeung et al., 2004; Handy et al., 2005). Chronic 
treatment with DL-Hcy in this study induced significant increases in ROS production in 
HUVEC leading to sustained oxidative stress. However, antioxidants like NAC were able 
to suppress ROS generation by DL-Hcy and also managed to reverse DL-Hcy-induced JNK 
activation. Therefore, once ROS generation was returned to basal levels, DL-Hcy was not 
able to activate the JNK pathway which indicates strongly that oxidative stress is the 
mechanism by which chronic DL-Hcy treatment activates the JNK pathway. Furthermore, 
treatment of the cells with DL-Hcy and the antioxidants NAC or vitamin C reversed DL-
Hcy-induced EC:neutrophil interactions under flow conditions indicating that the CAM 
which mediated DL-Hcy effects under flow were not up-regulated in the absence of 
elevated ROS. These data could be summarized by suggesting that DL-Hcy induces 
continuous ROS generation which leads to sustained JNK pathway activation. 
Subsequently, both activated JNK and ROS might lead to up-regulation of different CAM 
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and chemokines which together mediate the EC:leukocyte interactions under flow. The fact 
that antioxidants inhibited DL-Hcy-induced JNK activation and inhibited DL-Hcy-induced 
interactions under flow, collectively suggest that ROS were responsible for activating the 
JNK pathway and therefore, inducing up-regulation of several CAM and potentially 
chemokines which mediated EC:neutrophil interactions under flow conditions. 
These findings indicate the importance of antioxidants in reversing DL-Hcy 
atherogenic effects and therefore present a possible therapeutic approach to protect hHcy 
patients from CVD risk. Even though clinical trials using antioxidants have not so far been 
successful in decreasing the risk of CVD (Paolini et al., 2003; Stanner et al., 2004), our 
data agree with the findings of many in vivo and in vitro studies which indicate that 
restoring the redox balance help in improving EC functions and in reversing Hcy-induced 
EC activation/dysfunction (Chambers et al., 1999; Nappo et al., 1999). The reason for this 
contradiction is still unclear but could be that the use of only one antioxidant in some of 
these trials which might not be able to overcome the oxidative stress or could be due to the 
low dose used in in vivo studies compared to those used in in vitro studies. This issue is still 
in debate and needs more studies to uncover the efficiency of such treatment.  
It has been shown so far that DL-Hcy induces ROS generation. However, the 
question which remains unanswered is how DL-Hcy induces ROS generation. Cys which 
shares the same free thiol group with Hcy was not able to induce ROS generation. This 
indicates that the Hcy-mediated ROS production is not due to the auto-oxidation of its thiol 
group but might be due to direct effects on ROS-producing enzymes or ROS-scavenging 
enzymes. Different theories have been suggested (Figure 8) including that Hcy decreases 
the expression of antioxidant enzymes such as glutathione peroxidase (Handy et al., 2005), 
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Hcy decreases the bioavailability of NO or Hcy induces eNOS uncoupling and the 
production of superoxide anions at the expense of NO (Topal et al., 2004). The results of 
this study along with the published data can be gathered in a possible theory including 
minor and major routes for ROS generation (Figure 52). Hcy activates NADPH oxidase 
which will start producing O2
•−
. It was suggested this would be a minor route because that 
will oxidize BH4 to BH2 therefore, inhibiting NO-generating activity of eNOS and inducing 
its O2
•−
-generating activity (Zhang et al., 2000). Hcy was also shown to decrease the 
intracellular uptake of L-arginine in addition to activate arginase which is responsible for 
degrading L-arginine (Forstermann and Munzel, 2006) thus could reduce the intracellular 
levels of arginine (Jin et al., 2007). Lack of BH4 and arginine leads to eNOS uncoupling 
which will then start producing O2
•−
 and that will be the major route. This O2
•−
 interacts 
with NO to form peroxinitrite which is a very potent oxidant. O2
•−
 produced by NADPH 
oxidase was suggested to work as an upstream for inducing more production of O2
•−
 by 
other enzymatic systems (Gao and Mann, 2009). Therefore, NADPH oxidase could be the 
initial source of ROS and thereafter, uncoupled eNOS contributes to amplify the O2
•−
 
generation within Hcy-treated. Furthermore, Hcy ability to inhibit different antioxidant 
systems in the cell will amplify the effects of produced ROS.  
In addition to generating superoxide anions, uncoupled eNOS has been shown to 
stop generating NO which is known to down-regulate the expression of CAM (Armstead et 
al., 1997; Spiecker et al., 1998; Zampolli et al., 2000) and hence, inhibit leukocyte 
adhesion on EC. Therefore, the decrease in the bioavailable NO might play an important 
role in amplifying Hcy-induced EC activation which might worsen the Hcy-induced injury. 
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Thus, the potential therapeutic effects of NO in reversing Hcy effects and restoring EC 
quiescence were investigated.  
 
 
 
Figure 52: Minor and major routes for ROS production induced by Hcy. 
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Most previous studies have shown a role of NO in regulating de novo synthesis of 
CAM. Surprisingly, short incubations with exogenous NO conducted in this thesis were 
able to reverse the effects of chronic DL-Hcy treatment on EC under flow and no 
EC:neutrophil interactions were recorded. NO requires a number of hours to alter the de 
novo synthesis of CAM like E-selectin and ICAM-1 and thus to down-regulate their 
expression. Therefore, the short-term incubation with NO in this study (10min) was 
unlikely to be enough to down-regulate the expression of these two CAM and hence, they 
are likely to be still expressed on the EC surface. However, the question remains as to why 
neutrophils did not interact with DL-Hcy/NO-treated cells. NO can nitrosylate some 
proteins altering their activity and included in those proteins are the NSF superfamily 
which mediate WPB exocytosis. Therefore, within 10min of NO treatment, we believe 
these proteins were nitrosylated leading to inhibition of WPB exocytosis. Both P-selectin 
and IL-8 are stored in WPB and require vesicle exocytosis to be released. Collectively, 
short-time treatment with NO might have inhibited WPB exocytosis and thus inhibited P-
selectin surface expression, the main mediator of tethering, and IL-8 release, one of the 
main chemokines required for leukocyte recruitment. Therefore, NO short treatment 
prevented neutrophils tethering to EC and this step was showed to be essential for 
leukocyte activation and their integrin conformational change to the adhesive form 
(Lawrence and Springer, 1991; Lorant et al., 1993), both of which are required for the 
rolling and firm adhesion stages to happen. Therefore, none of the neutrophils were able to 
roll directly or adhere without being activated through the tethering step first. Therefore, all 
the stages were inhibited and neutrophils did not interact at all with EC. It could be 
concluded that short-term treatment with NO inhibited DL-Hcy atherogenic effects and 
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these findings suggest possible use of exogenous NO in treating or protecting 
hyperhomocysteinemic patients from atherosclerosis risk. 
The last part of this study was to investigate the involvement of chemokines and 
cytokines in mediating DL-Hcy effects. Chronic DL-Hcy induced a significant increase in 
the expression of IL-8 protein but did not up-regulate mRNA. That means DL-Hcy induced 
the translation of IL-8 mRNA to the protein, which is an essential chemokine that helps in 
recruiting leukocytes to activated EC. IL-8 expression in addition to CAM up-regulation 
work together on mediating DL-Hcy-induced HUVEC:neutrophil interactions under flow 
conditions. Furthermore, chronic treatment with DL-Hcy induced increased expression of 
TNF-α mRNA but not its protein. TNF-α is a very well characterized proinflammatory 
cytokine and it has been shown to induce ROS generation (Gu et al., 2002) which is shown 
to inhibit JNK phosphatases (Chen et al., 2001a) leading to JNK activation and thereafter 
up-regulation of different CAM and chemokines. TNF-α might have peaked in the early 
few hours after DL-Hcy treatment and then dropped down to an undetectable level. This 
early increase could have induced the expression of several proinflammatory cytokines 
which mediated and/or amplified DL-Hcy atherogenic effects. The findings of this study 
are in line with most published studies which failed to record any TNF-α in EC (Dalal et 
al., 2003; Kerkeni et al., 2006; Nikitina et al., 1997). It might be more helpful to study the 
expression of other proinflammatory cytokines like IL-1 which is already known to be 
expressed in EC. 
Even though, different clinical trials (explained earlier in section 1.1.5.4.2) have 
used vitamin B6, B12 or folate to lower Hcy levels, they failed to report any benefit of this 
reduction on CVD risk. However, the results of this thesis contradict with the finding of 
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these clinical trials and they illustrate a clear role for Hcy in inducing EC damage and 
initiating for atherosclerosis. Furthermore, three possible therapeutic approaches were 
discussed and suggested from results obtained in this thesis, the use of JNK inhibitors 
which would be not easy to control as there is a need to target specific cells at specific 
times in order not to disturb the necessary inflammatory response. However, targeting 
specific JNK isoforms, such as JNK1 might present a possible solution to avoid the 
unwanted side effects. The second approach is by using NO which has potentially a great 
application in patients with MI as a quick intervention. However, the long term use of 
exogenous NO donors in a protective manner has not been fully investigated yet. 
Antioxidant treatment presents the third approach which is safe and easy to use; however, 
the clinical trials were not as successful as the in vitro studies. More studies are still needed 
to evaluate any combination or required doses for antioxidants. The negative outcome of 
clinical trials using antioxidants in CVD patients (explained in section 1.3.4) might suggest 
an additional therapeutic option by targeting specific enzymes like NADPH oxidase or 
eNOS which could provide more efficient solution to restore antioxidant system to protect 
against or reverse some effects of CVD. 
To summarize, the results of this thesis provide, for the first time, clear evidence 
that chronic treatment with DL-Hcy induced EC activation which was characterized by 
sustained activation of the JNK pathway through an ROS-mediated mechanism. 
Furthermore, activation of the JNK pathway led to continuous up-regulation of different 
CAM and chemokines secretion. Thereafter, surface expressed CAM and secreted 
chemokines mediated different sorts of interactions between EC and neutrophils under flow 
representing the earliest interaction in atherosclerosis progress. The long-term treatment 
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with DL-Hcy along with the in vitro flow model used in this thesis together provided a 
much reliable results than previous experimental approaches which used short-term 
treatment with DL-Hcy and/or evaluated DL-Hcy effects under static conditions. The 
outcome of this study clearly illustrates the importance of DL-Hcy as a primary risk factor 
in atherosclerosis. Different studies have suggested different approaches to lowering Hcy 
levels in patients at high risk by using vitamins such as vitamin B12 and folate (Bonaa et 
al., 2006; Lonn et al., 2006). However, these studies were of no benefit in reducing 
cardiovascular risk, this may be attributed to the complex metabolic networks involving 
homocysteine and vitamins (Loscalzo, 2006). This study evaluated the efficiency of 
different therapeutic approaches to reverse Hcy-induced activation of EC under static and 
flow conditions, such as using antioxidants, NO donors or being more specific by targeting 
some JNK isoforms. Despite showing Hcy as a primary risk factor that is implicated in 
different atherogenic consequences, this study highlighted the possibility to protect or cure 
from Hcy effects. 
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7.2. Future studies 
This thesis provides strong evidence for atherogenic effects of chronic Hcy. 
However and due to time and cost efficiency, there are some limitations to the work 
conducted in this thesis. Additional techniques could be used to answer more questions on 
the mechanisms of Hcy-induced EC activation and atherosclerotic initiation. 
Firstly, using small interfering RNA (siRNA) technology to inhibit different gene 
expression provides a specific technique to selectively inhibit some proteins. siRNA could 
be used to inhibit the expression of each CAM individually and then study EC:leukocyte 
interaction under flow conditions. That would provide clear evidence for the role of each 
CAM in each stage of EC:leukocyte interaction and explore any overlapping between them 
in mediating the different stages. Furthermore, since it was shown that EC are unlikely to 
produce TNF-α, the involvement of other proinflammatory cytokines, known to be 
expressed in EC, such as IL-1 could be a good aspect of study using the same siRNA 
technology. That would provide a clear evidence of the actual role of proinflammatory 
cytokines in Hcy-induced atherogenic effects. Furthermore, using the same technique to 
inhibit JNK might give a more reliable answer for its role in CAM up-regulation than using 
selective inhibitors as some researchers argue about the specificity of these inhibitors. 
Secondly, the dramatic and instant effects of NO on Hcy-induced EC:neutrophil 
interactions need more investigation. The surface expression of different CAM after a 
short-term NO treatment could be further investigated to identify NO ability to induce the 
shedding of these CAM. Immunofluorescence techniques could be used to study these 
CAM expression using direct immunostaining that was used in this thesis or using more 
sensitive techniques such as fluorescence-activated cell sorting (FACS). Furthermore, WPB 
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exocytosis could be studied at real time by transfecting EC with the green fluorescent 
protein (GFP) P-selectin probe which will identify P-selectin and therefore allow 
visualizing vesicle trafficking in real time. That would be very helpful in studying the 
inhibitory effects of NO on this process. Nitrosylation could be further investigated by 
using reducing agents with less damaging effects than DTT, to study whether these 
compounds can reverse NO inhibitory effects. That could give a supporting evidence for 
the nitrosylation effects. Furthermore, protein nitrosylation after exposure to exogenous NO 
donors could be detected using the biotin switch assay and this technique could be made 
more specific by immunoprecipitating JNK first and then using the biotin switch assay to 
detect any nitrosylation of JNK. Finally, Better flow model can be used like that developed 
by Sheikh et al (2003) where cells were cultured under flow. That model gives the 
opportunity to study the effects of chronic Hcy on shear stress induced NO production and 
whether shear stress anti-atherogenic effects might overcome Hcy atherogenic 
consequences. 
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APPENDIX 1  
The in vitro system used to study HUVEC:neutrophil interactions under flow 
conditions. 
 
The system is ready for flow experiment. A: camera attached on the top of the 
microscope. B: syringe pump through which neutrophils suspension is pulled. C: flow 
chamber is located on the microscope stage connected to the vacuum system (to the back) 
and to syringe installed on the syringe pump (to the right) and to the tube containing 
neutrophils (to the left).  
A
B
C
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APPENDIX 2 
The buffers which have been used in western blot 
Buffer 1 (Resolving gel): pH = 8.4 
Reagents Grams/L Grams/500ml 
1.5M Tris Base  181.5 90.75 
0.4% w/v SDS 4 2 
 
Buffer 2 (Stacking gel): pH = 6.8 
Reagents Grams/L Grams/500ml 
0.5M Tris Base  60.5 30.25 
0.4% w/v SDS 4 2 
 
 
Resolving Gel (amounts per gel): 
   10% 
H2O ml 9.6 
Buffer 1 ml 6 
Acrylamide ml 8 
TEMED 
N,N,N,N tetramethylene 
persulfate µl 8 
APS  
Ammonium persulfat µl 90 
 
 
Stacking Gel (amounts per gel):  
   10% 
H2O ml 9.75 
Buffer 2 ml 3.75 
Acrylamide ml 1.5 
TEMED µl 20 
APS µl 150 
 
 
Running Buffer 
  1 Litre 2 L 3 L 5 L 
Tris G 3 6 9 15 
Glycine G 14.4 28.8 43.2 72 
SDS (for final conc of 0.1%) G 1 2 3 5 
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Blotting Buffer  
  1 Litre 2 L 3 L 5 L 
Tris G 3 6 9 15 
Glycine G 14.4 28.8 43.2 72 
Methanol ml 200 400 600 1000 
 
 
TBS-T (Tris Base Salline-T) pH = 7.4 
  1 L 2 L 3L 5L 
NaCl G 8.78 17.56 26.3 15 
Tris base G 2.42 4.84 7.2 72 
Tween µl 1000 2000 3000 5000 
 
 
ECL1 
 
Luminol stock   1 ml 
P-coumaric   0.44 ml 
Tris base (1M, pH= 8.5) 10 ml 
 
Continue to 100 ml with water 
 
ECL2 
 
H2O2 (30%)   64 µl 
Tris base (1M, pH= 8.5) 10 ml 
 
Continue to 100 ml with water 
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APPENDIX 3 
Assessment of Hcy interaction with NAC using mass spectrometry 
The following solutions were prepared and incubated overnight at 37°C and 5% 
CO2 in humidified incubator  
DL-Hcy (1mM) 
NAC (1mM, pH=2.2) which is termed unbuffered NAC 
NAC (1mM, pH=7.7 adjusted with 1M sodium bicarbonate) which is termed 
buffered NAC 
Mix of DL-Hcy (1mM) and buffered NAC (1mM) 
Mix of DL-Hcy (1mM) and unbuffered NAC (1mM) 
 
Table 1: The different solutions prepared for Mass Spectrometry experiments 
 
All stock solutions were prepared in dH2O and then diluted (1:10) in 100% 
methanol before being infused into MS to detect any changes to the structure of these 
compounds once mixed after the indicated period of time. A negative control of 100% 
methanol was used to eliminate any non-specific background.  
Mass spectrometry to detect interactions between Hcy and NAC  
Mass spectrometry (MS) is an analytical technique used to determine the molecular 
mass of the sample and can give structural information of a sample or a molecule. 
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Micromass Quattro Ultima (triple quad mass spectrometry, Micromass UK Ltd, 
Manchester, UK) was used in this chapter to study any possibility for interactions between 
DL-Hcy and NAC which might lead to generating a third compound with different 
structure and properties from Hcy and NAC. Samples of Hcy and NAC at a concentration 
of 0.1mM (prepared as indicated above) were directly infused via a Harvard syringe pump 
at 10µl/min into the ionization source and then the components of the sample were ionized 
in the negative mode. Subsequently, ions will be directed to an electric field where the 
motion of the ions as they move within the electromagnetic field is translated into mass to 
charge ratio and thereafter, the molecular ion of each compound can be identified.  
Settings of the machine were adjusted as follows: capillary set at 3.5 kilovolt, cone 
(35v) and desolvation temperature 150°C. For product scan of newly formed compounds 
(daughter fragmentation), a collision voltage of 5 was used. Molecule ionization was done 
in negative mode and therefore, the molecular weights of the detected compounds were 
calculated as follows: 
MW = number displayed on the peak +1 
Preliminary Results and Discussion 
Mass spectrometry experiments were used to study any possibility that interactions 
between DL-Hcy and NAC which might reverse Hcy effects by altering its structure or by 
forming third compounds such as Hcy-NAC conjugates which might have less harmful 
effects on EC. The structure and mass to charge (m/z) values for Hcy and NAC and any 
expected new molecules which might have been formed in these experiments are displayed 
in Figure 53.  
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Figure 53: Chemical structures and m/z values of the molecules detected in ESI-MS 
(negative mode): Hcy, homocysteine (Hcy dimer), NAC, NAC dimer (NAC-NAC) and 
the expected structure for the 5
th
 compound (Hcy-NAC). 
 
 
As methanol was used to dilute all samples, 100% methanol alone was analyzed to 
eliminate any possible non-specific peaks and it showed only two peak (m/z 212 and m/z 
127) (Figure 54). These are a background peaks possibly due to plasticizers in system. 
However, the m/z 127 ion did not appear in any of the other spectra which indicate that 
these data are unreliable. DL-Hcy solution showed three different significant peaks but one 
of them seems same as those of methanol. The smallest one represents Hcy while the 
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biggest one represents the dimer (homocystine). Hcy therefore is forming disulphide bonds 
with another Hcy through their free thiol groups to form homocystine molecule (Figure 
55A). Unbuffered NAC solution also showed both monomer and dimer peaks (Figure 55B). 
Furthermore, the mix solution of (DL-Hcy and unbuffered NAC) showed both monomers 
and dimers of Hcy and NAC in addition to a third form compound (peak number of 297) 
(Figure 55C and Figure 56). The m/z value of the third ion suggests that it is formed from 
one molecule of Hcy and one molecule of NAC through a disulphide bond (Hcy-NAC). On 
the other hand, adjusting the pH of NAC solution with NaHCO3 resulted in the 
disappearance of the NAC dimer in the buffered solution showing only the monomer to be 
present (Figure 57A). Furthermore, the solution of DL-Hcy and buffered NAC lacked the 
third compound (Hcy-NAC) (Figure 57C).  
 
 
 
Figure 54: ES1-MS spectrum of the negative control (100% methanol). 
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Figure 55: ES1-MS spectrum of: A: DL-Hcy alone, B: unbuffered NAC, C: DL-Hcy and 
unbuffered NAC. 
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Figure 56: ES1-MS spectrum of: A DL-Hcy and unbuffered NAC. B: ES1-MS/MS 
spectrum of the third compound w/z 297. 
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Figure 57: ES1-MS spectrum of: A: DL-Hcy alone, B: buffered NAC, C: DL-Hcy and 
buffered NAC. 
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We proposed that the thiol group of Hcy might form a disulphide bond with the 
thiol group of NAC forming a third compound (Figure 53) which might not be able to be 
taken up intracellularly, therefore reducing the intracellular uptake of Hcy. Decreasing Hcy 
cellular uptake would decrease its deleterious effects and that might present another 
mechanism by which NAC is preventing Hcy detrimental effects. To examine this theory, 
mass spectrometry was used to analyze the different compounds which are present in 
differently prepared solutions as explained in (Table 1). It would have been more relevant 
to study the interaction between Hcy and NAC in culture media supernatant. However, 
culture media supernatant contains many different compounds which can result in matrix 
effects and signal suppression and would make it very difficult to judge the possible 
formation of a new intermediate compound (Hcy-NAC). Therefore, the compounds were 
prepared in dH2O and incubated in conditions similar to cell incubation conditions (37°C 
and 5% CO2 in humidified atmosphere). Furthermore, NaHCO3 was used to buffer the 
NAC solution before adding it to cells in culture (pH 7.7). Therefore, and to study the 
effects of NaHCO3 on the formation of the intermediate compound (Hcy-NAC), the 
solutions were prepared with buffered and unbuffered NAC (as explained in Table 1). Both 
NAC and Hcy were shown to be present in two different forms, monomer and dimer. 
However, the NAC dimer form was unstable at pH 7.7 (Figure 57). Furthermore, a third 
compound Hcy-NAC was detected in the unbuffered mix (Figure 55C and Figure 56). 
However, this third compound also disappeared once the pH was adjusted to 7.7 (Figure 
57C). Therefore, it could be concluded that the dimers of Hcy and NAC were not stable at 
pH 7.7. Collectively, this preliminary data has shown that a third compound could be 
formed of Hcy and NAC together, however the stability of this compound is extremely 
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weak at physiological pH. This suggests that in culture media which has a pH of 7.7, the 
third compound is not likely to be formed and therefore Hcy structure won’t be affected by 
the presence of NAC. Therefore, all the observed effects of NAC in reversing Hcy-induced 
JNK activation and also reversing Hcy-induced EC:neutrophil interactions most likely to be 
due to its effects as an antioxidant. 
On the other hand, there are some limitations for the protocol designed to do these 
experiments. The contamination noticed in negative control (methanol) indicated that this 
control was unreliable and therefore invalidated the particular data. Furthermore, there 
might be some possible issues with the buffer used to prepare the solutions (NaHCO3) as 
this buffer is not normally used in MS and would most likely induce matrix effects causing 
ion suppression. Alternately, ammonium bicarbonate could have been used because 
ammonium bicarbonate is compatible with mass spectrometry and its buffer range is (6.8-
11.3). However, due to the fact that in experiments conducted on cells in culture, NaHCO3 
was used to buffer NAC solutions and thus, using another compound to buffer solutions in 
MS experiments will make the results incomparable. Therefore and as a future step, 
designing the experiments using the ammonium bicarbonate to buffer solutions in MS 
could be more relevant. Furthermore, in order to compare the in vitro results with the MS 
results, some of the in vitro experiments could be repeated, using ammonium bicarbonate, 
to check whether the results will be reproducible with different buffering solution. 
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APPENDIX 5 
 
